

## Presymptomatic testing in myotonic dystrophy: genetic counselling approaches

Siv Fokstuen, Jenny Myring, Christine Evans, Peter S Harper

**EDITOR**—We report the genetic counselling approaches used in a series of 72 presymptomatic genetic tests for myotonic dystrophy undertaken in our centre over an eight year period. The study has identified factors which influenced the counsellor's approach, and which can provide a basis for further, more systematic research.

Genetic counselling in myotonic dystrophy has always been difficult and complex, owing to the extreme variability of the disorder, in both severity and age at onset, with anticipation between generations and influence of the sex of the affected parent.

The identification of a CTG repeat expansion within the 3' untranslated region of the myotonic dystrophy protein kinase gene on chromosome 19<sup>1</sup> as the primary molecular defect has transformed our understanding of the genetic aspects of this disorder and provides the basis for an accurate and specific diagnostic and presymptomatic test. The broad correlation of the size of the CTG expansion with age at onset and severity of the phenotype allows a limited degree of prognosis to be given to those found to have the mutation, particularly for very large or minimal gene expansions. Subjects carrying a minimal expansion (less than 100 repeats)<sup>2</sup> usually show few or no muscle symptoms, but may develop cataract in later life; they contribute to a pool of mutation carriers who may transmit clinically significant disease to their offspring as a result of anticipation.

Presymptomatic genetic testing for late onset dominantly inherited disorders first became possible for Huntington's disease (HD),<sup>3</sup> for which extensive experience has resulted in widely accepted guidelines for genetic counselling protocols; these comprise two pre-test sessions for information and preparation combined with post-test support.<sup>4</sup> With appropriate adaptation, this has become a model for other late onset genetic disorders of the nervous

system and to some extent also for the familial cancers. Although direct presymptomatic testing for myotonic dystrophy has now been available for eight years, we are not aware of studies so far on the counselling approach for this disorder in relation to presymptomatic testing. This lack of knowledge has prompted the present study, in conjunction with experience of direct molecular testing as a service in our centre, reported separately.<sup>5</sup>

### Patients and methods

Since the identification of the specific gene mutation in 1992, up to June 2000, out of a total of 287 molecular analyses for the disorder in subjects living in Wales (population 2.9 million), there were 78 presymptomatic tests for myotonic dystrophy; by comparison 205 diagnostic tests on symptomatic subjects were performed and four prenatal tests. The laboratory methods used and the overall composition and outcomes of the series are described in the accompanying paper.<sup>5</sup> For the purpose of the present study, we only included the 72 subjects seen for presymptomatic testing by 11 different clinical geneticists providing the clinical genetics service for Wales over this eight year period, based in the Institute of Medical Genetics, Cardiff, the remaining six samples having been received from neurologists and paediatricians. Data about the counselling approach were ascertained through the clinical genetics service notes and correspondence, supplemented by further discussion with the relevant clinical geneticist. We did not recontact any patients.

No single or specific counselling approach to presymptomatic testing in myotonic dystrophy has been advocated in Wales over this period, though one of us (PSH) has had a long standing clinical and research interest in the disorder. In general, subjects requesting presymptomatic testing were seen in their local medical genetics clinic by the clinical geneticist and genetics nurse specialist with designated responsibility for the particular district, not in a specialist clinic for the disorder.

### Results

When grouped according to the perspective of the subject tested, three different presymptomatic test situations could be distinguished (table 1). The largest group of subjects (A, n=58) represented the classical presymptomatic test situation with persons at 50% risk.

J Med Genet  
2001;38:846–850

**Institute of Medical Genetics, University of Wales College of Medicine, Heath Park, Cardiff, CF4 4XN, UK**  
S Fokstuen\*  
J Myring  
C Evans  
P S Harper

Correspondence to:  
Professor Harper,  
harperps@cardiff.ac.uk

\*Present address: Division of Medical Genetics, Centre Médicale Universitaire, 1 Rue Michel-Servet, 1211 Geneva 4, Switzerland, siv.fokstuen@hcuge.ch

Table 1 Presymptomatic testing for myotonic dystrophy: principal indications

Presymptomatic test situation	Total	Test results	
		Normal	Abnormal
(A) Direct request for presymptomatic testing	58	48	10
(B) Presymptomatic testing considered in relation to possible testing of ongoing pregnancy	5	5	0
(C) Testing of asymptomatic parent in relation to diagnostic investigation of child	9	3	6
Total	72	56	16

Table 2 Different approaches for presymptomatic testing used in Wales

Approach	Total	Normal/abnormal molecular result
(1) Two stage approach		
A Blood taken at second genetic counselling session	7	7/-
B Offer of a two step approach, rejected by the person at risk	2	1/1
(2) Intermediate approach		
A Blood taken by family doctor or genetic nurse specialist at interval after first genetic counselling session	3	3/-
B Blood taken at first genetic counselling session, stored until confirmation to proceed from patient.	5	5/-
(3) One stage approach		
A Blood taken at first genetic counselling session	46	35/11
B Blood taken by the genetic nurse specialist at home, genetic counselling clinic session only in case of an abnormal result	9	5/4
Total	72	56/16

Table 3 Relevant factors for counselling approach in presymptomatic testing for myotonic dystrophy

Factors
Age
Clinical assessment
Familiarity with disorder
Family dynamic
Subject's perception of possible symptoms
Time pressure (pregnancy)

Ten proved to have an abnormal result. Two of them showed minimal clinical abnormalities at the time of testing, but did not regard their symptoms as abnormal. Patients with an ongoing pregnancy formed a separate subgroup (B, n=5). All five (four females, one male) were healthy subjects at 50% risk asking for a presymptomatic test during an ongoing pregnancy. Three of them wished for a prenatal diagnosis in case of an abnormal presymptomatic test result. Results proved normal in all of them. The third category (C) concerned patients with no known family history of myotonic dystrophy at the time of the testing. For all of them, the issue of presymptomatic testing arose during the genetic counselling session although their original request had concerned another issue. We included nine cases in this group, six of them parents (five mothers, one father) of newly diagnosed affected children. All were referred as part of making the diagnosis in their children. They felt healthy, although five showed minor clinical features of myotonic dystrophy. Molecular testing was abnormal in all of them. The other three (one couple and a mother) had lost a fetus with unexplained arthrogryposis and/or neuromuscular abnormalities and wanted to know the risk for a further pregnancy. All three were completely healthy at clinical examination and the test result was normal in all of them.

As summarised in table 2 and discussed below, three different counselling approaches to presymptomatic testing for myotonic dystrophy could be identified. The most common practice (n=46) was to take the blood sample at the end of the initial genetic counselling session. The factors which decided the choice of the approach are listed in table 3.

### Discussion

There is a general consensus that presymptomatic testing for late onset, mendelian, genetic disorders should not be considered as a purely laboratory procedure, but that it should be

linked to appropriate genetic counselling in order to achieve a proper foundation of information, preparation, and support.<sup>6</sup> How this can be ensured will vary according to the disorder and a universal model cannot be applied. There is, however, a range of issues common to most genetic disorders of late onset. These issues include the implications of an abnormal result for reproductive decisions, the genetic implications to offspring and other relatives, consequences for future employment and insurance, strategies for coping with an abnormal result, and the availability of support from family, friends, and professionals. Most reported experience so far has come from Huntington's disease, which represents an extreme situation regarding its severity and current lack of therapy.<sup>7</sup> A two step approach has generally been recommended, both to allow the complex issues to be discussed fully and to give space to think about the testing process.<sup>4</sup>

For myotonic dystrophy, however, no guidelines have been produced so far, and the approaches used have been based on individual patterns of clinical practice. One clear difference between the two disorders relates to the penetrance of the gene, since whereas in Huntington's disease a considerable risk of serious disease exists for healthy subjects at risk who have passed 50 years of age, for myotonic dystrophy the great majority of offspring of an affected person will show definite clinical features of the disorder by early adult life, while most late onset cases are clinically mild. Brunner *et al*<sup>8</sup> showed in a total of 139 clinically normal offspring of myotonic dystrophy patients that the residual risk of carrying the myotonic dystrophy gene mutation is approximately 8% between the ages 20 and 39 and a comparable risk (8.6%) was shown in a linkage based series.<sup>9</sup> In the present series, the proportion of abnormal presymptomatic test results in clinically normal subjects (seven out of 69, 10.1%) was comparable. However, in only two such cases (males aged 19 and 37 years) was the abnormal expansion in the range likely to be associated with significant neuromuscular symptoms (>100 repeats). Thus, likelihood of a clinically normal myotonic dystrophy relative carrying a mutation significant for their own health is small, especially after the age of 40 years.

We can now consider in turn the different approaches to genetic counselling identified in this series (table 2). The factors listed in table 3 are among those particularly relevant to the approach that may be most appropriate.

The two stage approach, corresponding to that used for Huntington's disease and comparable late onset neurodegenerative disorders, was used in only seven of the 72 cases, being offered but rejected in two others. Factors favouring this approach include unfamiliarity with the disorder and its consequences, complexities of family relationships and dynamics, and young age of the person to be tested, giving a greater likelihood that an abnormal result might indicate relatively severe disease. In general, we would advocate it in any situation where the person is uncertain about a decision to be tested and where the amount or complexity of new

information to be considered is too great to be given satisfactorily in a single session or where a period of reflection is needed.

In contrast to Huntington's disease, where this complex situation is almost invariably present, this is not always the case for myotonic dystrophy, so we see no need for a two step approach to be recommended in all presymptomatic testing situations for myotonic dystrophy; equally, where it is suggested but declined, as occurred in two cases in our series, we see no reason why it should be insisted on.

In the great majority of presymptomatic tests in the present series (46 out of 72), a blood sample for analysis was taken at the end of the initial genetic counselling session. This approach seems particularly appropriate where the subject is familiar with the disorder, where there are no family complexities, or where their age (over 40 years) makes the likelihood of an abnormal result small and where even an abnormal result is unlikely to have major clinical significance. This last factor contrasts strongly with presymptomatic testing for Huntington's disease, where the chance of an abnormal result remains high at a relatively advanced age and where the clinical consequences of the disorder are serious regardless of age at onset. In myotonic dystrophy, older subjects detected as having clinically insignificant expansions should perhaps be considered gene carriers rather than affected patients.

In eight instances in this series, an intermediate approach was used (2A and B in table 2), where opportunity was given for reflection following the interview by either storing the blood sample until the person had confirmed that they wished testing to proceed (five cases) or by arranging for the blood sample to be taken after an interval by the family doctor or genetics nurse specialist (three cases). This would appear to provide a useful option when the case does not clearly fall into either the two stage or single stage situations.

In five cases, the request for presymptomatic testing was made in the context of an ongoing pregnancy, with prenatal diagnosis being wished for in three of these. There was thus a situation of time pressure, making a full two step approach difficult even if considered desirable, a problem not infrequently met also in presymptomatic testing for Huntington's disease. In all three cases potentially requiring prenatal diagnosis, blood was taken at the end of the first interview; all had a normal result so that no further action was required. In the two cases where prenatal diagnosis was not wished for, an intermediate approach as outlined above was used.

In nine cases in this series, blood was taken at a home visit by the genetics nurse specialist before the genetic counselling clinic attendance, this only being arranged if the result was abnormal. This was considered appropriate at the time in cases where no special complexities were expected and it is likely that some unanticipated difficulties would have been detected at the home visit, allowing the sampling to be postponed. However, we would not now recommend this approach for a number of reasons. First, it

gives no opportunity for clinical assessment before testing is undertaken, a factor of considerable importance in view of the high frequency of asymptomatic subjects at risk who show clinical abnormalities. Second, while some of the relevant issues would have been able to be discussed at the home visit, it is unlikely that a full picture of the potential consequences of testing would have been obtained in this way. Thirdly, by seeing only those subjects with an abnormal result in clinic, no opportunity was given to those with a normal outcome to discuss the disorder and its consequences for affected family members, something that might be relevant to them as a relative, even though not affecting themselves.

Two areas which require particular discussion are the role of clinical examination in the presymptomatic testing process and the importance of the subject's perception as to whether testing was presymptomatic or diagnostic. Previous family studies have clearly shown that a considerable proportion of asymptomatic family members show definite clinical abnormalities on examination (17.6% in one early study).<sup>8</sup> In the present study, some clinical abnormalities were present in nine of the 16 cases with an abnormal presymptomatic test result, in the total series of 78 cases (see accompanying paper<sup>5</sup> for details). By contrast, the likelihood of an abnormal genetic test result in a carefully examined and clinically normal adult is low (around 8% in the studies discussed above). The figure of seven out of 78 cases in the present series is comparable. It can thus be argued that clinical assessment is likely to make a greater contribution to outcome than laboratory analysis and should always be undertaken before genetic testing. On the other hand, since some people request testing primarily for reproductive reasons and may not recognise the possibility of being themselves affected, this possibility and the reasons for clinical assessment will need careful explanation before testing is performed, with the timing of the assessment depending on the individual situation.

A related important issue is the possible difference in perception of the person being tested and the clinician involved as to whether the testing is "presymptomatic" or "diagnostic". We have considered as presymptomatic in our series all those cases who had no complaints, even though abnormal or suspicious clinical features might have been present at the time of testing. When the referring clinician has recognised these features it is possible that the test situation may be handled as a diagnostic confirmation. A particular issue in myotonic dystrophy exists for the mothers of children suspected of having congenital myotonic dystrophy, who may be tested as part of their child's diagnosis, whereas for the mother, the situation is likely to be presymptomatic. Example 1 illustrates this.

Example 1 illustrates the difficulty in disclosing the diagnosis in minimally affected subjects with no subjective complaints and who are not familiar with the disorder. The reaction of the mother clearly shows that she was caught in a dilemma and did not have enough space to understand what was going on or to think about



**Example 1**

A 3 year old boy, accompanied by his mother, was referred by a paediatrician for evaluation of a possible genetic cause for his unexplained motor difficulties. The mother wanted to know the diagnosis in her son and the risk for further children. The family history was unremarkable. Clinical examination of the son showed reduced muscle tone and slight developmental delay. The mother had grip myotonia on examination, but had not previously regarded it as abnormal. She stated that she and her son both slept without fully closing their eyes. For the clinical geneticist involved, the diagnosis of myotonic dystrophy was clear. A possible clinical connection between the symptoms of both were discussed and blood was taken for molecular testing for myotonic dystrophy from the mother only. At the second appointment, the test result, which confirmed the diagnosis in the mother, was discussed. The mother was very upset about the result and a pause for reflection was necessary before testing the son. At the third appointment, all medical and reproductive implications were discussed in detail and blood was taken from the son for molecular analysis. The result showed an abnormal expansion.

her own health. The diagnosis became shifted towards herself although the clinical request had concerned her son. For the clinician, the mother's situation appeared diagnostic. The view of the authors, however, is that as such people consider themselves healthy, a presymptomatic rather than diagnostic approach seems more appropriate. This means that there is a need for information and counselling before molecular testing. It seems appropriate to answer first the question of the diagnosis in the child and postpone the blood sampling in the mother until she is informed, prepared, and supported.

No instance of presymptomatic testing of a healthy young child was recorded in our series, the youngest being aged 16 years. In general, the policy recommended for late onset disorders was followed<sup>6</sup> with full discussion, clinical assessment where required, but with postponing of genetic testing until an age was reached where the implications of testing could be understood and consent given.

In general, this policy was understood and supported by parents, but in a small number of cases a strong and persistent wish for testing of a healthy child was expressed, as outlined in example 2.

Example 2 shows how perceived barriers can interfere with full appreciation of the issues involved in a difficult situation. One possible explanation of the outcome might be that removal of the perceived barrier allowed a fuller understanding of the potential problems, even though these had been repeatedly explained on previous occasions.

A final counselling issue requiring mention relates to the potential need for disclosure of genetic test results in relation to insurance, a

**Example 2**

Presymptomatic testing was requested for a 1 year old child by the mother on account of a family history of myotonic dystrophy in the child's father. At the time of the consultation, the parents had separated and it was not possible to determine whether or not the father was clinically affected, though the diagnosis of myotonic dystrophy in other family members was clear. The child was healthy and developing normally; clinical examination was offered and was entirely normal. It was explained that in view of this, it would be wise for presymptomatic testing to be postponed until the child was of an age to consent and annual review was offered. Despite this, the mother remained determined that the child should be tested, although recognising the issues of the child being unable to consent and that there were no specific medical or other benefits from childhood testing. The mother and child were seen on three further occasions, with the mother's demand unchanged despite normal clinical assessments. Following discussion between the professionals involved, it was considered that the issue of testing was itself becoming a significant problem that might outweigh any disadvantages. Four years after the initial consultation, testing of the child was offered, again in the context of full explanation of the potential consequences, and the mother was requested to bring the child at a convenient time for a blood sample to be taken. She did not return and has not requested testing of the child over the subsequent two years.

topic of considerable debate in the UK and elsewhere. Although most of the period covered by our retrospective study predated the emergence of this issue, it is now a topic that requires discussion with people before testing. However, the small number of subjects in the series (two out of 78) who were clinically normal, yet had an abnormal test result of clinical significance to themselves, suggests that there is little need for insurers to have access to such results, and that a normal clinical assessment is a more relevant factor.

In conclusion, the counselling approach in relation to presymptomatic testing for myotonic dystrophy needs to be flexible, so as to respond to the variable and complex issues that may arise. Adherence to a two stage process does not seem required for the majority of situations, but each instance requires careful consideration and at least one full interview giving opportunity for detailed discussion of the issues would seem essential. While the retrospective nature of the present study makes it unwise to draw definitive conclusions, the issues raised should provide the starting point for further, more systematic study, as well as giving a general framework that may be useful for those involved with presymptomatic testing for this important and exceptionally variable condition.

We thank all the clinical staff of the Institute of Medical Genetics for permission to report information on their patients and, in particular, Professor Angus Clarke and Dr Helen Hughes for helpful discussions. Siv Fokstuen was supported by a grant from the Swiss Academy of Medical Sciences.

- 1 Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Stanton VP, Thirion JP, Hudson T. Molecular basis of myotonic dystrophy expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein-kinase family member. *Cell* 1992;**68**:799-808.
- 2 Gennarelli M, Novelli G, Andreasi BF, Martorell L, Cornet M, Menegazzo E, Mostacciolo ML, Martinez JM, Angelini C, Pizzuti A, Baiget M, Dallapiccola B. Prediction of myotonic dystrophy clinical severity based on the number of intragenic (CTG)<sub>n</sub> trinucleotide repeats. *Am J Med Genet* 1996;**65**:342-7.
- 3 Huntington's Disease Collaboration Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell* 1993;**72**:971-83.
- 4 International Huntington's Association and World Federation of Neurology. Guidelines for the molecular genetic predictive test in Huntington's disease. *J Med Genet* 1994;**31**:555-9.
- 5 Fokstuen S, Myring J, Meredith L, Ravine D, Harper PS. Eight years experience of direct molecular testing for myotonic dystrophy in Wales. *J Med Genet* 2001;**38**:e42.
- 6 Advisory Committee on Genetic Testing. *Genetic testing for late onset disorders*. London: Department of Health, 1997.
- 7 Harper PS, Lim C, Craufurd D. Ten years of presymptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium. *J Med Genet* 2000;**37**:567-71.
- 8 Brunner HG, Smeets HJM, Nillesen W, Van Oost BA, Van Den Biezenbos JBM, Joosten EDMG, Pinckers AJLG, Hamel BCJ, Theeuwes ADGM, Wieringa B, Ropers HH. Myotonic dystrophy predictive value of normal results on clinical examination. *Brain* 1991;**114**:2303-11.
- 9 Reardon W, Floyd JL, Myring J, Lazarou LP, Meredith AL, Harper PS. Five years experience of predictive testing for myotonic dystrophy using linked DNA markers. *Am J Med Genet* 1992;**43**:1006-11.
- 10 Harper PS. *Myotonic dystrophy*. 3rd ed. London: Saunders, 2001.

## website extra

The accompanying paper<sup>6</sup> can be found on our website

[www.jmedgenet.com](http://www.jmedgenet.com)

# Trinucleotide repeat contraction: a pitfall in prenatal diagnosis of myotonic dystrophy

Jeanne Amiel, Valérie Raclin, Jean-Marie Jouannic, Nicole Morichon, H el ene Hoffman-Radvanyi, Marc Dommergues, Josu e Feingold, Arnold Munnich, Jean-Paul Bonnefont

**EDITOR**—Myotonic dystrophy (DM) is a common autosomal dominant disorder characterised by myotonia, muscle weakness, ECG abnormalities, cataracts, hypogonadism, and frontal balding in the typical adult form (MIM 160900). The genetic defect consists of the amplification of an unstable CTG trinucleotide repeat in the 3' untranslated region of the dystrophin myotonia protein kinase gene (*DMPK*), which maps to 19q13.3.<sup>1,2</sup> Normal subjects have five to 37 repeat copies while affected subjects have over 50 repeats.<sup>1</sup> There is some correlation between repeat length and clinical symptoms, especially with respect to the age at onset.<sup>3-6</sup> In the vast majority of cases, the number of repeats increases during parent-offspring transmission of the mutant allele, thus providing some molecular basis to the observation of anticipation (increased severity of the disease in successive generations).<sup>7,8</sup> However, a decrease in repeat size is occasionally observed in the offspring, mostly in the case of paternal transmission of an expansion of over 600 trinucleotide repeats,<sup>9</sup> but contraction of a parental expanded repeat back to the normal range when transmitted to offspring seems to be an extremely rare phenomenon.<sup>10-12</sup> Here we report such a case and emphasise the direct impact of this situation on prenatal diagnosis (PND) of DM.

## Material and methods

### PATIENTS

DM was diagnosed in II.2 (fig 1), who presented with mild atrophy of the head and neck muscles, myotonia of the hands, and frontal balding at the age of 37 years, while his first wife (II.1) was pregnant. The sister of patient II.2 (II.4) was more severely affected, with marked impairment

of walking from the age of 43 years. Their father, I.2, had no symptoms of DM at the age of 61 years. III.1, the first offspring of II.2, was severely affected with muscular weakness and mental retardation. II.2 was first referred to our unit during the pregnancy of his second wife (II.3) for first trimester PND.

### METHODS

DNA was extracted from leucocytes of II.2 and II.3 and from CVS performed at 11 menstrual weeks. Study of the CTG repeat size was carried out by Southern blotting (*EcoRI/PM10M6* and *PstI/PM10M6*)<sup>13</sup> and PCR amplification with primers flanking the CTG repeat in parental and fetal DNA.<sup>1</sup> Poly (CA) microsatellite markers were used both for linkage analysis at the DM locus and to rule out false paternity (D19S223, D19S412, D19S606, D19S596, D19S879, D20S194, D12S78, with heterozygosity of 81, 80, 81, 53, 76, 91, and 91% respectively, data available through Genebank).

### Results

The healthy mother (II.3) had two alleles of 10 CTG repeats, while the father (II.2) displayed a wild type allele of 13 CTG repeats and a mutated allele of approximately 200 CTG repeats (figs 2 and 3). The DM allele in I.2, II.4, and III.1 had previously been estimated as approximately 60, 400, and 600 CTG repeats in size, respectively (data not shown for II.4 and III.1). PCR amplification of the CTG repeat region from the CVS DNA showed two normal alleles, a 10 trinucleotide repeat allele inherited from the mother and a 30 trinucleotide repeat allele not found in the father. Fetal DNA testing by Southern blotting failed to detect any expanded allele (fig 3). Results of the CVS DNA analysis were confirmed both by

*J Med Genet*  
2001;**38**:850-852

D epartement de  
G en etique et Unit e  
INSERM U-393,  
H opital  
Necker-Enfants  
Malades, 149 rue de  
S evres, 75743 Paris  
cedex 15, France


J Amiel  
V Raclin  
N Morichon  
J Feingold  
A Munnich  
J-P Bonnefont

Maternit e, H opital  
Necker-Enfants  
Malades, Paris, France  
J-M Jouannic  
M Dommergues


Service de Biochimie,  
H opital Ambroise  
Par e, Boulogne,  
France  
H Hoffman-Radvanyi

Service de Biochimie  
B, H opital  
Necker-Enfants  
Malades, Paris, France  
J-P Bonnefont

Correspondence to:  
Dr Bonnefont,  
[bonnefont@necker.fr](mailto:bonnefont@necker.fr)



**Figure 1** Linkage analysis at the *DMPK* locus in I.2, II.2, II.3, and III.3. The poly (CA) microsatellite markers used and genetic distances are as follows: cen - *D19S223* - (4.2 cM) - *D19S217* - (2.1 cM) - *D19S412* - (6.3 cM) - *D19S606* - (1.4 cM) - *D19S596* - (1.3 cM) - *D19S879* - tel. The *DMPK* gene lies between *D19S217* and *D19S412*. Note that III.3 inherited the paternal DM allele. The number of CTG repeat evaluated by PCR amplification is given in parentheses.



**Figure 2** PCR amplification of the CTG repeat region. DNA analysis from three controls (C) and patients I.2, II.2, II.3 (leucocytes) and III.3 (CVS) are shown. The PCR products were loaded onto a 2% agarose gel. The estimated number of CTG repeats for both alleles for each subject is as follows: C1: 5/42, C2: 5/20, C3: 5/90, I.2: 20/60, II.2: 13/-, II.3: 10/10, III.3: 10/30. The minor PCR product, larger than the predominant product, seen in the controls, II.2, and III.3, is likely to be a non-specific PCR product.

PCR amplification of the CTG repeat region and Southern blotting of DNA extracted from cultured amniocytes. Linkage analysis in I.2, II.2, II.3, and III.3, using poly (CA) microsatellite markers flanking the *DMPK* gene, showed that the fetus had inherited the paternal DM allele (fig 1). The probability of false paternity was assessed to be less than  $10^{-3}$ . The parents were informed about this unusual situation implying some uncertainty regarding the fetal status and subsequently decided to continue the pregnancy.

## Discussion

Here we report on the contraction of a large expanded DM allele to the normal range during a father-offspring transmission. To our knowledge, this is the first case where contraction of a parental expanded allele back to the normal range has been detected during the prenatal period. No somatic mosaicism could be identified in either chorionicocytes or amniocytes. A recombination event at the DM locus appears unlikely, based on both haplotype analysis and PCR amplification of the CTG repeat, indicating that the fetus did not inherit the paternal wild type DM allele (fig 1). Such a contraction of a DM allele back to the normal range has seldom been reported.<sup>10-12</sup> In one case, a discontinuous gene conversion between the wild type and the DM allele was shown.<sup>11</sup> In the other three cases, as in the case reported here, this mechanism appears unlikely, because of the different numbers of CTG repeats in the father/offspring wild type alleles.<sup>10-12</sup> A contraction of the DM allele or a double recombination disrupting the CTG repeats is a possibility. These events could be either meiotic or early mitotic. It is worth mentioning that in all cases reported to date, the contraction event was paternal in origin, making the hypothesis of a meiotic event more likely. In one case, long term follow up established that the offspring remained asymptomatic at or beyond the age of disease onset in the transmitting parent, also favouring the hypothesis of a meiotic event.<sup>9</sup> Understanding when and how the contraction event occurs would be of importance to appreciate both the risk for the children of developing the disease and their own risk of transmission of DM to their offspring.

A partial reduction in size of a trinucleotide repeat above the normal range during parent-offspring transmission seems to be far more frequent than a reduction back to the normal range. In a large series of 1489 DM parent-offspring pairs reported by Ashizawa *et al.*,<sup>9</sup> a partial reduction was noted in 6.4% of cases. Such a contraction was more frequently observed in paternal than in maternal transmissions (10% versus 3%, respectively).<sup>9</sup> In these cases, the size of the parental DM allele varied from approximately 500 to 1000-1500 CTG repeats. Interestingly, the observed number of sibships whose members had inherited a contracted CTG repeat was greater than expected. This could argue either for a predisposition to reduction during transmission of an expanded allele in some subjects or for negative selection against sperm carrying the largest CTG expansions. This last hypothesis has been raised in FRAXA, where males carrying a full mutation in their somatic cells transmit only premutated alleles to their daughters (MIM 309550).<sup>14</sup>

While expansion of a mutated DM allele during parent-offspring transmission is almost invariably associated with clinical anticipation, the rare events of contraction raise difficult issues with respect to PND and genetic counselling in DM. In the large series of Ashizawa *et al.*,<sup>9</sup>






Figure 3 Southern blotting (*EcoRI/PM10M6*) in patients III.3, II.3, I.2, and II.2. The expanded allele in II.2 is not found in his offspring III.3.

approximately half of the offspring who inherited a contracted allele showed clinical anticipation despite the reduced CTG repeat size. In all these cases, however, the size of the contracted allele remained above the normal range. Moreover, Southern blot analysis showed some overlap between the boundaries of the “smear” in some parent-offspring pairs. Conversely, in the four cases where the transmitted DM allele reverted to the normal range, the clinical phenotype seemed to be normal, taking into account the absence of data regarding long term follow up in these cases.<sup>9-12</sup>

Taken together, these data strengthen the well known fact that direct analysis of fetal DNA should be used as the primary approach in PND, since a reliable prediction of the seriousness of the phenotype cannot be based upon haplotyping using polymorphic markers linked to the *DMPK* locus. Moreover, the detection of a contraction event in a fetus by Southern blotting warrants further molecular investigations in order to assess the size of the CTG repeat accurately. Indeed, while detection of a DM allele remaining above the normal

range does not preclude clinical anticipation, the observation of a contracted allele back to normality should allow reassurance of couples at risk for transmitting DM.

- Buxton J, Shelbourne P, Davies J, Jones C, Van Tongeren T, Aslanidis C, de Jong P, Jansen G, Anvret M, Riley B, Williamson R, Johnson K. Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy. *Nature* 1992;355:547-8.
- Harley HG, Rundle SA, Reardon W, Myring J, Crow S, Brook JD, Harper PS, Shaw DJ. Unstable DNA sequence in myotonic dystrophy. *Lancet* 1992;339:1125-8.
- Suthers GK, Huson SM, Davies KE. Instability versus predictability: the molecular diagnosis of myotonic dystrophy. *J Med Genet* 1992;29:761-5.
- Tsilfidis C, MacKenzie, AE, Mettler G, Barcelo J, Korneluk RG. Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy. *Nat Genet* 1992;1:192-5.
- Harley HG, Rundle SA, MacMillan JC, Myring J, Brook JD, Crow S, Reardon W, Fenton I, Shaw DJ, Harper PS. Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. *Am J Hum Genet* 1993;52:1164-74.
- Hamshere MG, Harley H, Harper P, Brook JD, Brookfield JF. Myotonic dystrophy: the correlation of (CTG) repeat length in leucocytes with age at onset is significant only for patients with small expansions. *J Med Genet* 1999;36:59-61.
- Harper PS, Harley HG, Reardon W, Shaw DJ. Anticipation in myotonic dystrophy: new light on an old problem. *Am J Hum Genet* 1992;51:10-16.
- Lavedan C, Hofmann-Radvanyi H, Shelbourne P, Rabes JP, Duros C, Savoy D, Dehaupas I, Luce S, Johnson K, Junien C. Myotonic dystrophy: size- and sex-dependent dynamics of CTG meiotic instability, and somatic mosaicism. *Am J Hum Genet* 1993;52:875-83.
- Ashizawa T, Anvret M, Baiget M, Barcelo JM, Brunner H, Cobo AM, Dallapiccola B, Fenwick RG Jr, Grandell U, Harley H, Junien C, Koch ME, Korneluk RG, Lavedan C, Miki T, Mulley JC, López de Munain A, Novelli G, Roses AD, Seltzer WK, Shaw DJ, Smeets H, Sutherland GR, Yamagata H, Harper PS. Characteristics of intergenerational contractions of the CTG repeat in myotonic dystrophy. *Am J Hum Genet* 1994;54:414-23.
- Shelbourne P, Winqvist R, Kunert E, Davies J, Leisti J, Thiele H, Bachmann H, Buxton J, Williamson B, Johnson K. Unstable DNA may be responsible for the incomplete penetrance of the myotonic dystrophy phenotype. *Hum Mol Genet* 1992;1:467-73.
- O'Hoy KL, Tsilfidis C, Mahadevan MS, Neville CE, Barcelo J, Hunter AG, Korneluk RG. Reduction in size of the myotonic dystrophy trinucleotide repeat mutation during transmission. *Science* 1993;259:809-12.
- Brunner HG, Jansen G, Nillesen W, Nelen MR, de Die CE, Howeler CJ, van Oost BA, Wieringa B, Ropers HH, Smeets HJ. Brief report: reverse mutation in myotonic dystrophy. *N Engl J Med* 1993;328:476-80.
- Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Stanton VP, Thirion JP, Hudson T, John R, Zemelman B, Snell RG, Crow S, Davies J, Shelbourne P, Buxton J, Jones C, Juvenon V, Johnson K, Harper PS, Shaw DJ, Housman DE. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. *Cell* 1992;68:799-808.
- Mandel JL. Questions of expansion. *Nat Genet* 1993;4:8-9.

## Psychological studies in Huntington's disease: making up the balance

Magdalena Duisterhof, Rutger W Trijsburg, Martinus F Niermeijer, Raymund A C Roos, Aad Tibben

EDITOR—Huntington's disease (HD) is an incurable neurodegenerative disease, characterised by involuntary movements, changes in behaviour and personality, and cognitive impairment, leading to death 15 to 20 years after its onset.<sup>1</sup> HD is an autosomal dominantly inherited disorder, the gene for which is localised on the short arm of chromosome 4.<sup>2</sup> Subjects carrying the gene will develop the disease in the absence of other causes of death. The

mean age of onset is 40 years, by which time gene carriers may have passed on the gene to their offspring. The age of onset ranges from 2 to 75 years<sup>3</sup> so that those at risk (that is, risk carriers at 50% or 25% genetic risk) can never be sure of having escaped HD.

Since 1986, presymptomatic DNA testing using genetic linkage analysis has made it possible for risk carriers to have their risk modified to approximately 98% or 2%. After

*J Med Genet*  
2001;38:852–861

**Department of  
Medical Psychology  
and Psychotherapy,  
Erasmus University  
Medical Centre  
Rotterdam, Dr  
Molewaterplein 50,  
Room CF 226, 3015 GE  
Rotterdam, The  
Netherlands**  
M Duisterhof  
R W Trijsburg  
A Tibben

**Department of Clinical  
Genetics, Erasmus  
University Medical  
Centre Rotterdam,  
Rotterdam, The  
Netherlands**  
M F Niermeijer  
A Tibben

**Department of  
Neurology, Leiden  
University Medical  
Centre, Leiden, The  
Netherlands**  
R A C Roos  
A Tibben

Correspondence to: Dr  
Duisterhof,  
duisterhof@mpp.fgg.eur.nl

identification of the HD gene mutation in 1993, CAG repeat size analysis of the huntingtin gene allowed complete certainty of either having or not having HD.<sup>2</sup>

Risk carriers, being raised in a family in which HD played a major role, could be expected to have specific adjustment problems. Yet, only one study addressed the psychological functioning of people at risk for HD before presymptomatic testing was introduced. Most psychological studies were started when clinicians and researchers became concerned about the effects of a presymptomatic test on people at risk.

The aim of this article is to review studies addressing psychological and psychiatric adjustment of people at risk for HD. The methods used by the studies (that is, objectives, inclusion and exclusion criteria, recruitment, assessment, design, and statistical analyses) and their results are presented. General trends and limitations of the present work are described and a direction for future research is presented.

The term “carriers” is used to designate all subjects who underwent linkage or mutation analysis and were found to have an increased risk or were identified with a pathological repeat length of the *IT15* huntingtin gene. The term “non-carriers” denotes those with a decreased risk result or those having a normal repeat size of the *IT15* gene.

### Methods

A search of published reports was conducted in the MEDLINE and PsycLIT databases using the keywords “Huntington’s disease”, “psychological”, “psychiatric”, “predictive testing”, “adjustment”, and “family”. Cross references in identified papers were also used. Quantitative studies on the psychological wellbeing of those at risk were included; this could be conducted by

questionnaire or by interview. Studies addressing attitudes are included when they indirectly refer to wellbeing in the pre- and/or post-test period. Case descriptions or clinical impressions were excluded from this analysis as well as neurological and pharmacological studies.

### Results

A total of 18 articles provided a quantitative analysis on the wellbeing of subjects at risk for HD.<sup>4–21</sup> Characteristics of the studies are summarised in table 1.

#### STUDY OBJECTIVES

Before predictive testing became possible, Folstein *et al*<sup>11,12</sup> analysed psychological characteristics and psychiatric disorders among the offspring of HD patients and other at risk people. The pre- to post-test adjustment of carriers and non-carriers was evaluated in seven studies.<sup>5,9,14,15,19–21</sup> Attitudes, indirectly referring to wellbeing, before test disclosure<sup>4</sup> or in the post-test period were addressed in four studies.<sup>4,6,16,18</sup> A few studies also compared adjustment in test applicants with adjustment in their partners.<sup>15,16,18,20</sup> In order to identify those subjects who were at risk for poor adjustment after the test, predictive studies were introduced.<sup>7,8,10,13,17</sup>

#### INCLUSION AND EXCLUSION CRITERIA

In the study of Folstein,<sup>12</sup> subjects at 50% and 25% risk were included. Folstein *et al*<sup>11</sup> included offspring (aged 15 years and older) of HD patients. Exclusion criteria were not reported in these studies.

Studies on adaptation after testing for HD had comparable criteria for inclusion in pre- and post-test studies: people aged over 18 years and at risk for HD. Exclusion criteria were: having symptoms of HD, a severe depression or

Table 1 Studies of psychological functioning of HD risk carriers

Study	Sample size	Carrier/ non-carrier/ uninformative*	Mean age	Measurement time	Objective	Statistical methods
Boston						
Meissen <i>et al</i> <sup>14</sup>	15	4/7/5	—	Baseline, 3 mth, 9 mth		Percentages
Vancouver						
Bloch <i>et al</i> <sup>8</sup>	51	NA	39.3	Before test	Description	Percentages
Wiggins <i>et al</i> <sup>21†</sup>	135	37/58/40	37.5	Baseline, 1 wk, 6 mth, 12 mth	Course	ANOVA, Kruskal-Wallis test
Lawson <i>et al</i> <sup>13‡</sup>	135	37/58/40	37.5	Baseline, 1 wk, 6 mth, 12 mth	Prediction, description	<i>t</i> tests or Mann-Whitney U tests, chi-square test
Baltimore						
Folstein <i>et al</i> <sup>11</sup>	112	NA	26.7	NA	Description	Percentages, chi-square test
Brandt <i>et al</i> <sup>6</sup>	55	12/30/13	35.4	Baseline, 3 mth, 6 mth, 9 mth, 12 mth	Description, baseline, course	Percentages
Folstein <sup>12</sup>	147/161	NA	—	NA	Description	Clinical impressions
Codori and Brandt <sup>6</sup>	68	17/51	37.7	8 visits in 3 y after test	Description	Percentages
Codori <i>et al</i> <sup>7</sup>	160	52/108/—	34.4	Baseline, 3 mth, 6 mth, 9 mth, 12 mth	Prediction	F tests
Rotterdam/Leiden						
Tibben <i>et al</i> <sup>6</sup>	18	9/9	35.9	12 mth	Description	Percentages, clinical impressions
Tibben <i>et al</i> <sup>17‡</sup>	63	29/44	31.6	Baseline, 6 mth	Prediction	Backward regression analysis
Tibben <i>et al</i> <sup>18‡</sup>	63	24/39	31.6	6 mth	Description	Percentages
Tibben <i>et al</i> <sup>19‡</sup>	73	29/44	32.1	Baseline, 1 wk, 6 mth	Course	MANOVA
Tibben <i>et al</i> <sup>20‡</sup>	49	20/29	32.2	Baseline, 1 wk, 6 mth, 3 y	Course	MANOVA
DudokdeWit <i>et al</i> <sup>9§</sup>	25	9/16	39.5	Baseline, 1 wk, 6 mth	Course	MANOVA
DudokdeWit <i>et al</i> <sup>10§</sup>	25	9/16	39.5	Baseline, 6 mth	Prediction	Multiple regression analysis
Leuven						
Decruyenaere <i>et al</i> <sup>8</sup>	53	22/31	34	Baseline, 1 mth, 12 mth	Prediction, course	Multiple regression analysis, <i>t</i> tests
Indianapolis						
Quaid and Wesson <sup>15</sup>	19	5/14	36.9	Baseline, 3 mth, 6 mth, 9 mth, 12 mth	Comparison of groups	Mann-Whitney U test

\*Genetic status not assessable in linkage test.

†‡§Same population.

NA: not applicable.



Table 2 Descriptive/course studies: used questionnaires

Study	Questionnaires
Vancouver	
Bloch <i>et al</i> <sup>8</sup>	SCL-90-R (GSI), BDI, GWS (MHI), Behaviour Survey, Reasons for Living Scale, AQ
Wiggins <i>et al</i> <sup>21</sup>	SCL-90-R (GSI), BDI, GWS
Baltimore	
Brandt <i>et al</i> <sup>9</sup>	SCL-90-R, BDI, BHS, MCMI-2
Codori and Brandt <sup>6</sup>	Nine items regarding effects of test result
Folstein <sup>12</sup>	EPI, GHQ-30
Folstein <i>et al</i> <sup>11</sup>	—
Boston	
Meissen <i>et al</i> <sup>14</sup>	BDI
Rotterdam/Leiden	
Tibben <i>et al</i> <sup>16</sup>	AQ, BHS
Tibben <i>et al</i> <sup>18</sup>	AQ
Tibben <i>et al</i> <sup>19</sup>	BHS, GHQ-60, IES
Tibben <i>et al</i> <sup>20</sup>	BHS, IES
DudokdeWit <i>et al</i> <sup>7</sup>	IES
Indianapolis	
Quaid and Wesson <sup>15</sup>	SCL-90-R (GSI, PSDI, PST), BDI, BHS, GWS (MHI), Life Satisfaction Index

Abbreviations are shown in the Appendix.

other major psychiatric illness, or, by history, being at risk for suicide (Baltimore Group, USA,<sup>23</sup> Boston, USA,<sup>14</sup> Indianapolis, USA,<sup>24</sup> Leuven Group, Belgium,<sup>25</sup> Rotterdam/Leiden Group, The Netherlands,<sup>26</sup> Vancouver Group, Canada<sup>27</sup>). In the study by Meissen *et al*,<sup>14</sup> secondary exclusion criteria were: a recently experienced stressful event, moderate depression, a suicide attempt more than 10 years before testing, or a family history of suicide.<sup>14</sup> The Leuven group included risk carriers with a psychiatric history, provided that social support was available and that the risk carriers were receiving psychiatric treatment (M Decruyenaere, 1999, personal communication).

Postponement or exclusion from testing were reported for various reasons: because of manifest symptoms of HD (n=4<sup>4</sup> and 10<sup>5</sup>), severe depression (n=3,<sup>6</sup> 1,<sup>14</sup> and 3<sup>23</sup>), and evaluation by a psychiatrist (n=2<sup>14</sup>). These exclusion criteria were not applied in any of the studies of Decruyenaere, DudokdeWit, and Tibben *et al* (personal communications, 1999).

#### RECRUITMENT

In the studies unrelated to presymptomatic testing, offspring of patients were asked to participate in the study and were identified either through a survey of HD patients in Maryland<sup>11</sup> or when they visited the Baltimore Huntington's Disease Project Research Clinic with questions concerning their own and/or parents' future.<sup>12</sup>

Psychological pre- and post-test follow up was offered on a research basis, by requesting

informed consent from presymptomatic test participants. Information on the availability of the presymptomatic testing reached risk carriers through the Newsletters of the HD Society, the general practitioner, neurologist, clinical genetics service, relatives, or the public networks. Pre-test written information was provided in several centres. General information was mailed to all 50% risk carriers in one group.<sup>15</sup> The Vancouver Group mailed a description of the research project to all families on the HD registry, requesting them to contact the researcher.<sup>27</sup>

#### ASSESSMENT OF PSYCHOLOGICAL ADAPTATION

Wellbeing was assessed through self-report questionnaires and by means of interviews. The questionnaires used are summarised in tables 2 and 3. Folstein *et al*<sup>11</sup> performed psychiatric examination by means of a structured interview, the Diagnostic Interview Schedule (DIS), which yields diagnoses according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-III); an independent psychiatric interviewer validated these diagnoses. In other studies, the interviews provided additional information to the self-report questionnaires. Brandt *et al*<sup>9</sup> administered the Schedule of Affective Disorders and Schizophrenia (SADS)-Change Interview<sup>28</sup> to assess at least moderate to severe symptoms in one or more domains. Lawson *et al*<sup>13</sup> asked counsellors and clinicians to indicate participants who had experienced adverse events, for example, a suicide attempt or the formulation of a suicide plan, psychiatric hospitalisation, depression lasting longer than two months, a marked increase in substance abuse, or the breakdown of important relationships. Tibben *et al*<sup>16</sup> evaluated feelings and cognition in carriers and non-carriers and their partners.

The design and statistical analyses of the investigated studies are summarised in table 1.

#### Results of reviewed studies

##### STUDIES UNRELATED TO PRESYMPTOMATIC TESTING

Children of HD patients had a high rate of psychiatric disorder (25% conduct disorder or antisocial personality disorder, 18% major depression).<sup>11</sup> Most conditions (anxiety and depression) were mild or occurred only in adolescence (conduct disorder).<sup>12</sup> Introversion/

Table 3 Outcome variables and predictor variables in studies predicting psychological well being

Study	Predictor variables	Outcome variables
Tibben <i>et al</i> <sup>17</sup>	Intrusion (IES), avoidance (IES), hopelessness (BHS), psychopathological states (GHQ), social support (SSQ)	Intrusion (IES), avoidance (IES), hopelessness (BHS)
Decruyenaere <i>et al</i> <sup>8</sup>	General anxiety (STAI trait), situational anxiety (STAI state), depression (BDI), ego strength (MMPI), coping styles (UCL)	General anxiety (STAI trait), situational anxiety (STAI state), depression (BDI), ego strength (MMPI)
Codori <i>et al</i> <sup>7</sup>	Genetic status, gender, marital status, parenting status, risk perception, estimated years to onset of HD in those testing positive	Hopelessness (BHS), depression (BDI)
Lawson <i>et al</i> <sup>13</sup>	Global Severity Index (SCL-90), depression (BDI), social support (SSQ), adverse events questionnaire	Adverse events*
DudokdeWit <i>et al</i> <sup>10</sup>	Intrusion (IES), avoidance (IES), anxiety (HADS), depression (HADS), psychological problems (SCL-90), hopelessness (BHS), loneliness (loneliness scale), social support (SSQ), family functioning (FACES), gender, age, religion, marital status, parenting status	Intrusion (IES), avoidance (IES)

\*A suicide attempt or the formulation of a suicide plan, psychiatric hospitalisation, depression lasting longer than two months, a marked increase in substance abuse, the breakdown of important relationships, increases on BDI and or GSI (SCL-90).  
For abbreviations see table 2.

extraversion and neuroticism were similar to those in the general population.<sup>12</sup>

#### DESCRIPTIVE STUDIES RELATED TO PRESYMPTOMATIC TESTING

##### ***Psychological wellbeing of test applicants before disclosure of test result***

The mean scores of psychological wellbeing and Huntington specific distress before disclosure of the test result (baseline level) fell within the normal range.<sup>4 5 7 9 19-21</sup> In the Dutch studies,<sup>19 29</sup> the mean scores of risk carriers indicated mild signs of hopelessness; this could not be confirmed in other studies.<sup>7 15</sup> Approximately 20% of the risk carriers scored at mild levels of depression and hopelessness, whereas very few scored at the level of moderate or severe depression.<sup>4</sup> For about 20% of the risk carriers, their scores on the GHQ-60 indicated the possible presence of psychiatric morbidity.<sup>19 30</sup>

Most test applicants had a normal psychological profile.<sup>31</sup> In comparison to the general population, they were more socially extraverted, had higher ego strength, and reacted more with active coping, palliative coping, social support seeking, and comforting ideas.

Later identified carriers and non-carriers did not differ in general wellbeing and Huntington specific distress.<sup>5 8 9 15 19-21</sup>

##### ***Course of psychological wellbeing after the test result***

###### *General measures of psychological wellbeing and Huntington specific distress*

Analysis of distress in identified gene carriers at seven days post-test showed more depression, hopelessness, and a decrease in general wellbeing.<sup>5 8 19-21</sup> However, their mean scores remained in the mild range. A return to baseline levels of anxiety and depression occurred in the first month.<sup>8</sup> Hopelessness, depression, and general wellbeing returned to baseline level within six months<sup>5 19 21</sup> and remained there one and three years post-test.<sup>8 20 21</sup> Although not differing from baseline, Wiggins *et al*<sup>21</sup> found linear declines for distress and depression over a 12 month period. Only Brandt *et al*<sup>7</sup> reported a slight increase in general distress after one year. However, because the dropout rate in their sample was extremely high (75%), this finding should be interpreted with caution.

The non-carriers were more optimistic regarding their future at seven days post-test; however, this more positive view of the future disappeared after six months and three years.<sup>18 20</sup> On the other hand, anxiety and depression decreased from baseline one month and one year after the test result.<sup>8</sup> Also, general distress, assessed by means of the GSI index, decreased in the first year after the test result.<sup>5 21</sup>

In comparison to carriers, non-carriers reported less general distress, less depression, less hopelessness, and a greater sense of wellbeing one week after the test result.<sup>19 21</sup> This difference disappeared in the first year. At six months follow up, only general wellbeing

was significantly greater for the non-carriers, but this difference disappeared at 12 months up to three years after the test result, returning to baseline level.<sup>8 21 32</sup> Only Quaid and Wesson<sup>15</sup> found a higher general wellbeing for carriers than non-carriers after 12 months.

In comparison to a “no change” group, consisting of 23 subjects who did not want to take the test and 17 subjects for whom the test was uninformative, both carriers and non-carriers scored lower for depression and higher for wellbeing.<sup>21</sup> However, it cannot be inferred from these findings that testing has benefits, since particularly an uninformative result can lead to an increase in distress, the wish for certainty about carrier status being frustrated.

A subgroup of both carriers and non-carriers had difficulties adjusting to their new carrier status. About 10-20% of both carriers and non-carriers showed psychological problems in the post-test period.<sup>8 13 16 19 21 32 33</sup> Interviews with carriers, three months after the result, indicated that half of the carriers had periods of severe depression, whereas the other half had suffered moderate depression.<sup>14</sup> Therapists identified a minority of carriers and non-carriers as having psychiatric symptoms in the first year after the test.<sup>5</sup> However, very few people committed or attempted suicide or needed psychiatric hospitalisation after predictive testing.<sup>34</sup>

With regard to Huntington specific distress, carriers showed a slight increase of avoidance behaviour in the first six months, which returned to baseline level after three years.<sup>20</sup> Non-carriers showed a decrease in avoidance during the first six months post-test,<sup>9 19</sup> which returned to baseline level at the three year follow up.<sup>20</sup> For both groups, intrusive thoughts decreased in the first six months,<sup>9 19</sup> whereas these increased to baseline level at the three year follow up.<sup>20</sup>

The observations by Lawson *et al*<sup>13</sup> underline the general impression that both carriers and non-carriers have problems in adapting to the test result, but at different moments in time. The number of adverse events was similar for carriers and non-carriers. For the carriers, adverse events took place within 10 days after the test result, whereas for non-carriers adverse events occurred six months after the result or later. Seventy percent of these events were identified by clinical criteria, that is, suicidal ideation, depression lasting longer than two months, substance abuse, or a breakdown of an important relationship, either alone or in conjunction with a raised score on one or more questionnaires.<sup>13</sup>

###### *Attitudinal studies regarding the test result*

Before a test result was given, risk carriers expressed concern about the future and guilt about the possibility of passing on the gene.<sup>4</sup> After six months, half of the carriers stated that the results had not influenced their lives and half of them also rarely thought of the result, indicating that denial plays a role.<sup>18</sup> The non-carriers expressed relief in the first weeks after the test result was given, but after six months half of the non-carriers appeared to

deny the impact of the test result, as was reflected by absence of relief and emotional numbness.<sup>18</sup> Some of them have expressed survivor guilt.<sup>6 16</sup>

#### *Comparison of at risk population and partners*

At baseline, spouses reported more depression than their at risk partners,<sup>15</sup> whereas hopelessness was comparable for carriers and their partners.<sup>16</sup> During the three year follow up, carriers and their partners showed similar patterns of avoidance, intrusion, and hopelessness, whereas non-carrier partners reported less avoidance, intrusion, and hopelessness than the non-carriers.<sup>32</sup> After three years, partners of carriers were still showing more avoidance than partners of non-carriers. In contrast, Quaid and Wesson<sup>15</sup> found comparable distress for carrier partners and non-carrier partners in the first year after disclosure of the test result.

Whereas distress was similar for carriers and their partners, their attitudes towards the test result differed. Carriers did not report an increase in problems after they received an unfavourable test result. Their partners did mention having problems, but expressed reluctance to seek help or to talk about it with their spouse, owing to feelings of guilt and not wanting to hurt them. This was especially the case for those who became aware of the risk for HD at a later stage, for example, after marriage. For the non-carriers, most of them did not experience relief, whereas their partners did.<sup>16 18</sup>

Having children proved to be an additional stress factor for partners during and after the test procedure.<sup>20</sup> At baseline, partners with children were significantly more hopeless than partners without children. One week after the test, carrier partners with children reported significantly more hopelessness, avoidance thoughts, and intrusive feelings than carrier partners without children. At six months and three years after the test, this difference in avoidance thoughts and intrusive feelings was sustained.

#### *Prediction of wellbeing*

Five studies aimed to identify pre-test variables that predict the way subjects adapt to their test result<sup>7 8 10 13 17</sup> (for the variables see table 3).

#### *Test result*

In general, test outcome did not predict psychological adjustment. Only Codori *et al*<sup>7</sup> found carriers to be more likely to be pessimistic about their future than non-carriers.

#### *General and Huntington specific distress*

The level of psychological adaptation after the test (anxiety, depression, hopelessness, intrusion, and avoidance) was predicted by the same measures at baseline.<sup>7 8 10 17</sup> The more depressive symptoms reported at baseline, the more distress subjects reported at the one year follow up, and the greater the chances that they were rated as having experienced an adverse event, as defined by Lawson *et al*.<sup>13</sup> Pessimism, a low avoidance, and dissatisfaction with available support at the moment of testing predicted

pessimism at six months.<sup>17</sup> Those severely anxious before the test were more likely to show low intrusion six months after disclosure.

#### *Biographical variables*

Having children predicted post-test intrusion and hopelessness.<sup>7 10</sup> Women showed more intrusion and avoidance than men six months after disclosure of the test result.<sup>10</sup> For carriers, being married or having children predicted hopelessness, as did the estimated years to onset of HD.<sup>7</sup>

#### *Social support*

Subjects who were satisfied with the perceived quality of support of others felt less hopeless after either test result.<sup>17</sup> The more pre-test avoidance and the less satisfaction with available support, the more avoidance behaviour was reported six months post-test.<sup>17</sup> However, the larger the number of persons perceived as being supportive before the test, the more avoidance was reported post-test.<sup>10</sup>

#### *Risk perception*

Risk perception refers to the expectations one has about the test result. No support was found for the hypothesis that for identified carriers, those with a low perceived risk of being a carrier would have a less favourable adjustment than persons with a high perceived risk.<sup>7</sup>

#### *Personality measures and coping strategies*

Ego strength was associated with a lower general anxiety and depression level one year after the test. Moreover, ego strength in combination with the coping strategy "comforting ideas" predicted a lower general anxiety.<sup>8</sup>

## **Discussion**

Reviewing psychological research on wellbeing in Huntington patients and those at risk showed only a few studies that were unrelated to presymptomatic testing. HD in a parent proved to have a profound impact on adolescence. A high rate of psychiatric disorders in adolescents was seen, but not among adults. Most of the research was carried out as part of the presymptomatic testing protocol. In general, wellbeing of the group of test applicants was normal before test disclosure. Both carriers and non-carriers had difficulties in adapting to the test result, but at different moments in time. Distress in carriers increased in the first weeks post-test, which returned to baseline level within one year. The relief non-carriers expressed in the first weeks disappeared afterwards; they experienced most distress at six months. Within one year, non-carriers seemed to be somewhat less distressed than they were before test disclosure, but they had not developed more optimistic future expectations.

A subgroup of both carriers and non-carriers had long lasting adaptation problems. Those reporting to be distressed before test disclosure most often had problems in adapting to the test result. Although wellbeing seemed to be independent of test outcome, wellbeing was



related to having children, certain personality traits (ego strength, coping), and the subjective estimation of the number of years before onset of HD.

These findings have been shown to be helpful in guidance and counselling of risk carriers in testing programmes. However, the research still has some serious limitations that need to be overcome for progress to be made in this research field. Limitations and a promising new direction will be discussed below.

#### STUDY POPULATION

In the study of Folstein *et al.*<sup>11</sup> 60% were not willing to participate in the study, leading to a possible underestimation of the problems of risk carriers. The study population in other studies consisted of risk carriers who visited a genetic centre and/or applied for a predictive test. The percentage of those at risk who requested testing when approached by registries or testing centres varied from 9% in Wales, 10% in Indiana, 16% in the Manchester area, to 20% in the Vancouver area.<sup>35</sup> In The Netherlands, 752 out of 1032 subjects at risk, applying for presymptomatic testing in the period 1987 to 1997, decided to be tested, which is 24% of the at risk persons registered in the Leiden Roster for HD.<sup>36</sup> It was suggested<sup>37</sup> and confirmed<sup>4 31</sup> that persons who participate in the studies on testing form a resourceful self-selected group. Those who decided not to be tested had more frequent expectations of unfavourable emotional reactions and showed more hopelessness than tested subjects.<sup>6 38</sup> On the other hand, the level of anxiety, ego strength, and coping strategies were not different between the tested and untested groups.<sup>39</sup> Also, the untested participants form a self-selected resourceful group; both tested and untested participants had a higher ego strength in comparison to the general population.<sup>31</sup> Little is known about the wellbeing of those who do not seek testing and who do not participate in psychological studies. Therefore, bias seems to be involved in the estimation of adaptation in HD risk carriers.

Although we need to be careful to generalise the findings to the whole HD population, we should take into account that differences were observed within the group of test applicants. Some subjects acknowledged the burden of HD, but saw themselves as being able to face the truth. Others denied a burden of HD in their lives and disagreed that the results had a profound impact on their lives.<sup>4 40</sup>

Moreover, the dropout rates in most follow up studies are high. Information from relatives about the wellbeing of these dropouts suggest that those who declined participation in follow up research, both carriers and non-carriers, often have serious problems they do not want to disclose, indicating that risk carriers applying for the test may have more problems than the studies suggest.

#### SELF-REPORT MEASUREMENT

Adjustment was usually assessed by means of self-report questionnaires. Interpretations of findings based on self-reporting may be

problematical because low scores on mental health questionnaires may indicate that people deny problems, trying to maintain an illusion of mental health.<sup>41</sup> Since denial may arise in reaction to stressful or traumatic experiences,<sup>42</sup> this can be expected in a testing procedure for HD. Tibben *et al.*<sup>16</sup> found that some carriers did not mention having had depressive periods in the post-test period, whereas their partners reported the opposite about them.<sup>16</sup> Moreover, test applicants were more defensive when filling out the MMPI than the general population. Also, female participants obtained a higher lie score than women in the general population.<sup>31</sup>

DudokdeWit *et al.*<sup>29</sup> introduced the possibility of assessing the manner in which participants discuss the disease, the test, and its implications in terms of coherence. Coherence refers to the ability to discuss and to reflect upon emotions, feelings, and ideas without becoming entangled in it or avoiding discussion of the subject.<sup>43</sup> DudokdeWit *et al.*<sup>29</sup> found that one third of the participants spoke incoherently about their possible inherited disease, the majority of them (two thirds) using an avoidance (dismissing) strategy, one third being entangled. It turned out that those showing avoidance reported fewer problems than those being entangled did. Dismissing subjects generally have more psychological and psychiatric problems than others do.<sup>44</sup>

These findings support the impression of clinicians and counsellors that a group of HD risk carriers who report themselves to be functioning well are in fact having difficulty with being aware of the impact of their experiences with HD on their lives, reflected in sustained numbness.<sup>10 45</sup> This numbness may reflect warding off a variety of guilt feelings, anger, resentment, and hostility towards the family and its HD history and the inability to create new life perspectives. When the reality of a situation is avoided, it cannot be integrated into one's personal life, which might lead to adaptation problems. To gain more insight into the psychological dynamics, denial and other psychological defences need to be studied; since defences are unconscious, more subtle measures are required.

#### GLOBAL MEASUREMENT

Another problem is that most measures used are global ones. The IES is the only Huntington specific questionnaire that provides insight into the process of a person's working through the situation. Research with more specific and sensitive measures is needed for assessment of the process of adjustment between and within test applicants in the post-test period.

#### THEORETICAL FRAMEWORK

Tibben *et al.*<sup>19</sup> and DudokdeWit *et al.*<sup>9</sup> used the stress response theory of Horowitz *et al.*<sup>16</sup> to formulate their hypotheses. In other studies, it is unclear which underlying theoretical assumptions are used, the design and statistics not being guided by clear hypotheses. A theoretical framework is needed to provide more insight into the observations.<sup>37 47</sup> A

psychological model or theory will contribute to our understanding about the psychological dynamics that characterise this study population.

#### LACK OF FAMILY PERSPECTIVE ON WELLBEING OF RISK CARRIERS

HD is a family disease.<sup>12</sup> The initial onset of symptoms is usually between 30 and 50 years, a period when people are raising a family. People at risk were generally familiar with the disease from early childhood, knowing the symptoms in the parent and/or other family members. Clinicians have shown how the presence of HD in a family can affect the family dynamics.<sup>48-51</sup> In some of the reviewed studies, the influence of HD on family dynamics can be inferred. Post-test studies indicated the difficult and different processes test participants and their partners go through. Marriage and career need to be reconsidered<sup>14</sup> and the necessary social support may no longer be available. Having children is an additional stress factor for both carriers and their partners.<sup>20</sup>

However, wellbeing in HD risk carriers has rarely been related to their childhood experiences. Folstein *et al*<sup>11</sup> investigated how childhood experiences contribute to a more or less favourable adaptation in later life. They found conduct disorder in adolescents and antisocial personality disorder in adults to be related to experiences of having lived in a disorganised household. No relation was found between anxiety or depression and family factors. Recently, Decruyenaere *et al*<sup>52</sup> found a low but significant correlation between the participants' age at which the parent showed the first symptoms and psychological functioning before test disclosure. Psychological adjustment to the test result was not correlated with the age of the participant at onset of HD in the parent.

To identify adjustment problems in adult risk carriers, childhood experiences and family dynamics need to be taken into account. In our opinion, the attachment theory<sup>53</sup> provides a meaningful theoretical framework for describing childhood experiences in HD families and generating hypotheses concerning the influence of childhood experiences on later adaptation.

#### ATTACHMENT THEORY

Attachment theory, developed by John Bowlby, postulates a universal human need to form close affectionate bonds. It is a normative theory of how the "attachment system" functions in all humans.<sup>54</sup> The attachment theory concerns the nature of early experiences of children, and the impact of these experiences on aspects of later functioning. The central assumption of attachment theory is that individual social behaviour may be understood in terms of generic mental models of social relationships constructed by the person.<sup>55</sup> These models, although constantly evolving and subject to modification, are strongly influenced by the child's experiences with the primary caregivers. The attachment system serves as a primary mechanism for the regulation of infant safety and survival and is highly

activated in times of danger.<sup>53</sup> An infant is considered securely attached if he or she regards the parents as people to rely on when facing a frightening situation. A responsive and sensitive way of parenting generally gives rise to a secure attachment pattern. Secure infants are able to explore new situations and to experience proximity and comfort in times of distress, illness, or tiredness. Insecure attachment is often found in those who in childhood have experienced rejection or neglect by one or both parents, or who were asked to take care of the parent instead of being taken care of.<sup>56</sup> Insecure attachment in either infancy or adulthood is related to the occurrence of psychopathology in adulthood.<sup>57</sup>

Three types of insecure attachment can be discerned. An avoidant (dismissing) attached infant shifts attention away from rejecting caregivers and minimises displays of distress. An ambivalent (preoccupied) attached infant is highly focused on the caregiver and maximises distress through insistent demands for care and attention. A third group of infants appear to exhibit a range of seemingly undirected behavioural responses giving the impression of disorganisation and disorientation.<sup>58</sup> These infants may display (momentarily) bizarre and contradictory behaviour. Frightening experiences with caregivers who behaved in threatening, frightened, or dissociated ways and experiences of loss and trauma may lead to a disorganised attachment pattern.<sup>59-60</sup> It is generally held that for such infants the caregiver has served both as a source of fear and as a source of reassurance, thus the arousal of the attachment behavioural system produces strong conflicting motivations. Not surprisingly, a history of severe neglect or physical or sexual abuse is often associated with the manifestation of this pattern.<sup>61-62</sup> It is generally held that the patterning of attachment related behaviour is underpinned by different strategies adopted by children to regulate their emotional reactions.<sup>63</sup> As affect regulation is acquired with the help of the child's primary caregiver, the child's strategy will be inevitably a reflection of the caregiver's behaviour towards him/her. Established attachment patterns or working models guide a person's response to frightening situations and interpretation of the caregiver's response.

The stability of early childhood attachment patterns is well demonstrated. During development from infancy to childhood, attachment working models become difficult to change. However, current experiences with attachment figures continue to influence the attachment working model.<sup>64-66</sup>

How can the attachment theory be relevant for people dealing with Huntington's disease? We speculate that the presence of HD in a family involves specific stressors, which might influence the attachment relationship between parents and their children for different reasons. First, the affected parent in the onset phase of HD may become preoccupied with the diagnosis, their own future, and the frightening recollections of his/her parent or other relatives going through the HD disease progression. As

the disease progresses, the patient is less receptive to the questions of the children and may become depressive or aggressive. These mood and personality changes, together with the choreic movements, may frighten or alienate their offspring.<sup>67</sup> Second, the disease may lead to changes in the family system. The unaffected parent will experience a change in responsibilities and dependency of the spouse in the relationship; the affected spouse becomes a person who insidiously needs care. Some healthy partners may feel unable to take up this task and will leave the household. Changes in the household may lead to neglect of the children. Some children may take up the care of the ill parent. The unaffected parent may seek one of the children as a substitute partner.<sup>48</sup> Third, the fact that the children are at risk for developing HD also puts stress on parent-child bonding. The parents may be concerned about the carrier status of the child and may have feelings of guilt by having passed on the gene. Knowing that their children may get the disease can also create an emotional distance.<sup>67</sup> Some parents also have predictions or even fantasies about their children, thinking that they may or may not develop HD.<sup>68</sup> The healthy parent often has the difficult task of rearing these children and informing them about their risk without the help of the partner.<sup>69-70</sup> With regard to testing, having children is an additional stress factor for the healthy parent.<sup>20</sup> To summarise, a family burdened by a genetic disorder may have to deal with several types of loss: loss of the physical capacity of the affected person, loss of his or her own personality, loss of the old family system, and loss through death. This may be accompanied by shame, secretiveness, and social isolation.

Mental representations of attachment in adults are assessed by means of the Adult Attachment Interview (AAI).<sup>71</sup> The AAI asks subjects about childhood attachment relationships and the meaning which a person currently gives to attachment experiences. The instrument is rated according to the scoring system developed by Main and Goldwyn<sup>72</sup> which classifies people into Secure/Autonomous, Insecure/Dismissing and superimposed on these Insecure/Preoccupied, Unresolved/Disorganised with respect to loss or trauma, categories according to the structural qualities of their reports of early experiences. The assessment of attachment by means of coherence<sup>43</sup> may help to overcome problems with self-report measures in previous studies. Next to the attachment representation, the Adult Attachment Interview generates information about the psychodynamics and defences in a person.

Although Huntington's disease is a highly dramatic disorder with an increased chance for children to become traumatised, we speculate that the findings are also important for other genetic disorders that have been passed on to consecutive generations. This does not need to be restricted to autosomal dominant, late onset diseases with full or partial penetrance, but also for X linked disorders and diseases with

## Appendix

AQ, Attitude Questionnaire  
 BDI, Beck Depression Inventory (BDI)<sup>76</sup>  
 BHS, Beck Hopelessness Scale (BHS)<sup>77</sup>  
 EPI, Eysenck Personality Inventory  
 FACES, Family Adaptability and Cohesion Evaluation Scales  
 GHQ, General Health Questionnaire<sup>30</sup>  
 GSI, Global Severity Index  
 GWS, General Wellbeing Scale<sup>78</sup>  
 HADS, Hospital Anxiety Depression Scale<sup>79</sup>  
 IES, Impact of Event Scale<sup>46</sup>  
 MCMI-2, Millon Clinical Multiaxial Inventory II<sup>80</sup>  
 MHI, Mental Health Index  
 MMPI, Minneapolis Multiphasic Personality Inventory<sup>81</sup>  
 PSDI, Positive Symptom Distress Index (SCL-90)  
 PST, Positive Symptom Total (SCL-90)  
 SCL-90, Symptom Checklist 90<sup>82</sup>  
 SSQ, Social Support Questionnaire  
 STAI, State Trait Anxiety Questionnaire<sup>83</sup>  
 UCL, Utrecht Coping List<sup>84</sup>

recessive inheritance patterns. There is further important evidence that attachment relationships may play a key role in the transgenerational transmission of hardship and deprivation. People categorised as secure are three or four times more likely to have children who are securely attached to them.<sup>60</sup> This turns out to be true even in prospective studies where parental attachment is assessed before the birth of the child.<sup>55-73-75</sup> These findings also emphasise the importance of quality of parenting in determining the child's attachment classification. Investigation of the attachment relationship in HD families and its influence on adult functioning may contribute to a greater understanding of earlier research findings and serve to improve genetic counselling and intervention.

- 1 Harper P. *Huntington's disease*. London: WB Saunders, 1996.
- 2 Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. *Cell* 1993;72:971-83.
- 3 Roos RA, Vegter-van der Vlis M, Hermans J, Elshove HM, Moll AC, van de Kamp JJ, Bruyn GW. Age at onset in Huntington's disease: effect of line of inheritance and patient's sex. *J Med Genet* 1991;28:515-19.
- 4 Bloch M, Fahy M, Fox S, Hayden MR. Predictive testing for Huntington disease. II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. *Am J Med Genet* 1989;32:217-24.
- 5 Brandt J, Quaid KA, Folstein SE, Garber P, Maestri NE, Abbott MH, Slavney PR, Franz ML, Kasch L, Kazazian HH. Presymptomatic diagnosis of delayed-onset disease with linked DNA markers. The experience in Huntington's disease. *JAMA* 1989;261:3108-14.
- 6 Codori AM, Brandt J. Psychological costs and benefits of predictive testing for Huntington's disease. *Am J Med Genet* 1994;54:174-84.
- 7 Codori AM, Slavney PR, Young C, Miglioretti DL, Brandt J. Predictors of psychological adjustment to genetic testing for Huntington's disease. *Health Psychol* 1997;16:36-50.
- 8 Decruyenaere M, Evers-Kiebooms G, Boogaerts A, Cassiman JJ, Cloostermans T, Demyttenaere K, Dom R, Frysns JP, Van den Berghe H. Prediction of psychological functioning one year after the predictive test for Huntington's disease and impact of the test result on reproductive decision making. *J Med Genet* 1996;33:737-43.
- 9 DudokdeWit AC, Duivenvoorden HJ, Passchier J, Niermeijer MF, Tibben A. Course of distress experienced by persons at risk for an autosomal dominant inheritable disorder participating in a predictive testing program: an explorative study. Rotterdam/Leiden Genetics Workgroup. *Psychosom Med* 1998;60:543-9.
- 10 DudokdeWit AC, Tibben A, Duivenvoorden HJ, Niermeijer MF, Passchier J. Predicting adaptation to presymptomatic DNA testing for late onset disorders: who will experience distress? Rotterdam Leiden Genetics Workgroup. *J Med Genet* 1998;35:745-54.



- 11 Folstein SE, Franz ML, Jensen BA, Chase GA, Folstein MF. Conduct disorder and affective disorder among the offspring of patients with Huntington's disease. *J Psychol Med* 1983;13:45-52.
- 12 Folstein SE. *Huntington's disease. A disorder of families*. Baltimore: The Johns Hopkins University Press; 1991.
- 13 Lawson K, Wiggins S, Green T, Adam S, Bloch M, Hayden MR. Adverse psychological events occurring in the first year after predictive testing for Huntington's disease. The Canadian Collaborative Study Predictive Testing. *J Med Genet* 1996;33:856-62.
- 14 Meissen GJ, Myers RH, Mastromauro CA, Koroshetz WJ, Klinger KW, Farrer LA, Watkins PA, Gusella JF, Bird ED, Martin JB. Predictive testing for Huntington's disease with use of a linked DNA marker. *N Engl J Med* 1988;318:535-42.
- 15 Quaid KA, Wesson MK. Exploration of the effects of predictive testing for Huntington disease on intimate relationships. *Am J Med Genet* 1995;57:46-51.
- 16 Tibben A, Vegter-van der Vlis M, Skraastad MI, Frets PG, van der Kamp JJ, Niermeijer MF, van Ommen GJ, Roos RA, Rooijmans HG, Stronks D, Verhage F. DNA-testing for Huntington's disease in The Netherlands: a retrospective study on psychosocial effects. *Am J Med Genet* 1992;44:94-9.
- 17 Tibben A, Duivenvoorden HJ, Vegter-van der Vlis M, Niermeijer MF, Frets PG, van de Kamp JJ, Roos RA, Rooijmans HG, Verhage F. Presymptomatic DNA testing for Huntington disease: identifying the need for psychological intervention. *Am J Med Genet* 1993;48:137-44.
- 18 Tibben A, Frets PG, van de Kamp JJ, Niermeijer MF, Vegter-van der Vlis M, Roos RA, Rooijmans HG, van Ommen GJ, Verhage F. On attitudes and appreciation 6 months after predictive DNA testing for Huntington disease in the Dutch program. *Am J Med Genet* 1993;48:103-11.
- 19 Tibben A, Duivenvoorden HJ, Niermeijer MF, Vegter-van der Vlis M, Roos RA, Verhage F. Psychological effects of presymptomatic DNA testing for Huntington's disease in the Dutch program. *Psychosom Med* 1994;56:526-32.
- 20 Tibben A, Timman R, Bannink EC, Duivenvoorden HJ. Three-year follow-up after presymptomatic testing for Huntington's disease in tested individuals and partners. *Health Psychol* 1997;16:20-35.
- 21 Wiggins S, Whyte P, Huggins M, Adam S, Theilmann J, Bloch M, Sheps SB, Schechter MT, Hayden MR. The psychological consequences of predictive testing for Huntington's disease. *N Engl J Med* 1992;327:1401-5.
- 22 Tibben A, Frets PG, van de Kamp JJ, Niermeijer MF, Vegter-van der Vlis M, Roos RA, van Ommen GJ, Duivenvoorden HJ, Verhage F. Presymptomatic DNA-testing for Huntington disease: pretest attitudes and expectations of applicants and their partners in the Dutch program. *Am J Med Genet* 1993;48:10-16.
- 23 Brandt J, Quaid KA, Folstein SE. Presymptomatic DNA testing for Huntington's disease. *J Neuropsychiatry Clin Neurosci* 1989;1:195-7.
- 24 Quaid K. Presymptomatic testing for Huntington disease: recommendations for counseling. *J Genet Couns* 1992;1:277-302.
- 25 Evers-Kiebooms G. Predictive testing for Huntington's disease in Belgium. *J Psychosom Obstet Gynecol* 1990;11:61-72.
- 26 Tibben A. *What is knowledge but grieving? On psychological effects of presymptomatic DNA-testing for Huntington's disease*. PhD thesis. Erasmus University, Rotterdam, 1993.
- 27 Fox S, Bloch M, Fahy M, Hayden MR. Predictive testing for Huntington disease. I. Description of a pilot project in British Columbia. *Am J Med Genet* 1989;32:211-16.
- 28 Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. *Arch Gen Psychiatry* 1978;35:837-44.
- 29 DudokdeWit AC, Tibben A, Duivenvoorden HJ, Niermeijer MF, Passchier J, Trijsburg RW. Distress in individuals facing predictive DNA testing for autosomal dominant late-onset disorders: comparing questionnaire results with in-depth interviews. *Am J Med Genet* 1998;75:62-74.
- 30 Tarnopolsky A, Hand DJ, McLean EK, Roberts H, Wiggins RD. Validity and uses of a screening questionnaire (GHQ) in the community. *Br J Psychiatry* 1979;134:508-15.
- 31 Decruyenaere M, Evers-Kiebooms G, Boogaerts A, Cassiman JJ, Cloostermans T, Demyttenaere K, Dom R, Fryns JP, van den Berghe H. Predictive testing for Huntington's disease: risk perception, reasons for testing and psychological profile of test applicants. *Genet Couns* 1995;6:1-13.
- 32 Tibben A, Roos RA, Niermeijer MF. Psychological consequences of presymptomatic testing for Huntington's disease. *Lancet* 1997;349:809.
- 33 Huggins M, Bloch M, Wiggins S, Adam S, Suchowersky O, Trew M, Klimek ML, Greenberg CR, Eleff M, Thompson LP, Knight J, MacLeod P, Girard K, Theilmann J, Hedrick A, Hayden MR. Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. *Am J Med Genet* 1992;42:508-15.
- 34 Almqvist EW, Bloch M, Brinkman R, Craufurd D, Hayden MR. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. *Am J Hum Genet* 1999;64:1293-304.
- 35 Meiser B, Dunn S. Psychological impact of genetic testing for Huntington's disease: an update of the literature. *J Neurol Neurosurg Psychiatry* 2000;69:574-8.
- 36 Maat-Kievit A, Vegter-van der Vlis M, Zoetewij M, Losekoot M, van Haeringen A, Roos RA. Paradox of a better test for Huntington's disease. *J Neurol Neurosurg Psychiatry* 2000;69:579-83.
- 37 Kessler S. Predictive testing for Huntington disease: a psychologist's view. *Am J Med Genet* 1994;54:161-6.
- 38 van der Steenstraten IM, Tibben A, Roos RA, van de Kamp JJ, Niermeijer MF. Predictive testing for Huntington disease: nonparticipants compared with participants in the Dutch program. *Am J Hum Genet* 1994;55:618-25.
- 39 Decruyenaere M, Evers-Kiebooms G, Boogaerts A, Cloostermans T, Cassiman JJ, Demyttenaere K, Dom R, Fryns JP, van den Berghe H. Non-participation in predictive testing for Huntington's disease: individual decision-making, personality and avoidant behaviour in the family. *Eur J Hum Genet* 1997;5:351-63.
- 40 Tibben A, Niermeijer MF, Roos RA, Vegter van de Vlis M, Frets PG, van Ommen GJ, van de Kamp JJ, Verhage F. Understanding the low uptake of presymptomatic DNA testing for Huntington's disease. *Lancet* 1992;340:1416.
- 41 Shedler J, Mayman M, Manis M. The illusion of mental health. *Am Psychol* 1993;48:1117-31.
- 42 Zilberg NJ, Weiss DS, Horowitz MJ. Impact of Event Scale: a cross-validation study and some empirical evidence supporting a conceptual model of stress response syndromes. *J Consult Clin Psychol* 1982;50:407-14.
- 43 Grice HP. Logic and conversation. In: Cole P, Moran JL, eds. *Syntax and semantics*. New York: Academic Press, 1975:41-58.
- 44 Dozier M, Lee SW. Discrepancies between self- and other-report of psychiatric symptomatology: effects of dismissing attachment strategies. *Dev Psychopathol* 1995;7:217-26.
- 45 Tibben A, Vegter-vd Vlis M, vd Niermeijer MF, Kamp JJ, Roos RA, Rooijmans HG, Frets PG, Verhage F. Testing for Huntington's disease with support for all parties. *Lancet* 1990;335:553.
- 46 Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. *Psychosom Med* 1979;41:209-18.
- 47 Salkovskis PM, Rimes KA. Predictive genetic testing: psychological factors. *J Psychosom Res* 1997;43:477-87.
- 48 Hans MB, Koeppen AH. Huntington's chorea. Its impact on the spouse. *J Nerv Ment Dis* 1980;168:209-14.
- 49 Kessler S, Bloch M. Social system responses to Huntington disease. *Fam Process* 1989;28:59-68.
- 50 Kessler S. Forgotten person in the Huntington disease family. *Am J Med Genet* 1993;48:145-50.
- 51 Tibben A, Vegter-van der Vlis M, Roos RAC. Presymptomatic DNA-diagnostiek bij de chorea van Huntington: reacties op de zekerheid niet-gendragter te zijn. *Ned Tijdschr Geneesk* 1990;134:701-4.
- 52 Decruyenaere M, Evers-Kiebooms G, Boogaerts A, Cassiman JJ, Cloostermans T, Demyttenaere K, Dom R, Fryns JP. Psychological functioning before predictive testing for Huntington's disease: the role of the parental disease, risk perception, and subjective proximity of the disease. *J Med Genet* 1999;36:897-905.
- 53 Bowlby J. *Attachment*. 2nd ed. London: Penguin Books, 1989.
- 54 Bowlby J. *A secure base: parent-child attachment and healthy human development*. New York: Basicbooks, 1988.
- 55 Fonagy P, Steele M, Moran G, Steele M, Higgitt AC. The capacity for understanding mental states: the reflective self in parent and child and its significance for security of attachment. *Infant Ment Health J* 1991;13:200-16.
- 56 Bowlby J. Developmental psychiatry comes of age. *Am J Psychiatry* 1988;145:1-10.
- 57 Greenberg MT. Attachment and psychopathology in childhood. In: Cassidy J, Shaver PR, eds. *Handbook of attachment*. New York: The Guilford Press, 1999:469-96.
- 58 Main M, Solomon J. Procedures for identifying infants as disorganized/disoriented during the Ainsworth Strange Situation. In: Greenberg MT, Cicchetti D, Cummings EM, eds. *Attachment in the preschool years: theory, research, and intervention*. Chicago: University of Chicago Press, 1990:121-60.
- 59 Schuengel C, Bakermans-Kranenburg MJ, van Ijzendoorn MH. Frightening maternal behavior linking unresolved loss and disorganized infant attachment. *J Consult Clin Psychol* 1999;67:54-63.
- 60 van Ijzendoorn M. Adult attachment representations, parental responsiveness, and infant attachment: a meta-analysis on the predictive validity of the Adult Attachment Interview. *Psychol Bull* 1995;117:387-403.
- 61 Cicchetti D, Beeghly M. Symbolic development in maltreated youngsters: an organizational perspective. In: Cicchetti D, Beeghly M, eds. *Atypical symbolic development*. New Directions for Child Development. San Francisco: Jossey-Bass, 1987:5-29.
- 62 Main M, Hesse E. Parents' unresolved traumatic experiences are related to infant disorganized attachment status: is frightened and/or frightening parental behavior the linking mechanism? In: Greenberg DCM, Cummings EM, eds. *Attachment in the preschool years: theory, research and intervention*. Chicago: University of Chicago Press, 1990:161-82.
- 63 Kobak R. The emotional dynamics of disruptions in attachment relationships: implications for theory, research, and clinical intervention. In: Cassidy J, Shaver PR, eds. *Handbook of attachment*. New York: The Guilford Press, 1999:21-43.

- 64 Waters E, Merrick S, Treboux D, Crowell J, Albersheim L. Attachment security in infancy and early adulthood: a twenty-year longitudinal study. *Child Dev* 2000;71:684-9.
- 65 Hamilton CE. Continuity and discontinuity of attachment from infancy through adolescence. *Child Dev* 2000;71:690-4.
- 66 Weinfield NS, Sroufe A, Egeland B. Attachment from infancy to early childhood in a high-risk sample: continuity, discontinuity, and their correlates. *Child Dev* 2000;71:695-702.
- 67 Fanos JH. Developmental tasks of childhood and adolescence: implications for genetic testing. *Am J Med Genet* 1997;71:22-8.
- 68 Kessler S. Invited essay on the psychological aspects of genetic counseling. V. Preselection: a family coping strategy in Huntington disease. *Am J Med Genet* 1988;31:617-21.
- 69 Evers-Kiebooms G, Swerts A, Van Den Berghe H. Partners of Huntington patients: implications of the disease and opinions about predictive testing and prenatal diagnosis. *Genet Couns* 1990;1:151-9.
- 70 Martindale B, Bottomley V. The management of families with Huntington's chorea: a case study to illustrate some recommendations. *J Child Psychol Psychiatry* 1980;21:343-51.
- 71 George C, Kaplan N, Main M. *Adult attachment interview*. 3rd ed. Department of Psychology, University of California, Berkeley, 1996.
- 72 Main M, Goldwyn R. *Adult attachment scoring and classification systems*. University of California at Berkeley: unpublished manuscript, 1998.
- 73 Benoit D, Parker KCH. Stability and transmission of attachment across three generations. *Child Dev* 1994;65:1444-57.
- 74 Steele H, Steele M, Fonagy P. Associations among attachment classifications of mothers, fathers, and their infants. *Child Dev* 1996;67:541-55.
- 75 Ward MJ, Carlson EA. Associations among adult attachment representations, maternal sensitivity, and infant-mother attachment in a sample of adolescent mothers. *Child Dev* 1995;66:69-79.
- 76 Beck AT, Steer RA. *Beck Depression Inventory Manual*. San Antonio, Texas: The Psychological Corporation, 1987.
- 77 Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the hopelessness scale. *J Consult Clin Psychol* 1974;42:861-5.
- 78 Ware JEJ, Johnston SA, Davies-Avery A, Brook RH. *Conceptualization and measurement of health for adults in the Health Insurance Study*. Santa Monica, California: Rand, 1979.
- 79 Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;67:361-70.
- 80 Millon T. *Millon Clinical Multiaxial Inventory-II Manual*. Minneapolis: National Computer Scoring Systems, 1987.
- 81 Graham JR. *The MMPI. A practical guide*. New York: Oxford University Press, 1987.
- 82 Derogatis L. *SCL-90R Manual-II*. Towson, MD: Clinical Psychometric Research, 1983.
- 83 Van der Ploeg HM, Defares PB, Spielberger CD. *Handleiding bij de Zelfbeoordelingsvragenlijst: een Nederlandse bewerking van de Spielberger State Trait Anxiety Inventory*. New York: Swets & Zeitlinger, 1980.
- 84 Schreurs PJ, Van de Willige G, Tellegen B, Brosschot JF. *De Utrechtse Coping Lijst. Omgaan met problemen en gebeurtenissen*. Lisse: Swets & Zeitlinger, 1988.

## A novel 3' mutation in the *APC* gene in a family presenting with a desmoid tumour

Diana Eccles, John Harvey, Adrian Bateman, Fiona Ross

EDITOR—Desmoid tumours, also known as infiltrative fibromatoses, are rare benign tumours which often recur after local resection and can cause death through local infiltration of vital structures.<sup>1</sup> The estimated incidence in the general population of such tumours is 1-2 per million but in familial adenomatous polyposis (FAP) they occur in up to 15% of cases.<sup>2</sup> Likely precipitating factors include trauma and female sex hormones, since females are more often affected than males.<sup>3</sup> The majority of desmoid tumours in FAP (over 90%) arise in the mesentery of the bowel or in the abdominal wall musculature. In recent years, several families have been described where the predominant phenotype is of desmoid disease and where the colonic phenotype is minimal.<sup>3-6</sup> We describe another such family with a novel protein truncating mutation in the 3' end of the *APC* gene.

### Methods and results

#### CLINICAL DETAILS

The index case presented at 29 years of age with a firm, slightly tender swelling within the right rectus abdominus muscle. A 6 x 5 cm tumour was locally excised and conventional histological examination showed infiltrative fibromatosis. The tumour recurred after six years and was resected again along with 30 cm of adherent small bowel. A year later, a further abdominal wall recurrence was resected and on this occasion fresh tissue was submitted for cytogenetic analysis. Full colonoscopy before referral to the genetics service showed no

evidence of colonic adenomas throughout the colon. Repeat colonoscopy after the gene mutation was identified still failed to show any colonic pathology, although contrast dye spray was not undertaken on either occasion. The only relevant family history was that her father had a previous history of a sigmoid colectomy carried out at 56 years of age for a carcinoma of the colon. He had been discharged from follow up after seven years during which endoscopy had shown no further pathology and he has remained well and symptom free since. He had never had any palpable lumps. Review of the histopathology from the resection specimen showed a Dukes B adenocarcinoma of the colon with six adenomas in the surrounding colonic mucosa.

#### CYTOGENETIC ANALYSIS

Fresh desmoid tumour was subjected to cytogenetic analysis which showed normal fibroblasts mixed with abnormal cells showing an interstitial deletion involving chromosome 5q22.

#### MOLECULAR ANALYSIS

DNA from the index case was examined for mutations in the *APC* gene using denaturing high performance liquid chromatography (DHPLC). A single base substitution G>A was identified at nucleotide position 7511, codon 2504, which changes tryptophan (TGG) to a stop codon (TAG). The mutation was present in both the index case and her father.

*J Med Genet*  
2001;38:861-863

Wessex Clinical  
Genetics Service,  
Princess Ann Hospital,  
Southampton  
SO16 5YA, UK  
D Eccles

Wessex Regional  
Genetics Laboratory,  
Salisbury District  
Hospital, Wilts, UK  
J Harvey  
F Ross

Department of  
Histopathology,  
Southampton General  
Hospital,  
Southampton, UK  
A Bateman

Correspondence to: Dr  
Eccles, de1@soton.ac.uk

## IMMUNOHISTOCHEMISTRY

The colonic tumour and the desmoid tumour were examined for  $\beta$ -catenin expression using immunohistochemistry. This showed intense nuclear and cytoplasmic  $\beta$ -catenin expression in the colonic tumour. A similar, although less intense, pattern of nuclear expression with some cytoplasmic expression was apparent in the desmoid tumour from the index case.

**Discussion**

Classical familial adenomatous polyposis coli (FAP) is recognised by the presence of many hundreds of colonic adenomas throughout the colon. Since the identification of the gene responsible for FAP in 1991, it has been possible to recognise certain genotype/phenotype correlations which may not only allow the clinician to direct the molecular geneticist towards the most likely region where a mutation may be located, but conversely may predict the likely natural course of the disease associated with a given mutation and direct management strategies accordingly.<sup>7</sup> Where mutations fall into the 5' and 3' extremes of the gene, an attenuated colonic phenotype is usually seen with fewer and later onset polyps.<sup>8</sup> Whereas mutations at the 5' end of the gene (exons 1-4) are not associated with desmoid tumour development, mutations arising in the 3' half of the gene are more often associated with desmoid tumours, and in rare families this is the dominant phenotype with little else to suggest the diagnosis of polyposis on examination of the colon.<sup>3,5</sup> Although cytogenetic analysis of desmoid tumours is technically difficult and requires fresh tumour tissue, it may be a useful additional investigation where the phenotype for FAP is absent. Cytogenetic deletion of 5q in desmoid tumours is more frequently associated with FAP than apparently sporadic tumours,<sup>9,10</sup> so, even in the absence of typical FAP features, a cytogenetic deletion of 5q in the tumour may direct a careful search for possible underlying *APC* gene mutations.

*APC* is involved in many critical cellular functions including cell adhesion (via E-cadherin) and in negatively regulating  $\beta$ -catenin levels.  $\beta$ -catenin is involved in the transcriptional activation of several genes involved in cell cycle entry and progression. *APC* mutation leads to reduced degradation of  $\beta$ -catenin (reflected in overexpression of  $\beta$ -catenin shown using immunohistochemistry in the tumours described in this case).

The natural history of desmoid tumours is variable but they can follow a highly aggressive course. However, even in families where the desmoid phenotype is 100% penetrant,<sup>3,5</sup> the clinical course is unpredictable. The explanation for the particular predilection of 3' mutations to be associated with desmoid tumour formation is still a matter of speculation. Low levels of truncated protein product have been reported in similarly distal mutations, possibly owing to an unstable mRNA; the stability of the mRNA may vary according to tissue type.<sup>3,5</sup> There are likely to be both environmental and genetic modifiers exerting an effect on *APC* gene mutations in view of the

variation in phenotype between subjects with the same mutation. It is possible that the effect of these putative genetic modifiers will differ according to tissue type. Detection of such modifiers and determination of their mode of action could be extremely helpful in selecting potential medical treatment for patients with desmoid tumours, since surgery is best avoided if the tumours are not life threatening. A recent paper looking at second hits in adenomas and desmoid tumours in FAP included data only for patients with germline mutations 5' of codon 1462. In desmoid tumours from these patients, there was either loss of the wild type allele or a somatic *APC* mutation. The somatic mutations were consistently 3' of codon 1426. In our patient, there was loss of heterozygosity indicated by a cytogenetic deletion but a 3' germline mutation. This suggests that the siting of first and second hits may be interchangeable with respect to the end result (a desmoid tumour), but if somatic mutations in colonic epithelium are in some way reliant on the germline mutation this may explain the very different clinical phenotype presented by many patients with unusually 3' mutations.<sup>11</sup>

For families where the desmoid phenotype is the dominant clinical feature and the risk of colorectal cancer is likely to be lower than where adenomatous polyps are frequent, colonic resection should be reserved for situations where there is significant colonic pathology. There may be an argument for favouring subtotal colectomy and ileorectal anastomosis if colectomy becomes necessary. Giving clear information to at risk members of the family reported here is difficult, as the position of the mutation leads us to suspect a high risk for desmoid tumours although the clinical picture is not of 100% desmoid tumour penetrance. Although the colon cancer risk must also be increased, the position of the mutation in the family described, the association of desmoid tumours with trauma (and surgery in particular), the late onset, and the presence of only a few adenomas in the only identified gene carrier with colon cancer and the normal appearance of the colonic mucosa in the index case in her late thirties all suggest that a conservative approach to surgery is appropriate. We have offered genetic testing to at risk family members and suggested that a screening colonoscopy every two years starting at 20 years, with dye spray or random mucosal biopsies to determine whether any microadenomas are present, would be a reasonable course of action for a gene carrier or for a family member at 50% risk who chose not to have a predictive genetic test.

We know this disease is caused by a mutation in the *APC* gene and could therefore be called familial adenomatous polyposis (FAP) or perhaps better attenuated adenomatous polyposis coli (AAPC). This acknowledges that there is an increased colon cancer risk; however, this potentially underplays the significance of the desmoid tumour phenotype which may be a very important factor to take into account in making decisions about surgery.

We would like to thank Cdr P Barker for referring the patient and Dr Jane Collins for providing the  $\beta$ -catenin antibody.



- A diagnosis of a desmoid tumour should lead to a careful clinical and molecular search for evidence of familial adenomatous polyposis.
- Cytogenetic or molecular evidence of loss of an *APC* allele in the desmoid tumour is additional evidence of the likelihood of an underlying germline mutation.
- Mutations in the 3' part of the *APC* gene can be associated with a very attenuated colonic phenotype not clinically diagnostic of FAP.

- 1 Smith AJ, Lewis JJ, Merchant NB, Leung DH, Woodruff JM, Brennan MF. Surgical management of intra-abdominal desmoid tumours. *Br J Surg* 2000;87:608-13.
- 2 Klemmer S, Pascoe L, DeCose J. Occurrence of desmoids in patients with familial adenomatous polyposis of the colon. *Am J Med Genet* 1987;28:385-92.
- 3 Eccles DM, Van der Luijt RB, Breukel C, Bullman H, Bunyan DJ, Fisher A, Barber J, Du BC, Primrose J, Burn J, Fodde R. Hereditary desmoid disease is a phenotypic variant of attenuated polyposis due to a 3' frameshift mutation at codon 1924 of the *APC* gene. *Am J Hum Genet* 1996;59:1193-201.
- 4 Scott RJ, Froggatt NJ, Trembath R, Evans DGR, Hodgson SV, Maher ER. Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3' *APC* gene mutation. *Hum Mol Genet* 1996;5:1921-4.
- 5 Couture J, Mitri A, Lagace R, Smits R, Berk T, Bouchard HL, Fodde R, Alman B, Bapat B. A germline mutation at the extreme 3' end of the *APC* gene results in a severe desmoid phenotype and is associated with overexpression of beta-catenin in the desmoid tumor. *Clin Genet* 2000;57:205-12.
- 6 Halling KC, Lazzaro CR, Honchel R, Buflin JA, Powell SM, Arndt CA, Lindor NM. Hereditary desmoid disease in a family with a germline Alu I repeat mutation of the *APC* gene. *Hum Hered* 1999;49:97-102.
- 7 Vasen H, Van der Luijt RB, Slors JFM, Buskens E, de Ruyter P, Baeten CGM, Shouten WR, Oostvogel HJM, Kuijpers JHC, Tops C, Meera Khan P. Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. *Lancet* 1996;348:433-5.
- 8 Spirio L, Olschwang S, Groden J, Robertson M, Samowitz W, Joslyn G, Gelbert L, Thliveris A, Carlson M, Otterud B. Alleles of the *APC* gene: an attenuated form of familial polyposis. *Cell* 1993;75:951-7.
- 9 Bridge JA, Meloni AM, Neff JR, Deboer J, Pickering D, Dalence C, Jeffrey B, Sandberg AA. Deletion 5q in desmoid tumor and fluorescence in situ hybridization for chromosome 8 and/or 20 copy number. *Cancer Genet Cytogenet* 1996;92:150-1.
- 10 Giarola M, Wells D, Mondini P, Pilotti S, Sala P, Azzarelli A, Bertario L, Pierotti MA, Delhanty JD, Radice P. Mutations of adenomatous polyposis coli (*APC*) gene are uncommon in sporadic desmoid tumours. *Br J Cancer* 1998;78:582-7.
- 11 Lamml H, Papadopoulou A, Ilyas M, Rowan A, Gillet C, Hanby A, Talbot I, Bodmer W, Tomlinson I. *APC* mutations are sufficient for the growth of early colorectal adenomas. *Proc Natl Acad Sci USA* 2000;97:2225-8.

## A silent mutation in exon 14 of the *APC* gene is associated with exon skipping in a FAP family

Mariapina Montera, Francesca Piaggio, Cristiana Marchese, Viviana Gismondi, Alessandro Stella, Nicoletta Resta, Liliana Varesco, Ginevra Guanti, Cristina Mareni

*J Med Genet*  
2001;38:863-867

Dipartimento di  
Medicina Interna,  
Università di Genova,  
Viale Benedetto XV/6,  
16132 Genova, Italy  
M Montera  
F Piaggio  
C Mareni

Ospedale Mauriziano  
Umberto I, Torino,  
Italy  
C Marchese

Istituto Nazionale per  
la Ricerca sul Cancro,  
Genova, Italy  
V Gismondi  
L Varesco

Dipartimento di  
Medicina Interna e del  
Lavoro, Sezione di  
Genetica Medica,  
Università di Bari,  
Italy  
A Stella  
N Resta  
G Guanti

Correspondence to:  
Dr Mareni, mareni@unige.it

EDITOR—Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited disorder characterised by the development of hundreds to thousands of adenomatous polyps in the colon and rectum. If left untreated, there is a very high risk of colorectal cancer. Adenomatous polyps may also develop proximally in the stomach and the distal part of the duodenum. FAP is also associated with a variety of extracolonic benign and malignant manifestations, including congenital hypertrophy of the retinal pigment epithelium (CHRPE), dental abnormalities, desmoid tumours, osteomas, epidermoid cysts, hepatoblastoma, and thyroid neoplasia.<sup>1</sup> Germline mutations of the *APC* gene localised on chromosome 5q21.22 are responsible for FAP.<sup>2,3</sup> *APC* is a tumour suppressor gene encoding a 2843 amino acid protein, which contains multiple functional domains and which mediates growth regulatory signals by its association with a variety of cytoplasmic proteins. More than 300 different *APC* mutations have so far been identified distributed throughout the whole gene, with a higher concentration in the 5' part of exon 15 (codons 713-1597).<sup>4,5</sup> The majority of mutations are predicted to introduce premature termination signals resulting from single nucleotide alterations, small insertions or deletions, or splice

site mutations that lead to truncation of the normal protein product.<sup>4</sup> Missense mutations have rarely been reported and their functional implications are often unclear.<sup>6,7</sup> Larger deletions and insertions have been described, as well as genomic rearrangements resulting from recombinations mediated by Alu elements which cause inappropriate exon splicing.<sup>8-10</sup> Isoforms of *APC* transcripts lacking exon 9, exon 10A, and exon 14 encoded sequences have been reported.<sup>2,11-13</sup> Isoforms lacking exon 9 or exon 14 owing to splice site mutations have also been associated with a FAP phenotype.<sup>14-17</sup>

In this study, we describe a G→T transversion at nucleotide position 1869 in exon 14 which gives rise to a silent mutation, since both normal and mutated alleles encode an arginine residue at codon 623. This exonic mutation induces complete skipping of exon 14, leading to truncated *APC* protein and resulting in a FAP phenotype.

### Materials and methods

The index case of family GE08 (IV.1, fig 1, table 1) was referred to our institution for genetic counselling. The patient underwent a total colectomy for diffuse polyposis. A diagnosis of FAP was made on the basis of family history and histopathological results.




Figure 1 Pedigree of FAP family GE08. Grey symbols, colon polyposis; half filled symbols, colon cancer; open symbols, clinically unaffected subjects; G, the wild type nucleotide; G→T, R623R mutation; NT, not tested for mutation; number under symbols, age; III.6 and III.7, disease phenotypic unknown.

After informed consent had been obtained from numerous family members, medical records were reviewed to confirm the diagnosis of polyposis, polyposis and cancer, and the age of occurrence. The clinical information obtained is shown in table 1. The pedigree was constructed as shown in fig 1. Peripheral blood samples were obtained from the proband and family members III.5, IV.1, IV.2, IV.3, IV.4,

IV.5, IV.6, IV.15, IV.16, IV.18, IV.19, IV.20, IV.21, IV.22, IV.26, V.1, V.2, V.3, V.4, V.11, and V.12.

Mutation analysis was carried out on genomic DNA prepared from isolated leucocytes using SNAP Whole Blood DNA Isolation Kit (Invitrogen, Carlsbad, CA). DNA was also extracted from paraffin embedded normal tissue from subject III.5.<sup>18</sup> The protein truncation test (PTT) was performed to detect truncating mutations in exon 15.<sup>19</sup> Mutation screening of the entire *APC* coding sequence was performed on genomic DNA using single strand conformation polymorphism (SSCP). Thirty-seven different segments of the *APC* gene were amplified by PCR using the primer pairs reported elsewhere.<sup>2</sup> SSCP was carried out as described previously.<sup>18</sup> The variant conformer was confirmed in at least three different samples from the same person and by direct DNA sequence analysis using an ABI PRISM TM 377 DNA Sequencer (Perkin Elmer, Foster City, CA).

mRNA was isolated from IL-2 transformed lymphoblastoid cell lines by using the Micro-Fast Track mRNA Isolation Kit (Invitrogen, Carlsbad, CA). First strand cDNA was synthesised with 2 µg of polyA<sup>+</sup> RNA in a reaction mixture containing 1.5 mmol/l MgCl<sub>2</sub>, 10 mmol/l Tris HCl, 50 mmol/l KCl (pH 8.3), 200 µmol/l each dNTP, 200 U of M-MLV Reverse Transcriptase (Ambion, Austin, TX), 25 U RNase OUT (Life Technologies, Gaithersburg, MD), 50 µmol/l of primer RV7-A<sup>20</sup> and primer 15A-RP,<sup>2</sup> and 0.25 U *Taq* polymerase in a volume of 50 µl. Primers RV7-A and 15A-RP enabled the *APC* region corresponding to codon 493 to 759 to be amplified. The PCR products were visualised by gel electrophoresis on a 1.5% agarose gel stained with ethidium bromide. The band intensity was measured

Table 1 Characteristics and clinical data from FAP family GE08

Subjects	Clinical presentation*‡	Age at diagnosis polyps/cancer§	Number of adenomas	Exon 14 mutation
II.1	†Symptomatic	?	?	NT
II.3	†Symptomatic	?	?	NT
III.1	†Symptomatic	?	?	NT
III.4	†Symptomatic	?	?	NT
III.5	Symptomatic	61/61	>100	Present
IV.1	Symptomatic	46	>100	Present
IV.2	Call up	44	0	Absent
IV.3	Call up	42	0	Absent
IV.4	Symptomatic	40	6	Present
IV.5	Call up	36	0	Absent
IV.6	Call up	34	0	Absent
IV.9	NK	34	NK	NT
IV.10	Symptomatic	44	7	Present
IV.11	Call up	36	0	Absent
IV.12	Call up	40	0	Absent
IV.13	Call up	38	0	Present
IV.14	Symptomatic	34/34	>100	Present
IV.15	Call up	39	1	Absent
IV.16	Symptomatic	36/36	>100	Present
IV.17	NK	32	NK	NT
IV.18	NK	31	NK	NT
IV.19	NK	29	NK	NT
IV.20	Call up	25	0	Absent
V.1	Call up	15	0	Present
V.2	Call up	13	0	Absent
V.3	NK	11	NK	Absent
V.4	NK	10	NK	Absent
V.6	NK	11	NK	Present
V.7	NK	10	NK	Absent
V.8	NK	2	NK	NT

\*Symptomatic, patients showing symptoms of FAP and/or CRC.

†Symptomatic, no data available.

‡No extracolonic manifestations were present in affected subjects.

§Unaffected subjects and asymptomatic gene carriers, actual age, and age at DNA test are given. Call up, called for endoscopic examination as at risk subjects; NK, not known; NT, not tested.




Figure 2 (A) Agarose gel electrophoresis showing the expression of the two exon 14 isoforms of 793 and 578 bp;  $\Phi$ X174, DNA molecular marker; C, normal controls; IV.4, IV.1, IV.16, affected subjects. (B) Western blot analysis showing the 64 kDa APC truncated protein in patients IV.1 and IV.16 and the 62 kDa APC protein in the truncated control in M; C is the normal not truncated protein.

directly on the agarose gel by Gene Snap 4.00.00 and Gene Tools Version 3.00.13 Syn Gene software (Synoptics Ltd, Cambridge, UK). Amounts of each mRNA were expressed both as absolute values and as the ratio between the 793 band, which corresponds to cDNA encompassing the *APC* exon 11-15A, and the 578 band which corresponds to the alternatively spliced transcript lacking exon 14. *GAPDH* gene coamplification was carried out as an internal control. Moreover, the PCR products were separated by 6% silver stained polyacrylamide gel electrophoresis. The bands of 793 and 578 nucleotides were cut off and eluted in water overnight at 37°C. One  $\mu$ l of each mixture was then used to amplify the two bands separately with primers RV7-A and 15A-RP. The identity of the PCR products was ascertained by direct sequencing. A stretch of intronic 40 nucleotides upstream of exon 14 was also sequenced for analysing the acceptor site branch point.

Protein extraction and western blot analysis were performed according to Gismondi *et al*<sup>21</sup> using 10% SDS PAGE gel. EBV transformed cells of subjects IV.1, IV.16, a normal control, and a control carrying a nonsense mutation at codon 563 were analysed.

## Results

The index patient had a clinical diagnosis of FAP and underwent colectomy at the age of 46. The pedigree of family GE08 (fig 1) shows some peculiarities regarding the age of occurrence and the multiplicity of polyps. The age at which polyps and cancer appeared is later than in classical polyposis, except for IV.14 and IV.16 (table 1). These patients belonged to a branch of the family in which a consanguineous marriage had taken place between first cousins, both possible carriers of the disease. The number of adenomatous polyps ranged from six to more than 100 in affected members. No upper gastrointestinal tract lesions, CHRPE, or other extracolonic manifestations are present in the family.

During mutation screening of the *APC* coding region, a G→T transversion at nucleotide position 1869 was detected by SSCP and direct sequencing of exon 14 in the index patient IV.1. This mutation changes codon 623 from

CGG to CGT, both encoding arginine (R623R).<sup>22</sup> Since the entire open reading frame of the *APC* gene was analysed by SSCP and PTT several times without detecting any additional sequence variation, this is the only detectable DNA alteration unique to this patient.

The sequence at the branch point of the exon 14 acceptor site also did not show any alteration. Subsequent screening for the mutation in 21 additional relatives showed the presence of the mutation in three successive generations, as shown in fig 1, and its segregation with the disease. In patient III.5, the mutation was detected on paraffin embedded tissue. Direct sequencing of DNA from patients IV.14 and IV.16 did not show homozygosity for the R623R mutation. This allelic variant was not observed in any of 100 DNA samples from normal controls.

Messenger RNA purified from transformed lymphoblastoid cell lines from three affected subjects (IV.1, IV.4, IV.16) and from three normal controls was examined. The analysis of cDNA with primer sets RV7-A and 15A-RP showed the two isoforms representing the mRNA transcript containing exon 14 and the alternatively spliced transcript lacking exon 14 leading to a stop codon in exon 15A.

The densitometric ratio between the two isoforms of 793 and 578 bp amplicons was comparable in all normal controls, being 4.2. By contrast, the band intensity of 578 bp was greater in the three patients examined, with a densitometric ratio of 0.6 ( $p < 0.03$ ) showing a drastic increase in the alternatively spliced isoform of exon 14 (fig 2A).

Direct DNA sequencing of the two bands showed only the wild type allele in the 793 bp mRNA isoform containing the normal spliced RNA while the G→T transversion was not present. In the retrotranscribed, short 578 bp isoform, the mRNA showed a complete lack of exon 14.

Western blot analysis was performed on protein extracts from a normal control and from subjects IV.1 and IV.16. In addition, a FAP patient with a nonsense mutation at codon 563 was analysed as an APC protein truncated control (fig 2B). Using 10% SDS-PAGE analysis, the APC wild type protein was not



detectable; the only truncated protein was observed in subjects IV.1 and IV.16 and in the APC mutated control indicating that the mutant mRNA is translated into a stable truncated protein. No truncated APC protein was detected in the normal control.

### Discussion

The exonic silent mutation R623R reported here creates a complete skipping of exon 14 of the *APC* gene and gives rise to a stable truncated APC protein. This mutation has not been described previously and does not represent a polymorphic gene variant as it has been tested on more than 100 subjects. This mutation occurs as the only DNA change in all affected members of a large three generation FAP family. Clinically, the family is characterised by an unaggressive form of the disease in terms of age of onset and number of polyps (table 1, fig 1), except for the branch derived from a consanguineous marriage, both parents being possible carriers of FAP. This difference might occur because of the intrafamilial variability of FAP or because of some unknown recessive modifier gene inherited from both parents. Although alternative skipping of exon 14 is a physiological event observed in normal subjects, a splice acceptor site mutation leading to increased expression of an *APC* mRNA isoform without exon 14 has been previously described in a FAP family.<sup>16</sup> In our family, splice sites do not show any modification and, furthermore, to rule out the possibility of an intron alteration in the tract near the acceptor splice site, which might eliminate lariat formation at the branch point, a stretch of 40 nucleotides upstream of the exon 14 acceptor site was also sequenced.

Our data indicate that the mutation harbouring allele is expressed exclusively in the alternative isoform and that the DNA exonic silent mutation might be able to produce a complete skipping of exon 14, suggesting the existence of a mechanism of splicing regulation distinct from splice junctions. Silent mutations not leading to amino acid change are generally considered to be normal variants and are thought to have no role in disease. However, a few papers have described exonic silent mutations able to induce exon skipping in the fibrillin-1 gene, the *MLH1* gene, and the human phenylalanine hydroxylase gene, all associated with the corresponding diseases.<sup>23-25</sup>

Recent studies have indicated that sequence elements that are distinct from the splice sites are also needed for normal splicing. These elements are required for efficient splicing and may affect splice site recognition during constitutive and alternative splicing.<sup>26, 27</sup> They are found within coding exons and are called exonic splicing enhancers (ESE). Since no consensus sequence that describes ESE is recognised, these elements are difficult to identify, not least because they are not as purine rich as was originally thought.<sup>28</sup> Silent point mutations that affect ESE and lead to inappropriate exon skipping have been described in human genetic diseases. Frontotemporal dementia linked to chromosome 17 missense mutation affects

splicing of tau gene exon 10 by acting on an ESE.<sup>29</sup> Carbohydrate deficient glycoprotein syndrome is associated with a missense mutation that disrupts a splicing enhancer sequence, resulting in exon 5 skipping.<sup>30</sup> Splicing difference between the two forms of spinal muscular atrophy, SMN1 and SMN2, is attributed to a silent mutation in an ESE located in the centre of *SMN* exon 7.<sup>31</sup> Very recently, Liu *et al*<sup>32</sup> reported aberrant exon skipping in the *BRCA1* gene resulting from nonsense, missense, or translationally silent mutations, which have disrupted a critical ESE. The G→T silent genomic DNA mutation is the only change found in family GE08 and it is located in a purine rich DNA sequence (ACCG-GAGCCAG). This region in the middle of exon 14 might represent an ESE sequence necessary for the control of the alternative splicing and the one base substitution might disrupt this, thus provoking total exon 14 skipping. Experiments are being carried out to test enhancer activity of the exon 14 *APC* sequences by inserting them into another transcript that could be assayed by *in vitro* splicing and/or by transfection,<sup>33</sup> followed by mutagenesis of the sequence, to identify the elements that compose the putative enhancer.

- We describe a silent third base codon mutation in exon 14 of the *APC* gene, a G→T transversion at nucleotide 1869 (R623R), associated with complete skipping of exon 14 and production of a stable truncated APC protein. The R623R mutation segregates with the disease in a large FAP family. This mutation is the sole variation found in the entire APC coding sequence, is not a polymorphism, and has not been described before.
- To evaluate whether the silent genomic DNA variation could affect RNA transcription, RT-PCR analysis was carried out in affected subjects. Although exon 14 is subject to alternative splicing, an unbalanced expression of the two exon 14 isoforms was found. Sequence analysis of the two isoforms showed that the mutant *APC* allele expressed exclusively mRNA lacking exon 14. Western blot analysis showed that the mutant mRNA was translated into a stable truncated protein.
- Our findings show a possible new model of *APC* mutation causing disease and suggest that exonic elements might modulate the splicing of *APC* gene exon 14. They therefore underline the importance of investigating the significance of silent mutations.

This work was supported by MURST, Ministero dell'Università e della Ricerca Scientifica e Tecnologica, Cofinanziamento 1998, Ricerca Finalizzata-Ministero Sanità 1999, ICS030.1RF99.34. We also acknowledge Galliera Genetic Bank, Progetto Telethon C42.

1 Jagelman DG. Extracolonic manifestations of familial adenomatous polyposis. *Cancer Genet Cytogenet* 1987;27:319-25.

- 2 Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M, Sargeant L, Krapcho K, Wolff E, Burt R, Hughes JP, Warrington J, McPherson J, Wasmuth J, Le Paslier D, Abderrahim H, Cohen D, Leppert M, White R. Identification and characterization of the familial adenomatous polyposis coli gene. *Cell* 1991;66:589-600.
- 3 Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S, Hedge P. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. *Science* 1991;253:665-9.
- 4 Soussi T. APC mutation database, July 1999. Available at <http://perso.curie.fr/thierry.soussi/APC.html>
- 5 Wallis YL, Morton DG, McKeown CM, Macdonald F. Molecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of the APC amino acid changes in colorectal cancer predisposition. *J Med Genet* 1999;36:14-20.
- 6 Stella A, Montera M, Resta N, Marchese C, Susca F, Gentile M, Romio L, Pilia S, Prete F, Mareni C, Guanti G. Four novel mutations of the APC (adenomatous polyposis coli) gene in FAP patients. *Hum Mol Genet* 1994;3:1687-8.
- 7 Ficari F, Cama A, Valanzano R, Curia MC, Palmirotta R, Aceto G, Esposito DL, Crognale S, Lombardi A, Messerini L, Mariani-Costantini R, Tonelli F, Battista P. APC gene mutations and colorectal adenomatosis in familial adenomatous polyposis. *Br J Cancer* 2000;82:348-53.
- 8 Miyoshi Y, Ando H, Nagase H, Nishisho I, Horii A, Miki Y, Mori T, Utsunomiya J, Baba S, Petersen G, Hamilton SR, Kinzler, KW, Vogelstein B, Nakamura Y. Germline mutations of the APC gene in 53 familial adenomatous polyposis patients. *Proc Natl Acad Sci USA* 1992;89:4452-6.
- 9 DeRosa M, Scarano MI, Panariello L, Carlomagno N, Rossi GB, Tempesta A, Borgheresi P, Renda A, Izzo P. Three submicroscopic deletions at the APC locus and their rapid detection by quantitative-PCR analysis. *Eur J Hum Genet* 1999;7:695-703.
- 10 Su L, Steinbach G, Sawyer JC, Hindi M, Ward PA, Lynch M. Genomic rearrangements of the APC tumor-suppressor gene in familial adenomatous polyposis. *Hum Genet* 2000;106:101-7.
- 11 Joslyn G, Carlson M, Thliveris A, Albertsen H, Gelbert H, Samowitz W, Groden J, Stevens J, Spirio L, Robertson M, Sargeant L, Kraho K, Wolff E, Burt R, Hughes JP, Warrington J, McPherson J, Wasmuth J, Le Paslier D, Abderrahim H, Cohen D, Leppert M, White R. Identification of deletion mutations and three new genes at the familial polyposis locus. *Cell* 1991;66:601-13.
- 12 Sulekova Z, Ballhausen WG. A novel coding exon of the human adenomatous polyposis coli gene. *Hum Genet* 1995;96:469-71.
- 13 Samowitz WS, Thliveris A, Spirio LN, White R. Alternatively spliced adenomatous polyposis coli (APC) gene transcripts that delete exons mutated in attenuated APC. *Cancer Res* 1995;55:3732-4.
- 14 Cama A, Esposito DL, Palmirotta R, Curia MC, Ranieri A, Ficari F, Valanzano R, Modesti A, Battista P, Tonelli F, Mariani-Costantini R. A novel mutation at the splice junction of exon 9 of the APC gene in familial adenomatous polyposis. *Hum Genet* 1994;3:305-8.
- 15 Varesco L, Gismondi V, Presciuttini S, Groden J, Spirio L, Sala P, Rossetti C, De Benedetti L, Bafico A, Heouaine A, Grammatico P, Del Porto G, White R, Bertario L, Ferrara GB. Mutation in a splice-donor site of the APC gene in a family with polyposis and late age of colonic cancer death. *Hum Genet* 1994;93:281-6.
- 16 Bala S, Sulekova Z, Ballhausen WG. Constitutive APC exon 14 skipping in early-onset familial adenomatous polyposis reveals a dramatic quantitative distortion of APC gene-specific isoforms. *Hum Mutat* 1997;10:201-6.
- 17 Spirio L, Green J, Robertson J, Robertson M, Otterud B, Sheldon J, Howse E, Groden J, White R, Leppert M. The identical 5' splice-site acceptor mutation in five attenuated APC families from Newfoundland demonstrates a founder effect. *Hum Genet* 1999;105:388-98.
- 18 Montera M, Resta N, Simone C, Guanti G, Marchese C, Civitelli S, Mancini A, Pozzi S, De Salvo L, Bruzzone D, Donadini A, Romio L, Mareni C. Mutational germline analysis of hMSH2 and hMLH1 genes in early onset colorectal cancer patients. *J Med Genet* 2000;37:e7.
- 19 van der Luijt R, Khan M, Vasen H, van Leeuwen C, Tops C, Roest P, den Dunnen C, Fodde R. Rapid detection of translation-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test. *Genomics* 1994;20:1-4.
- 20 Spirio L, Olschwang S, Groden J, Robertson M, Samowitz W, Joslyn G, Gelbert L, Thliveris A, Carlson M, Otterud B, Lynch H, Watson P, Lynch P, Laurent-Puig P, Burt R, Hughes JP, Thomas G, Leppert M, White R. Alleles of the APC gene: an attenuated form of familial polyposis. *Cell* 1993;75:951-7.
- 21 Gismondi V, Stagnaro P, Pedemonte S, Biticchi R, Presciuttini S, Grammatico P, Sala P, Bertario L, Groden J, Varesco L. Chain-terminating mutations in the APC gene lead to alterations in APC RNA and protein concentration. *Genes Chrom Cancer* 1998;22:278-86.
- 22 Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. *Hum Mutat* 1998;11:1-3.
- 23 Liu W, Qian C, Francke U. Silent mutation induces exon skipping of fibrillin-1 gene in Marfan syndrome. *Nat Genet* 1997;16:328-9.
- 24 Nystrom-Lahti M, Holmberg M, Fildalpo P, Salovaara R, de la Chapelle A, Jiricny J, Peltomaki P. Missense and nonsense mutations in codon 659 of MLH1 cause aberrant splicing of messenger RNA in HNPCC kindreds. *Genes Chrom Cancer* 1999;26:372-5.
- 25 Chao HK, Hsiao KJ, Su TS. A silent mutation induces exon skipping in the phenylalanine hydroxylase gene in phenylketonuria. *Hum Genet* 2001;108:14-19.
- 26 Coulter LR, Landree MA, Cooper TA. Identification of a new class of exonic splicing enhancers by in vivo selection. *Mol Cell Biol* 1997;17:2143-51.
- 27 Cooper TA, Mattox W. The regulation of splice-site selection, and its role in human disease. *Am J Hum Genet* 1997;61:259-69.
- 28 Blencowe BJ. Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. *Trends Genet* 2000;25:106-10.
- 29 D'Souza I, Poorkai P, Hong M, Noehlin D, Lee VM, Bird TD, Shellenberg GD. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. *Proc Natl Acad Sci USA* 1999;96:5598-603.
- 30 Villamier-Barrot S, Barnier A, Cuer M, Durand G, Grandchamp B, Seta N. Characterization of the 415G>A (E139K) PMM2 mutation in carbohydrate-deficient glycoprotein syndrome type Ia disrupting a splicing enhancer resulting in exon 5 skipping. *Hum Mutat* 1999;14:543-4.
- 31 Lorson CL, Andronophy EJ. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. *Hum Mol Genet* 2000;2:259-65.
- 32 Liu HX, Cartegni L, Zhang MQ, Krainer A. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. *Nat Genet* 2001;27:55-8.
- 33 Liu HX, Chew SL, Cartegni L, Zhang MQ, Krainer A. Exonic splicing enhancer motif recognized by human SC35 under splicing conditions. *Mol Cell Biol* 2000;20:1063-71.

*J Med Genet*  
2001;38:867-870

**Laboratoire de  
Génétique Médicale,  
CHU Nancy-Brabois,  
Avenue du Morvan,  
54511 Vandoeuvre les  
Nancy, France**  
V Bourdon  
C Philippe  
P Jonveaux

**Laboratoire de  
Génétique et  
Physiopathologie des  
Retards  
Mentaux-ICGM,  
Faculté de Médecine  
Cochin, Paris, France**  
T Bienvenu  
J Chelly

**Site du Neuhof, Centre  
de Ressources en  
Matière de Déficiences  
Sensorielles et de  
Polyhandicaps Louis  
Braille - Raoul  
Clainchard - Auguste  
Jacoutôt, Strasbourg,  
France**  
B Koenig

**Département de  
Pédiatrie, Service de  
Neurologie, CHU  
Bicêtre, Le Kremlin  
Bicêtre, France**  
M Tardieu

Correspondence to:  
Dr Jonveaux,  
p.jonveaux@chu-nancy.fr


## Evidence of somatic mosaicism for a *MECP2* mutation in females with Rett syndrome: diagnostic implications

Violaine Bourdon, Christophe Philippe, Thierry Bienvenu, Bernadette Koenig, Marc Tardieu, Jamel Chelly, Philippe Jonveaux

EDITOR—Rett syndrome (RTT) (MIM 312750) is an X linked dominant neurodevelopmental disorder that occurs almost exclusively in females. Affected girls are considered to have a normal perinatal period followed by a

period of regression, loss of acquired purposeful manual and speech skills, hand wringing, gait disturbance, and growth retardation.<sup>1,2</sup>

A gene for RTT has been identified in the Xq28 region which encodes the methyl-CpG



**Figure 1** Detection of the two somatic mutations by heteroduplex analysis. (A) DGGE results for case 1. DNA extracted from a lymphoblastoid cell line (lane 1) and a fresh blood sample (lane 2). The homoduplex band corresponding to the deleted allele is missing in DNA extracted from lymphocytes. Ht, heteroduplex; Ho, homoduplex; 40%–90% formamide gradient. (B) CSGE results for case 1 (lanes 1–3) and case 2 (lane 5). Case 1: the somatic mutation is shown on DNA extracted from a fresh blood sample (lane 1); the father (lane 2) and the mother (lane 3) do not carry the 26 bp deletion. Case 2: a somatic deletion was detected on DNA extracted from lymphocytes as indicated by the absence of the deleted homoduplex band (lane 5). Lane 4 depicts a CSGE pattern of a 31 bp deletion localised in the deletion prone region of the *MECP2* gene; the two homoduplex bands are of equal intensity.

binding protein 2 (MeCP2) involved in transcriptional silencing.<sup>3–4</sup> This disorder most frequently occurs sporadically and results from a de novo mutation, although a few familial cases have been reported. Many studies<sup>5–10</sup> have shown that the *MECP2* gene is mutated in approximately 80% of patients with classical RTT and the *MECP2* mutation spectrum

includes missense, nonsense, and frameshift mutations, as well as larger rearrangements like deletions encompassing a few hundred bp.<sup>16</sup> The failure to detect *MECP2* mutations in the remaining 20% may indicate the presence of mutations in unexplored regions of the *MECP2* gene, such as regulatory elements or non-coding regions, notably in the new first exon<sup>17</sup> or in an additional RTT locus.

Here, we report for the first time mosaicism for a somatic *MECP2* mutation found in two unrelated females affected with RTT. These two girls were diagnosed according to the international criteria of the Rett Syndrome Diagnostic Criteria Work Group.<sup>18</sup>

### Case reports

The first patient (case 1) is 13 years old. She suffers from classical Rett syndrome with 7/9 of the necessary criteria, 4/8 of the supportive criteria, and none of the exclusion criteria.<sup>18</sup> More specifically, she had a normal neonatal period and head circumference at birth and a phase of social withdrawal at the age of 12 months when she lost purposeful hand skills and developed stereotypic hand movements, ataxia, and apraxia. She suffered from breathing dysfunction and peripheral vasomotor disturbances. She had severely impaired development but acquired independent walking at the age of 24 months. However, she did not acquire microcephaly or develop epilepsy.


The second patient (case 2) was reported as an atypical case of RTT without any period of regression. Both mental and motor development were very slow. At the age of 4 years, she had acquired microcephaly (–2 SD) and had very limited ambulation, but her hand use was correct without hand wringing movements. She developed epilepsy and progressive scoliosis. She is a placid girl without useful speech but she communicates well by eye movements.

### Methods and results

For case 1, an initial study on DNA extracted from a lymphoblastoid cell line by denaturing gradient gel electrophoresis (DGGE) and sequencing showed that she carried a 26 bp deletion starting at position 1165. To confirm this mutation, DNA was extracted from a fresh blood sample and the deletion was assessed by direct sequencing. Surprisingly and despite a careful examination of the sequence, we did not find the 26 bp deletion with DNA extracted from leucocytes. This sample was reanalysed by DGGE and heteroduplexes were detected while the homoduplex corresponding to the deleted band was absent (fig 1A). We confirmed this result by conformation sensitive gel electrophoresis (CSGE) analysis, which showed the heteroduplexes but not the mutant homoduplex (fig 1B). The results obtained from peripheral blood lymphocytes suggested mosaicism for a somatic mutation.

In order to determine the level of mosaicism, we used a semiquantitative approach based on fluorescent PCR. The *MECP2* gene exon 3 portion containing the deletion was PCR amplified, the reverse primer being conjugated





**Figure 2** Semiquantitative fluorescent PCR of the somatic mosaicism rate. (A) Case 1. Genotyper traces of the fluorescent PCR products obtained with three different tissues, blood (1), buccal mucosa cells (2), and hair bulb cells (3), shown with the three respective ratios of peak areas ( $X_1$ ,  $X_2$ ,  $X_3$ ). For each peak, the fragment size in bp and the peak area calculated by Genescan is indicated. We assumed that the mosaicism rate could be estimated by calculating the ratio between the deleted and the normal peak areas. (B) Case 2. Genotyper trace of a fluorescent PCR product obtained from blood with the ratio of peak areas ( $Y$ ).

to 6-FAM (6-carboxy-fluorescein). PCR products were analysed on an ABI 310 sequencer and peak areas were generated by ABI Genescan and Genotyper software. The ratio between the deleted and normal peak areas showed that only 36% of lymphocytes harboured the deletion, that is, 18% of X chromosomes bore the 26 bp deletion (fig 2A). This semiquantitative approach confirms that case 1 does have somatic mosaicism for the *MECP2* deletion. The relatively low level of somatic mosaicism could explain the normal sequencing result. Thus, mosaicism was quantified in different tissues. DNA was extracted from buccal mucosa cells<sup>19</sup> and hair bulb cells.<sup>20</sup> The level of mosaicism was about the same in buccal mucosa cells (30%) as in lymphocytes, but lower in hair bulbs cells (17.5%) (fig 2A).

### Discussion

On the basis of these results, we hypothesised that some patients with RTT may in fact carry a somatic mutation. Small deletions (from 7 to 170 bp) within the region between bp 1096 and 1165 of the *MECP2* gene have been recurrently identified.<sup>5 7 9 10 12 15 16</sup> They do not affect

the two functional domains but result in the loss of one fifth of the protein. Interestingly, it has been shown that the deletion of the carboxy-terminal 63 amino acids of the MeCP2 protein impairs binding with the nucleosomal DNA during the transcription regulation process.<sup>21</sup> These recurrent deletions may be the result of palindromic and quasipalindromic sequences within this region, which are believed to form secondary structures that render the region vulnerable to deletions. Therefore, using our fluorescent PCR approach, we reanalysed the 3' region of the *MECP2* gene, between bp 1096 and 1165, in a cohort of 29 patients diagnosed as typical or atypical RTT; for these patients, we failed to detect any mutation using a bidirectional sequencing strategy of the entire *MECP2* coding region. A second somatic mosaicism for a 27 bp deletion was identified in peripheral blood lymphocytes from case 2 with atypical RTT; the mosaicism rate was quantified with our fluorescent approach to be about 37% (fig 2B). We confirmed this result by CSGE analysis (fig 1B).

In both cases, numerical aberrations of the X chromosomes as a cause for the uncommon fluorescent PCR patterns were excluded by the presence of a normal 46,XX karyotype.

These two patients show a similar deletion with an equivalent mosaicism rate in blood, but a distinct clinical presentation. X inactivation study on proband 1 with typical Rett syndrome showed a random pattern of inactivation in the peripheral blood. Although the results have to be extrapolated from the peripheral blood cells, it would suggest that in the brain the majority of mutated X chromosomes may remain active in the girl with classical Rett syndrome. Our results illustrate clearly once again the difficulty in establishing a correlation between genotype and phenotype in RTT.

Recently, a boy with a mosaic mutation has been described.<sup>22</sup> To our knowledge, we show for the first time that somatic mosaicism for *MECP2* mutation in girls is not infrequent (two somatic mutations on 102 putative RTT cases studied) and may cause different phenotypes. These clinical and molecular findings suggest that multiple forms of mosaicism (X inactivation mosaicism and somatic mosaicism) may be present in a single patient with RTT. Mosaicism has been documented for chromosomal abnormalities, mitochondrial mutations, triplet repeats,<sup>23</sup> and in a growing number of dominant and recessive X linked gene disorders, such as Duchenne muscular dystrophy,<sup>24</sup> haemophilia B,<sup>25</sup> Conradi-Hünemann-Happle syndrome,<sup>26</sup> and double cortex/lissencephaly syndrome.<sup>27</sup> Because a proportion of cells carry the mutation not only in blood but also in tissues deriving from other cell lineages, it must be assumed that the mutation occurred very early during embryogenesis.

Finally, the detection of mosaic mutation depends mainly on the method used for the identification of mutations within the *MECP2* gene. Nowadays, the method of choice for identifying deleterious mutations relies on direct DNA sequencing. The ability of this method to detect mosaic mutations is poor, which is particularly true when the mosaicism rate is low. Our findings underline the need for at least two complementary approaches, such as methods based on heteroduplex analysis and sequencing, for an efficient screening of the *MECP2* gene.

We thank Dr Deblay for critical advice, Dr Florence Rousselet for her technical contribution, and l'Association Française du Syndrome de Rett, l'Association Française contre les myopathies, and the Ministère de l'Éducation Nationale, de la Recherche et de la Technologie for their financial support.

- Rett A. On an unusual brain atrophy syndrome in hyperammonemia in childhood. *Wien Med Wochenschr* 1966;11:723-6.
- Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. *Ann Neurol* 1983;14:471-9.
- Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked *MECP2*, encoding methyl-CpG-binding protein 2. *Nat Genet* 1999;23:185-8.
- Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. *Cell* 1997;21:471-81.
- Amir RE, Van den Veyver IB, Schultz R, Malicki DM, Tran CQ, Dahle EJ, Philippi A, Timar L, Percy AK, Motil KJ, Lichtarge O, Smith EO, Glaze DG, Zoghbi HY. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. *Ann Neurol* 2000;47:670-9.
- Amano K, Nomura Y, Segawa M, Yamakawa K. Mutational analysis of the *MECP2* gene in Japanese patients with Rett syndrome. *J Hum Genet* 2000;45:213-36.
- Bienvenu T, Carrie A, de Roux N, Vinet MC, Jonveaux P, Couvert P, Villard L, Arzimanoglou A, Beldjord C, Fontes M, Tardieu M, Chelly J. *MECP2* mutations account for most cases of typical forms of Rett syndrome. *Hum Mol Genet* 2000;9:1377-84.
- Buyse IM, Fang P, Hoon KT, Amir RE, Zoghbi HY, Roa BB. Diagnostic testing for Rett syndrome by DHPLC and direct sequence analysis of the *MECP2* gene: identification of several novel mutations and polymorphisms. *Am J Hum Genet* 2000;67:1428-36.
- Cheadle JP, Gill H, Fleming N, Maynard J, Kerr A, Leonard H, Krawczak M, Cooper DN, Lynch S, Thomas N, Hughes H, Hulten M, Ravine D, Sampson JR, Clarke A. Long-read sequence analysis of the *MECP2* gene in Rett syndrome patients: correlation of disease severity with mutation type and location. *Hum Mol Genet* 2000;9:1119-29.
- De Bona C, Zappella M, Hayek G, Meloni I, Vitelli F, Brutini M, Cusano R, Loffredo P, Longo I, Renieri A. Preserved speech variant is allelic of classic Rett syndrome. *Eur J Hum Genet* 2000;8:325-30.
- Hampson K, Woods CG, Latif F, Webb T. Mutations in the *MECP2* gene in a cohort of girls with Rett syndrome. *J Med Genet* 2000;37:610-12.
- Huppke P, Laccone F, Kramer N, Engel W, Hanefeld F. Rett syndrome: analysis of *MECP2* and clinical characterization of 31 patients. *Hum Mol Genet* 2000;9:1369-75.
- Obata K, Matsushita T, Yamashita Y, Fukuda T, Kuwajima K, Horiuchi I, Nagamitsu S, Iwanaga R, Kimura A, Omori I, Endo S, Mori K, Kondo I. Mutation analysis of the methyl-CpG binding protein 2 gene (*MECP2*) in patients with Rett syndrome. *J Med Genet* 2000;37:608-10.
- Wan M, Lee SS, Zhang X, Houwink MI, Song HR, Amir RE, Budden S, Naidu S, Pereira JL, Lo IF, Zoghbi HY, Schanen NC, Francke U. Rett syndrome and beyond: recurrent spontaneous and familial *MECP2* mutations at CpG hotspots. *Am J Hum Genet* 1999;65:1520-9.
- Xiang F, Buervenich S, Nicolao P, Bailey ME, Zhang Z, Anvret M. Mutation screening in Rett syndrome patients. *J Med Genet* 2000;37:250-5.
- Bourdon V, Philippe C, Labrune O, Amsallem D, Arnould C, Jonveaux P. A detailed analysis of the *MECP2* gene: prevalence of recurrent mutations and gross DNA rearrangements in Rett syndrome patients. *Hum Genet* 2001;108:43-50.
- Reichwald K, Thiesen J, Wiehe T, Weitzel J, Stätling WH, Kioschis P, Poustka A, Rosenthal A, Platzer M. Comparative sequence analysis of the *MECP2*-locus in human and mouse reveals new transcribed regions. *Mamm Genome* 2000;11:182-90.
- Trevarthen E, Moser HW, and the Diagnostic Criteria Working Group. Diagnostic criteria for Rett syndrome. The Rett Syndrome Diagnostic Criteria Work Group. *Ann Neurol* 1988;23:425-8.
- Philippe C, Porter DE, Emerton ME, Wells DE, Simpson AHRW, Monaco AP. Mutation screening of the *EXT1* and *EXT2* genes in patients with hereditary multiple exostoses. *Am J Hum Genet* 1997;61:520-8.
- Walsh PS, Metzger DA, Higuchi R. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. *Biotechniques* 1991;10:506-13.
- Chandler SP, Guschin D, Landsberger N, Wolffe AP. The methyl-CpG binding transcriptional repressor MeCP2 stably associates with nucleosomal DNA. *Biochemistry* 1999;38:7008-18.
- Clayton-Smith J, Watson P, Ramsden S, Black GCM. Somatic mutation in *MECP2* as a non-fatal neurodevelopmental disorder in males. *Lancet* 2000;356:830-2.
- Bernards A, Gusella JF. The importance of genetic mosaicism in human disease. *N Engl J Med* 1994;331:1447-9.
- Bunyan DJ, Robinson DO, Collins AL, Cockwell AE, Bullman HMS, Whittaker PA. Germline and somatic mosaicism in a female carrier of Duchenne muscular dystrophy. *Hum Genet* 1994;93:541-4.
- Costa J-M, Vidaud D, Laurendreau I, Vidaud M, Fressinaud E, Moisan JP, David A, Meyer D, Lavergne JM. Somatic mosaicism and compound heterozygosity in female hemophilia B. *Blood* 2000;96:1585-7.
- Has C, Bruckner-Tuderman I, Müller D, Floeth M, Folkers E, Donnai D, Traupe H. The Conradi-Hünemann-Happle syndrome (CDPX2) and emopamil binding protein: novel mutations, and somatic and gonadal mosaicism. *Hum Mol Genet* 2000;9:1951-5.
- Gleeson JG, Minnerath S, Kuzniacki RI, Dobyns WB, Young ID, Ross ME, Walsh CA. Somatic and germline mosaic mutations in the doublecortin gene are associated with variable phenotypes. *Am J Hum Genet* 2000;67:574-81.

# Temperature sensitive acyl-CoA oxidase import in group A peroxisome biogenesis disorders

Atsushi Imamura, Nobuyuki Shimozawa, Yasuyuki Suzuki, Zhongyi Zhang, Toshiro Tsukamoto, Tadao Orii, Takashi Osumi, Naomi Kondo

EDITOR—Peroxisome biogenesis disorders (PBDs) are lethal genetic diseases characterised by a number of peroxisomal metabolic abnormalities, including the oxidation of very long chain fatty acids (VLCFAs), biosynthesis of bile acids and plasmalogen, and detoxification of H<sub>2</sub>O<sub>2</sub>. Peroxisomal matrix proteins are synthesised on free polyribosomes and directed to the organelle by *cis* acting peroxisome targeting signals (PTSs). PTS1 is a C-terminal tripeptide Ser-Lys-Leu (SKL) sequence and later the consensus sequence was broadened to (S/A/C/K/N)-(K/R/H/Q/N/S)-L, based on subsequent studies. Acyl-CoA oxidase (AOX) has SKL and D bifunctional protein has AKL.<sup>1-4</sup> PTS2 is an N-terminal cleavable peptide (-R/KLX5Q/HL) that resides in peroxisomal 3-ketoacyl CoA thiolase (PT), alkyl-dihydroxyacetonephosphate synthase, and phytanoyl-CoA hydroxylase.<sup>5-9</sup> PBDs are genetically classified into at least 12 complementation groups (CGs) and each CG contains various clinical phenotypes, for example, Zellweger syndrome (ZS), neonatal adrenoleucodystrophy (NALD), and infantile Refsum disease (IRD).<sup>10-11</sup> ZS patients have severe neurological defects, liver dysfunction, and renal cysts and die before 1 year of age. NALD patients have symptoms similar to ZS patients, but they survive a little longer, and IRD patients show milder abnormalities in the central nervous system and survive even longer. We identified the restoration of peroxisome biogenesis in a temperature sensitive (TS) manner in fibroblasts from milder forms of PBDs, that is, all IRD patients and some NALD patients belonging to groups CG-A (CG8), CG-C (CG4), CG-E (CG1), CG-F (CG10), CG-H, and CG6.<sup>12-15</sup> In these cells, peroxisomes were formed at 30°C and biochemical activities of peroxisomes, including the oxidation of VLCFAs and dihydroxyacetonephosphate acyltransferase (DHAP-AT), and the import of peroxisomal enzymes, were also restored.<sup>16</sup> However, virtually no peroxisomes were formed in ZS cells at 30°C and import of peroxisomal enzymes did not improve.<sup>16</sup> Here, we elucidate temperature dependent import and processing of AOX at 30°C which is unique to fibroblasts from ZS patients belonging to CG-A. Correlation between the import of peroxisomal enzymes and biochemical functions of peroxisomes is also discussed.

## Materials and methods

### CELL LINES

Skin fibroblasts from the patients belonging to CG-A (CG8) including four with ZS (A-02,

06, 10, and 14), two with NALD (A-05 and 08), and one with IRD (A-04) were cultured at 37°C or 30°C in an atmosphere of 5% CO<sub>2</sub> in MEM supplemented with 10% fetal calf serum. A-02, A-06, and A-14 were Japanese babies diagnosed as ZS with typical dysmorphic features, who died at a few months of age. The clinical data of A-04 and A-08 have been previously reported, whereas those of A-05 and A-10 have not.<sup>12</sup> In addition, ZS fibroblasts belonging to CG-C (C-08), CG-E (E-14), and CG-F (F-01) were cultured under the same condition (the numbers and clinical data of these patients have been previously described<sup>12</sup>). All cell lines were classified by complementation analysis as previously described.<sup>10-17-18</sup>

### IMMUNOFLUORESCENCE STUDY

For the detection of peroxisomes and the import of PTSs, cells were fixed after 72 hours' incubation at either 37°C or 30°C, permeabilised with 0.1% Triton X-100, and processed for indirect immunofluorescence staining.<sup>19</sup> The first antibodies we used were rabbit antibodies to human catalase, AOX, D bifunctional protein, and PT, and in double immunofluorescence rabbit anti-rat PMP70 antibody was used.

### BIOCHEMICAL ASSAYS

Peroxisomal VLCFA oxidation in fibroblasts was assessed by the ratio of lignoceric acid (C24:0)/palmitic acid (C16:0) oxidation activity.<sup>20</sup> The activity of DHAP-AT, the first enzyme in the pathway leading to plasmalogen biosynthesis, was measured as described previously<sup>21</sup> using <sup>14</sup>C labelled DHAP as substrate. Continuous cell labelling with <sup>35</sup>S-methionine and immunoprecipitation of AOX with rabbit anti-human AOX antibody was performed as described previously.<sup>19-22</sup>

## Results

### IMMUNOFLUORESCENCE STUDY IN FIBROBLASTS FROM CG-A PATIENTS

The fibroblasts from PBD patients belonging to the CG-A were examined by immunofluorescence microscopy to determine the import of PTS1 and PTS2 containing peroxisomal matrix proteins. The immunoreactivity of these proteins in control cells showed the same punctate pattern as previous reports (data not shown).<sup>23</sup> The most striking result was that in the fibroblasts from ZS patients, the import of AOX was rescued apparently after incubation at 30°C, whereas it was severely reduced or absent at 37°C (fig 1C, D, table 1).

*J Med Genet*  
2001;38:871-874

Department of  
Paediatrics, Gifu  
University School of  
Medicine, 40  
Tsukasa-machi, Gifu  
500-8705, Japan  
A Imamura  
N Shimozawa  
Y Suzuki  
Z Zhang  
N Kondo


Department of  
Paediatrics, Ogaki  
Municipal Hospital,  
Ogaki, Gifu 503-8502,  
Japan  
A Imamura

Department of Life  
Science, Himeji  
Institute of  
Technology, Kamigori,  
Hyogo 678-1297, Japan  
T Tsukamoto  
T Osumi

Faculty of Human  
Welfare, Chubu  
Gakuin University,  
Sekai, Gifu 501-3936,  
Japan  
T Orii

Correspondence to:  
Dr Imamura,  
aimamura@cc.gifu-u.ac.jp





**Figure 1** Immunofluorescent staining for antibodies of peroxisome matrix proteins in fibroblasts from a ZS patient with CG-A (A-06). Cells were cultured for 72 hours at both 37°C (panels A, C, E, and G) and 30°C (panels B, D, F, and H), and stained with anti-human catalase (panels A and B), AOX (panels C and D), D bifunctional protein (panels E and F), and PT (panels G and H) rabbit antibody. Bar=10  $\mu$ m.

**Table 1** The import of peroxisome matrix proteins of fibroblasts from complementation group A (CG-A) patients

No	Type	Catalase		AOX		D bifunctional protein		PT	
		37°C	30°C	37°C	30°C	37°C	30°C	37°C	30°C
A-06	ZS	0	10	10	100	0	0	0	10
A-02	ZS	0	0	0	60	0	0	0	0
A-14	ZS	0	0	0	50	0	0	0	0
A-10	ZS	0	5	10	60	0	0	0	5
A-05	NALD	0	90	0	100	5	60	5	80
A-08	NALD	0	80	0	90	0	50	0	80
A-04	IRD	0	60	0	80	0	50	0	70

Cells were cultured for 72 hours at either 37°C or 30°C and immunostained by antibodies of peroxisome matrix proteins. Immunopositive cells were defined as over 100 immunoreactive particles stained by each antibody in a cell. Immunopositive cells among 20 cells were counted in five view fields at a magnification  $\times 1000$  and data are averages of these in percentages.

**Table 2** Biochemical assay of fibroblasts from complementation group A (CG-A) patients

No.	Type	C24/C16		DHAP-AT	
		37°C	30°C	37°C	30°C
A-06	ZS	0.040	0.069	0.09	0.15
A-14	ZS	0.011	0.042	0.18	0.30
A-10	ZS	0.007	0.030	0.27	0.46
A-05	NALD	0.077	0.199	0.39	1.65
A-08	NALD	0.013	0.287	0.19	1.55
Control		0.522	0.478	1.53	1.90

Fibroblasts were cultured for eight days at either 37°C or 30°C, and then assayed for beta oxidation activities of lignoceric (C24) and palmitic acids (C16) and the ratio of C24/C16 was calculated. DHAP-AT activity was measured in each cell line. These results were the average of duplicates. DHAP-AT activity was indicated as nmol/mg/120 min. The methods have been described in Suzuki *et al.*<sup>20</sup> and Shimozawa *et al.*<sup>21</sup>


The AOX and 70 kDa peroxisomal membrane protein (PMP70) were co-localised in these cells (data not shown). In other CGs, none of the ZS cell lines showed such TS characteristics. There was a little cross reactivity of AOX antibody with mitochondria (fig 1C) co-localised with anti-mitochondria antibody (data not shown). The import of catalase (fig 1A, B), D bifunctional protein (fig 1E, F), and PT (fig 1G, H) was defective after incubation at 30°C (table 1). In cell lines from NALD and IRD patients, the import of catalase, AOX, D bifunctional protein, and PT greatly improved after incubation at 30°C, whereas import of these enzymes was deficient at 37°C (table 1).

#### BIOCHEMICAL ANALYSIS OF FIBROBLASTS FROM CG-A PATIENTS

The relative VLCFA oxidation capacity was expressed as a ratio of C24:0/C16:0 fatty acid oxidation activity of the cell line. Using this assay, a lower ratio of C24:0/C16:0 fatty acid oxidation indicates lower peroxisomal VLCFA oxidation activity.<sup>20</sup> In the same way, the lower activity of DHAP-AT indicates lower plasmalogen biosynthesis capacity of peroxisomes.<sup>21</sup> The VLCFA oxidation ratio and the activity of DHAP-AT in ZS patients belonging to CG-A showed a very low level after incubation at 30°C, although a slight increase in activities was observed. Cell lines from NALD patients, showing TS import of PTSs, showed marked improvement in activities after incubation at 30°C (table 2). AOX, the first enzyme of the peroxisomal beta oxidation system, is processed into two smaller polypeptides in peroxisomes, and this processing was defective in the fibroblasts from patients with PBDs.<sup>22</sup> On continuous labelling of the cells from a ZS patient (A-06) at 30°C, the processed form of AOX (subunit B, 53 kDa) was identified in addition to the unprocessed form of AOX (subunit A, 75 kDa), as was the case with those from the control and NALD patient (A-05). These results indicate that at least AOX is processed in a temperature dependent manner even in ZS cells. In ZS cells belonging to CG-E and CG-F, subunit B was not detected at 30°C, indicating that these ZS cells were not temperature dependent (fig 2).

#### Discussion

The diagnosis in PBD patients is based on clinical features combined with a series of tests



**Figure 2** Biosynthesis and processing of AOX. Fibroblasts were cultured for 72 hours and then incubated for 24 hours in the presence of  $^{35}\text{S}$ -methionine at either 37°C (lanes 1, 3, 5, 7, and 9) or 30°C (lanes 2, 4, 6, 8, and 10). The cell lysate, the same amount of protein, was immunoprecipitated with anti-human AOX antibody and subjected to SDS-PAGE and fluorography. Lanes 1 and 2, control fibroblasts; 3 and 4, ZS with CG-A (A-06) fibroblasts; 5 and 6, NALD with CG-A (A-05) fibroblasts; 7 and 8, ZS with CG-E fibroblasts; 9 and 10, ZS with CG-F fibroblasts.

to assess peroxisomal function and structure, and the absence or reduction of both PTS1 and PTS2 protein imports are observed in the vast majority of cells from patients with PBDs.<sup>24</sup> In fibroblasts from milder forms of PBDs, we elucidated the TS restoration of peroxisome biogenesis including the import of PTSs after incubation at 30°C.<sup>12-16</sup> The temperature dependent manner of peroxisome biogenesis has been identified in cells from mildly affected patients belonging to various different CGs including CG-A in PBDs, whereas it has never been seen in those from ZS patients with these CGs.<sup>12-15</sup> In this study, we clarified the restoration of AOX import and processing after incubation at 30°C in fibroblasts from patients with ZS, NALD, and IRD belonging to CG-A. AOX is one of the PTS1 proteins, and is transported to the peroxisome by binding with Pex5p, a PTS1 receptor.<sup>25, 26</sup> Pex5p is severely reduced in the fibroblasts of patients with CG-A, C, and E. However, cells with those CGs share the ability to import small amounts of both PTS1 and PTS2 proteins.<sup>27</sup> The genes responsible for CG-C and E, *PEX6* and *PEX1*, encode Pex6p and Pex1p, respectively. These proteins belong to the AAA (ATPases associated with diverse cellular activities) family of proteins and are required for stability of the PTS1 receptor in yeast as well as in human cells.<sup>28-32</sup> The product of the CG-A gene, which is still unknown, may also physically function with Pex5p. The biochemical functions of peroxisome as measured by VLCFA oxidation and DHAP-AT activity are restored apparently in the fibroblasts from milder NALD patients, whereas they showed lower levels in the ZS cells even at 30°C as was the case with other CGs. This might be caused by the defective import of peroxisomal beta oxidation enzymes other than AOX. The impairment in fibroblast VLCFA beta oxidation and the clinical manifestations were more severe in bifunctional protein deficient than AOX deficient patients.<sup>33</sup> Therefore, ZS patients with CG-A showed as severe a clinical course and prognosis as those with other CGs, notwithstanding the AOX import was rescued at 30°C in the cells from patients with CG-A.<sup>12, 34</sup> TS import of AOX in

ZS fibroblasts is unique to CG-A. A peroxin encoded by the candidate gene for CG-A may interact with Pex5p independently or with the Pex5p-AOX complex, and may lead to the characteristic import of AOX at 30°C. Isolation of the PEX gene for CG-A will help to clarify the function of peroxin for CG-A and mechanism of the selective TS import of AOX in CG-A patients.

We thank T Hashimoto for anti-human catalase, acyl-CoA oxidase, and D bifunctional protein antibodies. This work was supported in part by a Grant in Aid for Scientific Research (10670718, 10670721) from the Ministry of Education, Science, Sports and Culture of Japan, by Health Science Research Grants from the Ministry of Health and Welfare of Japan, by the Mother and Child Health Foundation, and by the Ichiro Kanehara Foundation.

- Gould SJ, Keller GA, Hosken N, Wilkinson J, Subramani S. A conserved tripeptide sorts proteins to peroxisomes. *J Cell Biol* 1989;108:1657-64.
- Gould SJ, Keller GA, Subramani S. Identification of a peroxisomal targeting signal at the carboxy terminus of firefly luciferase. *J Cell Biol* 1987;105:2923-31.
- Amery L, Brees C, Baes M, Setoyama C, Miura R, Mannaerts GP, Van Veldhoven PP. C-terminal tripeptide Ser-Asn-Leu (SNL) of human D-aspartate oxidase is a functional peroxisome-targeting signal. *Biochem J* 1998; 336:367-71.
- Jiang LL, Miyazawa S, Souris M, Hashimoto T. Structure of D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein. *J Biochem (Tokyo)* 1997;121:364-9.
- Swinkels BW, Gould SJ, Bodnar AG, Rachubinski RA, Subramani S. A novel, cleavable peroxisomal targeting signal at the amino-terminus of the rat 3-ketoacyl-CoA thiolase. *EMBO J* 1991;10:3255-62.
- Osumi T, Tsukamoto T, Hata S, Yokota S, Miura S, Fujiki Y, Hijikata M, Miyazawa S, Hashimoto T. Amino-terminal presequence of the precursor of peroxisomal 3-ketoacyl-CoA thiolase is a cleavable signal peptide for peroxisomal targeting. *Biochem Biophys Res Commun* 1991;181:947-54.
- Tsukamoto T, Hata S, Yokota S, Miura S, Fujiki Y, Hijikata M, Miyazawa S, Hashimoto T, Osumi T. Characterization of the signal peptide at the amino terminus of the rat peroxisomal 3-ketoacyl-CoA thiolase precursor. *J Biol Chem* 1994;269:6001-10.
- Mihalik SJ, Morrell JC, Kim D, Sacksteder KA, Watkins PA, Gould SJ. Identification of PAHX, a Refsum disease gene. *Nat Genet* 1997;17:185-9.
- Jansen GA, Ofman R, Ferdinandusse S, Ijlst L, Muijsers AO, Skjeldal OH, Stokke O, Jakobs C, Besley GT, Wraith JE, Wanders RJ. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. *Nat Genet* 1997;17: 190-3.
- Shimozawa N, Suzuki Y, Zhang Z, Imamura A, Kondo N, Kinoshita N, Fujiki Y, Tsukamoto T, Osumi T, Imanaka T, Orii T, Beemer F, Mooijer P, Dekker C, Wanders RJ. Genetic basis of peroxisome-assembly mutants of humans, Chinese hamster ovary cells, and yeast: identification of a new complementation group of peroxisome-biogenesis disorders apparently lacking peroxisomal-membrane ghosts. *Am J Hum Genet* 1998;63:1898-903.
- Gould SJ, Valle D. Peroxisome biogenesis disorders: genetics and cell biology. *Trends Genet* 2000;16:340-5.
- Imamura A, Tsukamoto T, Shimozawa N, Suzuki Y, Zhang Z, Imanaka T, Fujiki Y, Orii T, Kondo N, Osumi T. Temperature-sensitive phenotypes of peroxisome-assembly processes represent the milder forms of human peroxisome-biogenesis disorders. *Am J Hum Genet* 1998; 62:1539-43.
- Imamura A, Tamura S, Shimozawa N, Suzuki Y, Zhang Z, Tsukamoto T, Orii T, Kondo N, Osumi T, Fujiki Y. Temperature-sensitive mutation in *PEX1* moderates the phenotypes of peroxisome deficiency disorders. *Hum Mol Genet* 1998;7:2089-94.
- Shimozawa N, Suzuki Y, Zhang Z, Imamura A, Toyama R, Mukai S, Fujiki Y, Tsukamoto T, Osumi T, Orii T, Wanders RJ, Kondo N. Nonsense and temperature-sensitive mutations in *PEX13* are the cause of complementation group H of peroxisome biogenesis disorders. *Hum Mol Genet* 1999;8:1077-83.
- Imamura A, Shimozawa N, Suzuki Y, Zhang Z, Tsukamoto T, Fujiki Y, Orii T, Osumi T, Wanders RJA, Kondo N. Temperature-sensitive mutation of *PEX6* in peroxisome biogenesis disorders in complementation group C (CG-C): comparative study of *PEX6* and *PEX1*. *Pediatr Res* 2000;48:541-5.
- Imamura A, Shimozawa N, Suzuki Y, Zhang Z, Tsukamoto T, Fujiki Y, Orii T, Osumi T, Kondo N. Restoration of biochemical function of the peroxisome in the temperature-sensitive mild forms of peroxisome biogenesis disorder in humans. *Brain Dev* 2000;22:8-12.
- Yajima S, Suzuki Y, Shimozawa N, Yamaguchi S, Orii T, Fujiki Y, Osumi T, Hashimoto T, Moser HW. Complementation study of peroxisome-deficient disorders by immunofluorescence staining and characterization of fused cells. *Hum Genet* 1992;88:491-9.

- 18 Shimozawa N, Suzuki Y, Orii T, Moser A, Moser HW, Wanders RJ. Standardization of complementation grouping of peroxisome-deficient disorders and the second Zellweger patient with peroxisomal assembly factor-1 (PAF-1) defect. *Am J Hum Genet* 1993;52:843-4.
- 19 Tsukamoto T, Miura S, Nakai T, Yokota S, Shimozawa N, Suzuki Y, Orii T, Fujiki Y, Sakai F, Bogaki A, Yasuno H, Osumi T. Peroxisome assembly factor-2, a putative ATPase cloned by functional complementation on a peroxisome-deficient mammalian cell mutant. *Nat Genet* 1995;11:395-401.
- 20 Suzuki Y, Shimozawa N, Yajima S, Yamaguchi S, Orii T, Hashimoto T. Effects of sodium 2-[5-(4-chlorophenyl)pentyl]-oxirane-2-carboxylate (POCA) on fatty acid oxidation in fibroblasts from patients with peroxisomal diseases. *Biochem Pharmacol* 1991;41:453-6.
- 21 Shimozawa N, Suzuki Y, Orii T, Yokota S, Hashimoto T. Biochemical and morphologic aspects of peroxisomes in the human rectal mucosa: diagnosis of Zellweger syndrome simplified by rectal biopsy. *Pediatr Res* 1988;24:723-7.
- 22 Suzuki Y, Shimozawa N, Orii T, Igarashi N, Kono N, Hashimoto T. Molecular analysis of peroxisomal beta-oxidation enzymes in infants with Zellweger syndrome and Zellweger-like syndrome: further heterogeneity of the peroxisomal disorder. *Clin Chim Acta* 1988;172:65-76.
- 23 Shimozawa N, Zhang Z, Suzuki Y, Imamura A, Tsukamoto T, Osumi T, Fujiki Y, Orii T, Barth PG, Wanders RJ, Kondo N. Functional heterogeneity of C-terminal peroxisome targeting signal 1 in PEX5-defective patients. *Biochem Biophys Res Commun* 1999;262:504-8.
- 24 Slaweck ML, Dodt G, Steinberg S, Moser AB, Moser HW, Gould SJ. Identification of three distinct peroxisome protein import defects in patients with peroxisome biogenesis disorders. *J Cell Sci* 1995;108:1817-29.
- 25 Dodt G, Braverman N, Wong C, Moser A, Moser H. W, Watkins P, Valle D, Gould SJ. Mutations in the PTS1 receptor gene, PXR1, define complementation group 2 of the peroxisome biogenesis disorders. *Nat Genet* 1995;9:115-25.
- 26 Wiemer EA, Nuttley WM, Bertolaet BL, Li X, Francke U, Wheelock MJ, Anne UK, Johnson KR, Subramani S. Human peroxisomal targeting signal-1 receptor restores peroxisomal protein import in cells from patients with fatal peroxisomal disorders. *J Cell Biol* 1995;130:51-65.
- 27 Dodt G, Gould SJ. Multiple PEX genes are required for proper subcellular distribution and stability of Pex5p, the PTS1 receptor: evidence that PTS1 protein import is mediated by a cycling receptor. *J Cell Biol* 1996;135:1763-74.
- 28 Fukuda S, Shimozawa N, Suzuki Y, Zhang Z, Tomatsu S, Tsukamoto T, Hashiguchi N, Osumi T, Masuno M, Imai-zumi K, Kuroki Y, Fujiki Y, Orii T, Kondo N. Human peroxisome assembly factor-2 (PAF-2): a gene responsible for group C peroxisome biogenesis disorder in humans. *Am J Hum Genet* 1996;59:1210-20.
- 29 Yahraus T, Braverman N, Dodt G, Kalish JE, Morrell JC, Moser HW, Valle D, Gould SJ. The peroxisome biogenesis disorder group 4 gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the PTS1 receptor. *EMBO J* 1996;15:2914-23.
- 30 Reuber BE, Germain-Lee E, Collins CS, Morrell JC, Ameritunga R, Moser HW, Valle D, Gould SJ. Mutations in PEX1 are the most common cause of peroxisome biogenesis disorders. *Nat Genet* 1997;17:445-8.
- 31 Portsteffen H, Beyer A, Becker E, Epplen C, Pawlak A, Kunau WH, Dodt G. Human PEX1 is mutated in complementation group 1 of the peroxisome biogenesis disorders. *Nat Genet* 1997;17:449-52.
- 32 Tamura S, Okumoto K, Toyama R, Shimozawa N, Tsukamoto T, Suzuki Y, Osumi T, Kondo N, Fujiki Y. Human PEX1 cloned by functional complementation on a CHO cell mutant is responsible for peroxisome-deficient Zellweger syndrome of complementation group I. *Proc Natl Acad Sci USA* 1998;95:4350-5.
- 33 Watkins PA, McGuinness MC, Raymond GV, Hicks BA, Sisk JM, Moser AB, Moser HW. Distinction between peroxisomal bifunctional enzyme and acyl-CoA oxidase deficiencies. *Ann Neurol* 1995;38:472-7.
- 34 Moser HW. Genotype-phenotype correlations in disorders of peroxisome biogenesis. *Mol Genet Metab* 1999;68:316-27.

*J Med Genet*  
2001;38:874-876

Department of  
Paediatrics, Hokkaido  
University School of  
Medicine, North-15  
West-7, Kita-ku,  
Sapporo 060-8638,  
Japan

I Kobayashi  
R Shiari  
M Yamada  
N Kawamura  
M Okano  
K Kobayashi

Paediatric Clinic,  
Naha Municipal  
Hospital, Naha, Japan  
A Yara

Paediatric Clinic,  
Kitami Red Cross  
General Hospital,  
Kitami, Japan  
A Iguchi  
N Ishikawa

Gene Therapy,  
Hokkaido University  
School of Medicine,  
Sapporo, Japan  
T Ariga  
Y Sakiyama

Division of  
Immunology,  
Infectious Disease and  
Rheumatology,  
Department of  
Pediatrics, University  
of Washington, Seattle,  
USA  
H D Ochs

Correspondence to:  
Dr Kobayashi,  
ichikoba@med.hokudai.ac.jp

## Novel mutations of *FOXP3* in two Japanese patients with immune dysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX)

Ichiro Kobayashi, Reza Shiari, Masafumi Yamada, Nobuaki Kawamura, Motohiko Okano, Asao Yara, Akihiro Iguchi, Nobuyoshi Ishikawa, Tadashi Ariga, Yukio Sakiyama, Hans D Ochs, Kunihiko Kobayashi

EDITOR—Immune dysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX), also known as X linked autoimmunity-allergic dysregulation syndrome (XLAAD), is characterised by enteropathy and involvement of the endocrine system, such as insulin dependent diabetes mellitus (IDDM) and thyroiditis, which develop in association with autoantibodies in early infancy (MIM 304930, 304790).<sup>1,2</sup> IPEX has been mapped to chromosome Xp11.23-Xq13.3.<sup>3,4</sup> Recent studies have indicated that *FOXP3*, a member of forkhead/winged-helix proteins, is a causative gene for both IPEX and an equivalent mouse, *scurfy*.<sup>5-8</sup> Human *FOXP3* consists of 11 exons and encodes 431 amino acids containing a zinc finger (Zn) domain, a leucine zipper (Zip) motif, and a forkhead domain.<sup>6,8</sup> We have previously reported two unrelated Japanese patients with X linked autoimmune enteropathy associated with tubulonephropathy and endocrinopathy.<sup>2,9,10</sup>

We report here novel mutations in the *FOXP3* gene of these patients.

### Patients and methods

Clinical and laboratory findings of our patients have been previously reported.<sup>2,9,10</sup> Briefly, patient 1, a boy, now 11 years old, was diagnosed as having autoimmune thyroiditis, autoimmune haemolytic anaemia, and autoimmune enteropathy at the age of 2 weeks, 2 months, and 5 months, respectively. Renal tubular dysfunction was also noted. His maternal uncle and his older brother had died of a similar diarrhoeal disease complicated by IDDM, suggesting X linked inheritance of the disease.<sup>2</sup> He has been treated with a combination of tacrolimus (0.3 mg/day) and beta-methasone (0.3-0.5 mg/day).<sup>9</sup> Hypocalcaemia and hypokalaemia often develop in spite of supplementation with calcium, potassium, and vitamin D, which suggests renal damage resulting from either the underlying disease or a side



Table 1 Primers used in the analyses of the *FOXP3* gene

	Forward primer	Reverse primer
Exon 1	5'-AGTATCTCATACCGCCCTAGCACACGTGTGA-3'	5'-ACAGTAAAGGTCCGGCACCTGTAGGTCCAGGTA-3'
Exons 2-3	5'-AGTGCAGAGTATTTGAATTAGACACAGAACAGTG-3'	5'-AGAATAGCCTACACTGCTCACAGCCAAGGATCTG-3'
Exons 4-5	5'-AGAGGCCCTTGTGGGCCAAGCTCCAGAGCCCA-3'	5'-GAGCTGAGATCTGCACCCCTAGACCTCTCCCCA-3'
Exon 6	5'-GCATGTGTTAAGGGAACGAGGGGTGT-3'	5'-GGTTTTGCGCACTATCCCTA-3'
Exon 7	5'-GGGATAGTGCACAAACC-3'	5'-CAGCAGTCTGAGTCTGCCACCA-3'
Exon 8	5'-GGCGACAGAGCAAGACTCAGTA-3'	5'-CACCCAGAGCCTGTGAGGATTAGGA-3'
Exon 9	5'-GACGGTGAGATCTCAGGCCTGTAGACTCACCTTG-3'	5'-AACCCACTCTGAGGGCACTCAGAGGGAGACA-3'
Exons 10-11	5'-AGGTCATAGCCCTCTAAACCCCAAGTTTG-3'	5'-ACCTCTGCCTCCACCAGTTTGGCCCTGTTCG-3'




Figure 1 Sequence analyses of exon 2 of patient 1 (A) and exon 10 of patient 2 (B). Arrowhead indicates a deletion of T at nt 227 in patient 1. Underline indicates an A to G transition at nt 1087 in patient 2.

effect of tacrolimus. In addition, he is suffering from osteoporosis associated with multiple compression fractures of the vertebral bodies and steroid induced cataract. He has failed to gain weight and height, although his diarrhoea has been fairly well controlled.

Patient 2, a boy, was diagnosed as having autoimmune enteropathy, tubulonephropathy, IDDM, and thyroiditis in his early infancy. He died of sepsis before using immunosuppressants at the age of 3 years. His maternal uncle died of intractable diarrhoea.<sup>9</sup> Both of the patients showed extremely high levels of serum IgE.<sup>10 11</sup>

Genomic DNA was isolated from Epstein-Barr virus transformed cell lines in patient 1 and his family and from a necropsy specimen in patient 2 using a standard method. Each exon including the exon-intron junction was amplified by polymerase chain reaction (PCR) (94°C for five minutes, followed by 35 cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for one minute) with primers listed in table 1. Additional primers were also used for sequence analyses.<sup>8</sup> PCR products were supplied for direct sequencing. Both PCR amplification and sequencing were performed using GeneAmp PCR System 2400 (Perkin Elmer).

Sequence analyses were performed by Gene Analyzer 310 (ABI PRISM).

### Results and discussion

Patient 1 showed a deletion of a single nucleotide T227 in exon 2, which results in a frameshift and generates a premature stop at codon 128 (fig 1A). Accordingly, the truncated protein in patient 1 lacks all of the domains and is apparently non-functional. This mutation was not observed in his healthy brother, sister, or father. His mother was found to be heterozygous for this mutation. Seven mutations of *FOXP3* have been reported in IPEX. Three cases carry single amino acid substitutions in the forkhead domain, whereas another has a single amino acid deletion in the Zip domain.<sup>6-8</sup> Deletion of the forkhead domain was reported in one case, which resulted from exon 9 skipping and a frameshift accompanied by premature termination.<sup>8</sup> The remaining two cases involve deletion of a stop codon which results in the addition of new residues.<sup>6 7</sup> Patient 2 showed an A1087G substitution in exon 10, which results in an Ile363Val substitution (fig 1B). Wildin *et al*<sup>6</sup> reported that no sequence variations are found in exons 10

and 11 in unaffected subjects, indicating that the Ile363Val substitution is not a polymorphism but a missense mutation. Ile363 is located in the middle of the second  $\alpha$ -helix of the forkhead domain and is highly conserved among FOX family members,<sup>13,14</sup> suggesting that Ile363 is critical for the function of FOXP3.

IPEX patients, as well as *scurfy* mouse, show autoimmune and allergic features which are associate with skewed expression of Th2 type cytokines.<sup>1-8,15-17</sup> Our patients showed various autoantibodies against the intestine, renal tubules, thyroid, or red blood cells.<sup>2,12</sup> In addition, overexpression of Th2 type cytokines such as interleukin-4 has also been found in the peripheral blood mononuclear cells from patient 1.<sup>11</sup> Thus, it is predicted that *FOXP3* contributes to maintenance of immune tolerance and regulates cytokine expression. Clarification of its precise function in normal immune systems could provide new insights into the mechanism of autoimmunity and allergy.

We thank family members for their participation in this study. This work was supported by Grant in Aid from the Ministry of Education, Science, Sports and Culture, Japan.

- Powell BR, Buist NRM, Stenzel P. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. *J Pediatr* 1982;100:731-7.
- Satake N, Nakanishi M, Okano M, Tomizawa K, Ishizaka A, Kojima K, Onodera M, Ariga T, Satake A, Sakiyama Y, Matsumoto S. A Japanese family of X-linked auto-immune enteropathy with haemolytic anaemia and polyendocrinopathy. *Eur J Pediatr* 1993;152:313-15.
- Ferguson PJ, Blanton SH, Saulsbury FT, McDuffie MJ, Lemahieu V, Gastier JM, Francke U, Borowitz SM, Sutphen JL, Kelly TE. Manifestations and linkage analysis in X-linked autoimmunity-immunodeficiency syndrome. *Am J Med Genet* 2000;90:390-7.
- Bennett CL, Yoshioka R, Kiyosawa H, Barker DF, Fain PR, Shigeoka AO, Chance PF. X-linked syndrome of polyendocrinopathy, immune dysfunction, and diarrhea maps to Xp11.23-Xq13.3. *Am J Hum Genet* 2000;66:461-8.
- Brunkow ME, Jeffery EW, Hjerrild KA, Paepfer B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F. Disruption of a new forkhead/winged-helix protein, *scurfy*, results in the fatal lymphoproliferative disorder of the *scurfy* mouse. *Nat Genet* 2001;27:68-73.
- Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Briccarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse *scurfy*. *Nat Genet* 2001;27:18-20.
- Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutation of *FOXP3*. *Nat Genet* 2001;27:20-1.
- Chatila TA, Blaese F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, Bowcock AM. JM2, encoding a forkhead-related protein, is mutated in X-linked autoimmunity-allergic dysregulation syndrome. *J Clin Invest* 2001;106:R75-81.
- Kobayashi I, Nakanishi M, Okano M, Sakiyama Y, Matsumoto S. Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy. *Eur J Pediatr* 1995;154:594-5.
- Kobayashi I, Imamura K, Yamada M, Okano M, Yara A, Ikema S, Ishikawa N, Kobayashi K, Sakiyama Y. A 75-kD autoantigen recognized by sera from patients with X-linked autoimmunity enteropathy associated with nephropathy. *Clin Exp Immunol* 1998;111:527-31.
- Kawamura N, Furuta H, Tame A, Kobayashi I, Ariga T, Okano M, Sakiyama Y. Extremely high serum level of IgE during immunosuppressive therapy: paradoxical effect of cyclosporine A and tacrolimus. *Int Arch Allergy Immunol* 1997;112:422-4.
- Kobayashi I, Imamura K, Kubota M, Ishikawa S, Yamada M, Tonoki H, Okano M, Storch WB, Moriuchi T, Sakiyama Y, Kobayashi K. Identification of an autoimmunity enteropathy-related 75-kilodalton antigen. *Gastroenterology* 1999;117:823-30.
- Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, Amati P, Bisceglia L, Zelante L, Nagaraja R, Porcu S, Ristalde MS, Marzella R, Rocchi M, Nicolino M, Lienhardt-Roussie A, Nivelon A, Verloes A, Schellesinger D, Gasparini P, Bonneau D, Cao A, Pilia G. The putative forkhead transcription factor *FOXL2* is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. *Nat Genet* 2001;27:159-66.
- Blixt A, Mahlapuu M, Atiola M, Peltto-Huikko M, Enerbäck S, Carlsson P. A forkhead gene, *FOXE3*, is essential for lens epithelial proliferation and closure of the lens vesicle. *Genes Dev* 2000;14:245-54.
- Lyon MF, Peters J, Glenister PH, Ball S, Wright E. The *scurfy* mouse mutant has previously unrecognized hematological abnormalities and resembles Wiskott-Aldrich syndrome. *Proc Natl Acad Sci USA* 1990;87:2433-7.
- Godfrey VL, Wilkinson JE, Russel LB. X-linked lymphoreticular disease in the *scurfy* (sf) mutant mouse. *Am J Pathol* 1991;138:1379-87.
- Kanangat S, Blair P, Reddy R, Deheshia M, Godfrey V, Rouse BT, Wilkinson E. Disease in the *scurfy* (sf) mouse is associated with overexpression of cytokine genes. *Eur J Immunol* 1996;26:161-5.

## Maternal uniparental isodisomy 11q13→qter in a dysmorphic and mentally retarded female with partial trisomy mosaicism 11q13→qter

Dieter Kotzot, Benno Röthlisberger, Mariluce Riegel, Albert Schinzel

*J Med Genet*  
2001;38:876-881

Institut für  
Medizinische Genetik,  
Universität Zürich,  
Rämistrasse 74,  
CH-8001 Zürich,  
Switzerland  
D Kotzot  
B Röthlisberger  
M Riegel  
A Schinzel

Correspondence to:  
Professor Schinzel,  
schinzel@medgen.unizh.ch

EDITOR—Partial trisomy mosaicism describes the presence of a normal cell line together with an unbalanced translocation in a second cell line. Its incidence is not known. Only a few cases have been published,<sup>1</sup> almost all with developmental delay and a pattern of dysmorphism. The presence of a normal cell line points towards postzygotic formation, but the origin and mechanism of formation have so far only been investigated in one case of partial trisomy 16p mosaicism and in another case of partial trisomy 21q mosaicism.<sup>2,3</sup> In the

former, a complex formation by trisomy first, translocation second, and uniparental disomy and partial trisomy third was inferred. In the latter, paternal meiotic origin of der(21;21)(q10;q10) mosaicism (46,XX/46,XX,der(21;21)(q10;q10),+21) in a girl with mild Down syndrome was described.

Here, we report on a 25 year old woman with mental retardation, dysmorphic features, partial trisomy 11q13→qter mosaicism (46,XX,der(19)t(11;19)(q13;p13.3)/46,XX), maternal uniparental isodisomy 11q13→qter in the




Figure 1 Face of the proband aged 6 months (A) and 6 years (B, C).

Table 1 Results of molecular investigations of genomic DNA from lymphocytes and fibroblasts using microsatellites mapping to chromosome 11

Marker	Location	(M/P blood/P fibroblasts/F)
D11S2071	p15.5	ab/a/a/ac
D11S922	p15.5	bd/ad/ad/ac
D11S1318	p15.5	ac/ab/ab/bc
D11S1334	p15.4	a/ab/ab/b
D11S860	p15	ac/ab/ab/bc
D11S1324	p14	bc/ab/ab/ac
D11S905	p12-p13	bc/ab/ab/ab
D11S436	p12-p11.22	bc/ab/ab/ab
Centromere		
D11S4191	q13.1	ac/ab/ab/bc
D11S1314	q13.1	ab/ac/ac/ac
D11S916	q13-q23	ac/ab/ab/ab
D11S527	q13.5 ?	ac/a/ab/bd
D11S2002	q21-q23	ab/b/bc/c
D11S901	q14	ad/d/bd/bc
D11S876	q14.1-q23.3	ab/b/ab/a
D11S940	q22	ab/bc(?)bc/c
D11S2000	q22	b/b/b/ab
D11S927	q22	bc/c/bc/ab
D11S1356	q23	ab/b/bd/cd
D11S528	q22.3	ac/a/ac/bc
D11S934	q23.3-q24	a/a/ab/bc
D11S912	q25	bd/d/cd/ac
D11S968	q24.1-q25	ac/c/cd/bd

Informative markers are underlined. F = father, P = patient, M = mother.

normal cell line, and two maternal and one paternal segment(s) 11q13→qter in the abnormal cell line.

### Case report

The female patient is the second child of a healthy, unrelated, white couple. An older brother is healthy. At the proband's birth, her mother was 38 years old and her father was 39 years old. Following information, the parents opted against prenatal cytogenetic diagnosis. Delivery by caesarean section took place at 42 weeks of a normal gestation. Weight (2500 g) and length (48 cm) were below the 10th centile. A right inguinal hernia, ipsilateral pes equinovarus, and left hip dysplasia were surgically corrected. At the age of 6 years, height (1.7 m) was on the 10th centile, weight (22 kg) on the 75th centile, and occipitofrontal head circumference (OFC) (51 cm) on the 50th centile. At the last re-examination at the age of

25 years, height (1.50 m) was below the 3rd centile and OFC (55 cm) was between the 50th and 75th centile. Dysmorphic features included deep set eyes, downward slanting palpebral fissures, broad nasal root, large nares, flat and broad philtrum, diastema of the lower incisors, small and low set ears, contractures at both elbows with inability to supinate or pronate, ulnar deviation of both hands at the wrists, slender fingers, clinodactyly of fingers IV and V, and small feet with hypoplastic nails and partial 2/3 syndactyly (fig 1). Severe developmental delay was obvious.

### Methods

Chromosome analysis was performed on GTG banded fibroblast and lymphocyte cell cultures at a level of about 550 bands according to standard procedures. Fluorescence in situ hybridisation (FISH) was done according to the manufacturer's instructions (Vysis Inc, Downers Grove, IL, USA).





Figure 2 Molecular results of marker D11S940 with two distinct maternal alleles (A) and two copies of the paternal allele (E) in genomic DNA from the parents, only one maternal allele in DNA from nucleated blood cells of the patient (B), but an additional paternal allele in genomic DNA from the patient's fibroblasts (C), and only the paternal allele in the derivative chromosome 19 microdissected from the patient's fibroblasts (D). The additional weak signal in DNA from nucleated blood cells of the patient (B) is either an artefact or represents low level mosaicism for a paternal allele.





**Figure 3** Diagram of the mitotic mechanisms 1 and 2 explaining the molecular results obtained in the patient. Mechanism 1. Postzygotic formation with segmental UPD (11q13→qter) in the normal cell line and in the abnormal cell line. The zygote is normal with biparentally inherited chromosomes 11 (line 1). During mitosis both homologues are duplicated regularly (line 2). Then, both paternal sister chromatids break at 11q13 and one paternal sister chromatid is lost (line 3a) resulting in a daughter cell with  $\text{del}(11\text{q}13\rightarrow\text{qter})$  (line 3b) and a second daughter cell with  $\text{t}(11;19)(\text{q}13\text{pter})$  (line 3c). Finally, most likely during interphase in both daughter cells, somatic reduplication of the maternal segment occurs (line 4a and b) resulting in segmental maternal UPD (11q13→qter) (line 5a and b). Mechanism 2. Postzygotic formation with segmental UPD (11q13→qter) in the normal cell line only. Again, the zygote is normal with biparentally inherited chromosomes 11 (line 1) and during mitosis both homologues are duplicated regularly (line 2). Then, the break occurs in only one paternal sister chromatid, which is translocated to one chromosome 19. Therefore, one daughter cell has  $\text{del}(11)(\text{q}13\rightarrow\text{qter})$  (line 3d), while the other has one normal maternal chromosome 11, one normal paternal chromosome 11, and an additional paternal segment 11q13→qter translocated to 19p (line 3e). At least, in the normal cell line during interphase, somatic reduplication occurs (line 4c) resulting in segmental maternal UPD (11q13→qter) (line 5c).

For molecular investigations, DNA was extracted from blood and cultured fibroblasts of the patient and from blood of both parents. PCR amplification of highly polymorphic microsatellites (Research Genetics®, Huntsville, AL, USA) was carried out under standard condition. Bands were visualised by silver staining.

For a more detailed investigation of the origin of the normal chromosomes 11 and of the segment 11q13→qter translocated onto one chromosome 19, a new technical approach recently developed in our laboratory was applied.<sup>4</sup> Briefly, the derivative chromosome 19

was microdissected from 10 metaphases according to standard procedures, the dissected chromosomes collected in a PCR tube containing 2 µl collection drop solution (10 mmol/l Tris/HCl, 10 mmol/l NaCl, 3 mg/ml proteinase K PCR grade), and incubated for two hours at 60°C. Subsequently, proteinase K was inactivated at 90°C for 10 minutes. Whole genome amplification was performed according to a slightly modified (no gelatine, 500 µmol/l dNTP, 1 mmol/l MgCl, 100 µmol/l totally degenerated, 15 nucleotide long primer) primer-extension-preamplification polymerase chain reaction (PEP-PCR) protocol.<sup>5</sup> Finally, multiple highly polymorphic microsatellites were analysed by time release PCR (0.1 mmol/l dNTP, 0.24 µmol/l primers, 1.25 U AmpliTaq Gold®, 1.5–2.5 mmol/l MgCl, using 5 µl aliquots of the preamplified DNA in a final volume of 50 µl in a Techne Progene® thermocycler for 56 cycles: 60–64°C for four minutes, 94°C for one minute), run on a 6% polyacrylamide gel, and bands visualised by silver staining.

## Results

Chromosome analysis from lymphocytes at the age of 6 years showed partial trisomy 11q mosaicism (46,XX,der(19)t(11;19)(q13;p13.3)[17]/46,XX[83]). Twenty years later, blood chromosome analysis showed a 46,XX karyotype in 40 metaphases. In fibroblasts, mosaicism was also present (46,XX,der(19)t(11;19)(q13;p13.3)de novo[30]/46,XX[20]). Involvement of chromosomes 11 and 19 in the rearrangement was confirmed by FISH with libraries of chromosomes 11 and 19 (Vysis® Inc, Downers Grove, IL, USA). FISH with a 19p subtelomeric probe (Vysis® Inc) showed signals on both chromosomes 11 and 19 in the normal cell line and on the normal and the derivative chromosome 19 in the abnormal cell line, and FISH with an “all telomeres” probe (Vysis® Inc) failed to show a telomere at the translocation breakpoint. Therefore, the breakpoint on 19p must be distal to the subtelomeric locus of this probe, and the rearrangement led to duplication of 11q13→qter without significant concomitant 19p deletion in the abnormal cell line. The karyotypes of both parents were normal.

Molecular investigations performed at the age of 25 years showed maternal uniparental isodisomy 11q13→qter in DNA from nucleated blood cells (table 1). In DNA from the patient's fibroblasts, paternal bands of weaker intensity of markers mapping to 11q13→qter were found (fig 2). The breakpoint was determined between markers D11S916 and D11S527. In blood and fibroblasts, biparental inheritance of chromosome 19 markers was shown. The results of investigations with several microsatellites from various other chromosomes were in agreement with correct paternity (data not shown).

Following microdissection of the derivative chromosome 19 from 10 metaphases, primer-extension-preamplification, and subsequent microsatellite analysis, only a paternal allele and no maternal allele was found at markers D11S912 and D11S940 (fig 2). The additional

weak signal in DNA from the patient's blood at the level of the paternal allele was interpreted as either an artefact or as representing low level mosaicism for the der(19) chromosome.

### Discussion


The unexpected molecular results obtained in the present case could theoretically be explained by three different mitotic and two meiotic mechanisms of formation.

(1) Each homologue of chromosome 11 was regularly duplicated in the late interphase of a normal mitosis (fig 3, left, line 2). Both paternal sister chromatids broke and simultaneously one chromatid segment 11q13→qter was translocated to one chromosome 19, while her sister chromatid segment was lost (line 3a). In the anaphase, one normal maternal chromatid and one deleted paternal chromatid segregated to each of the two daughter cells, as well as the derivative chromosome 19 to one of the daughter cells (line 3c) and the normal chromosome 19 to the other (line 3b). Finally, mitotic reduplication of the maternal segment 11q13→qter in both daughter cells (line 4a and b) resulted in maternal segmental uniparental isodisomy 11q13→qter in the normal (line 5a) as well as in the abnormal cell line (line 5b).

(2) Again, in a normal 46,XX zygote, inheritance of chromosome 11 was biparental and each homologue of chromosome 11 was duplicated in the late interphase of a regular mitosis

(fig 3, right, line 2). Subsequently, after separation of the sister chromatids, a break occurred in only one paternal chromatid at 11q13, and the segment 11q13→qter was translocated to chromosome 19. The complete paternal chromatid segregated together with the derivative chromosome 19 regularly to one daughter cell (line 3e), while the isolated part of the 11q chromatid segregated with the other daughter cell together with two normal chromosomes 19 (line 3d). Finally, mitotic reduplication of the maternal segment 11q13→qter in the daughter cell containing the deleted 11 (line 4) resulted in maternal uniparental disomy (UPD) (11q13→qter) in the now (through correction) normal cell line (line 5c) and, in contrast to the first mechanism, in biparental inheritance of the whole chromosome 11 in the abnormal cell line (line 5d).

(3) Considering the third mechanism, two independent mitotic events must be postulated (fig 4). The first is characterised by an exchange between two non-sister chromatids (line 3a) resulting in two daughter cells with opposite segmental UPD (11q13→qter) (line 6a and b). The cell line with maternal UPD (11q13→qter) would persist as shown in blood (line 6a), whereas the cell line with paternal segmental UPD (11q13→qter) would not be viable (line 6b). In another cell with biparental inheritance of chromosome 11 (line 2b), a break in either one (line 3c) or in both (line 3b)



**Figure 4** Diagram of the mitotic mechanism 3 explaining the molecular results obtained in the present case. After several mitotic cell divisions of a normal zygote (line 1) with biparentally inherited chromosomes 11, in one cell (line 2a) an exchange between two non-sister chromatids occurs (line 3a). The results are two cells with opposite maternal and paternal segmental UPD (11q13→qter) (line 6a and b). The cell with paternal UPD (11q13→qter) is not viable (line 6b). In addition, in a completely independent mitosis either a break in both (line 3b) or in only one chromatid (line 3c) occurs followed by a scenario as described in fig 2, except the lethality of the cell lines with del(11)(q13qter) (line 6d and g). In the also possible case of maternal UPD (11q13→qter) in the abnormal cell line, again the maternal segment 11q13→qter is mitotically reduplicated in interphase (lines 5 and 6c).




Figure 5 Diagram for mechanism 4 with partial endoreduplication and subsequent ("jumping") translocation onto chromosome 19 of the segment 11q13→qter.

chromatids would have occurred. In the latter case, one segment would have been translocated to one chromosome 19 (line 4), whereas the other would have been lost (line 6e). The cell line with  $\text{del}(11)(\text{q}13\text{qter})$  would not have been viable (line 6d). In the other cell line, maternal segmental UPD (11q13→qter) (line 6c) would have been formed by reduplication during interphase (line 5). In the alternative case of breaking of only one chromatid (line 3c), one cell line with  $\text{del}(11)(\text{q}13\text{qter})$  (lethal) (line 6g) and a second cell line with biparentally inherited chromosomes 11 and an additional translocation of the paternal segment 11q13→qter would have arisen (line 6f). This partial mechanism is less likely, because the molecular investigations showed a weaker intensity of the paternal versus the maternal alleles.

(4) A fourth mitotic mechanism (fig 5) would be characterised by a normal zygote and segmental mitotic reduplication on the maternal chromosome. Then, a crossing over between one paternal chromatid and the reduplicated segment as well as translocation of the paternal segment to 19p occurred. Segregation resulted in the karyotype described.

(5) A fifth, in part meiotic mechanism would require a balanced 11;19 translocation already present in the paternal gamete (fig 6, left, line 1a). Thereafter, again a mitotic reduplication of the maternal segment 11q13→qter must

have happened (line 2) and, in addition, in the normal cell line the loss of the translocated paternal segment 11q13→qter (line 5a) or even the loss of the entire derivative chromosome 19 combined with mitotic reduplication of its normal homologue must be postulated. The latter was excluded by the biparental inheritance of chromosome 19 in blood and fibroblasts (data not shown).


(6) A sixth, again in part meiotic mechanism would require a trisomic zygote resulting from maternal non-disjunction (fig 6, right, line 1b). Mitotic crossing over between the paternal chromatid and one maternal chromatid (line 4b) would result in two different daughter cells (line 5e and f). One with biparental chromosomes 11 and translocation of the paternal segment 11q13→qter to one chromosome 19 (line 5e), and a second with exclusively maternal 11q13→qter material (line 5f). In addition, in both cell lines, one chromosome must have been lost, the chromosome with  $\text{del}(11)(\text{q}13\text{→qter})$  in one (line 5d), and one complete maternal chromosome 11 in the other (line 5g). This mechanism is supported by the advanced maternal age of 38 years at delivery; on the other hand, complete isodisomy would better fit a postmeiotic formation.

In total, each mechanism requires a minimum of three subsequent or in part simultaneous events. With the presently available molecular investigations, it was not possible to define one single possible mechanism of formation. Isodisomy in the normal cell line could be considered to indicate mitotic formation. Apart from paternal UPD (11p15) in up to 20% of cases with Beckwith-Wiedemann syndrome,<sup>6</sup> segmental UPD has rarely been reported.<sup>7-11</sup> Similarly, paternal UPD of the whole chromosome 11 has been described only twice, in a fetus with severe intrauterine growth retardation, intestinal malrotation, and confined placental mosaicism,<sup>12</sup> and in a mosaic state in a girl with Beckwith-Wiedemann syndrome.<sup>13</sup> To the best of our knowledge, maternal segmental UPD of chromosome 11 has not been reported so far. Full trisomy 11 is not viable and non-mosaic duplication of 11q13→qter has been reported only rarely. The phenotype of the latter is characterised by cardiac anomalies, restricted elbow movements including supination and pronation, facial dysmorphism, small and low set ears, and mental retardation.<sup>1</sup>

The clinical consequences of the complex rearrangement found in our patient are difficult to evaluate. The phenotype strongly resembles several cases with duplication of 11q13→qter, and thus could be caused only by this. On the other hand, an additional effect of mosaicism for the loss of the normal homologue of an imprinted gene and/or of homozygosity for a mutated allele of a recessive gene cannot yet be fully excluded.

We are grateful to the family for their cooperation. The study was supported by the Swiss National Foundation, grant Nos 32-45604.95 and 32-56053.98.





**Figure 6** Diagram of the more complex and therefore more unlikely meiotic mechanisms to explain the molecular results obtained in the present case. **Mechanism 5.** A paternal 11;19 translocation is already present in the zygote (line 1a). Subsequently, during mitosis, somatic reduplication of the maternal segment 11q13→qter occurs (line 2). In a second mitosis the paternal segment 11q13→qter translocated to 19p must be lost (line 5a) to receive a cytogenetically normal cell line (line 5b). The last step seems particularly unlikely. **Mechanism 6.** Subsequent to a trisomic zygote owing to maternal non-disjunction (line 1a) a crossing over between the paternal and one maternal allele occurred (line 4b) and two daughter cells arose, one with biparental inheritance of chromosome 11 and translocation of 11q13→qter to chromosome 19 (line 5e) and one with UPD 11q13→qter (line 5f). In addition, one chromosome 11 deleted for 11q13→qter (line 5d) and one complete maternal chromosome 11 (line 5g) were lost during mitosis.

- A 25 year old woman with mental retardation, dysmorphic features, and partial trisomy mosaicism 11q13→qter (karyotype 46,XX,der(19)t(11;19)(q13;p13.3)/46,XX) is reported.
- Mosaicism for the abnormal karyotype was found in blood in childhood, whereas only the normal chromosomal complement was detectable at the age of 25 years, while in fibroblasts mosaicism was present.
- Molecular investigations showed maternal uniparental isodisomy 11q13→qter in the normal cell line in DNA from blood cells and a weaker additional paternal allele by analysing DNA extracted from cultivated fibroblasts.
- Using a new technical approach combining microdissection, primer-extension-preamplification PCR, and subsequent microsatellite analysis, we were able to show that the der(19) chromosome contains the paternal allele in the unbalanced cell line.

- Schinzl A. *Human cytogenetics database*. Oxford: Oxford Medical Databases Series, Oxford: Oxford University Press, 1994.
- Schinzl A, Kotzot D, Brecevic L, Robinson WP, Dutly F, Dauwerse H, Binkert F, Auserer B. Trisomy first, translocation second, uniparental disomy and partial trisomy third: a new mechanism for complex chromosomal aneuploidy. *Eur J Hum Genet* 1997;5:308-14.
- Kotzot D, Schinzl A. Paternal meiotic origin of der(21;21)(q10;q10) mosaicism (46,XX/46,XX, der(21;21)(q10;

- q10),+21) in a girl with mild Down syndrome. *Eur J Hum Genet* 2000;8:709-12.
- Röthlisberger B, Schinzl A, Kotzot D. A new molecular approach to investigate origin and formation of structural chromosome aberrations. *Chrom Res* 2000;8:451-3.
- Dietmaier W, Hartmann A, Wallinger S, Heinmöller E, Kerner T, Endl E, Jauch KW, Hofstädter F, Rüschoff J. Multiple mutation analyses in single tumor cells with improved whole genome amplification. *Am J Pathol* 1999;154:83-95.
- Henry I, Puech A, Riesewijk A, Ahnine L, Mannens M, Beldjord C, Bitoun P, Tournade MF, Landrieu P, Junien C. Somatic mosaicism for partial paternal isodisomy in Wiedemann-Beckwith syndrome: a post-fertilization event. *Eur J Hum Genet* 1993;1:19-29.
- Collier DA, Barrett T, Curtis D, Macleod A, Bunday S. DIDMOAD syndrome: confirmation of linkage to chromosome 4p, evidence for locus heterogeneity and a patient with uniparental isodisomy for chromosome 4p. *Am J Hum Genet Suppl* 1995;57:1084.
- Lopez-Gutierrez AU, Riba L, Ordonez-Sanchez ML, Ramirez-Jimenez, Cerrillo-Hinojosa M, Tusie-Luna MT. Uniparental disomy for chromosome 6 results in steroid 21-hydroxylase deficiency: evidence of different genetic mechanisms involved in the production of the disease. *J Med Genet* 1998;35:1014-19.
- Martin RA, Sabol DW, Rogan PK. Maternal uniparental disomy of chromosome 14 confined to an interstitial segment (14q23-14q24.2). *J Med Genet* 1999;36:633-6.
- Mergenthaler S, Wollmann HA, Kloos P, Albrecht B, Spranger S, Eggermann K, Zerres K, Eggermann T. Clinical indications for uniparental disomy (UPD) testing in growth retarded patients: presentation of own results by searching for UPDs 2, 6, 7, 14 and 20. *Am J Hum Genet* 2000;67(suppl 2):599.
- Yang XP, Inazu A, Yagi K, Kajinami K, Koizumi J, Mabuchi H. Abetalipoproteinemia caused by maternal isodisomy of chromosome 4q containing an intron 9 splice acceptor mutation in the microsomal triglyceride transfer protein gene. *Arterioscler Thromb Vasc Biol* 1999;19:1950-5.
- Webb A, Beard J, Wright C, Robson S, Wolstenholm J, Goodship J. A case of paternal uniparental disomy for chromosome 11. *Prenat Diagn* 1995;15:773-7.
- Dutly F, Baumer A, Kayserli H, Yüksel-Apak M, Zerova T, Hebisch G, Schinzl A. Seven cases of Wiedemann-Beckwith syndrome, including the first reported case of mosaic paternal isodisomy along the whole chromosome 11. *Am J Med Genet* 1998;79:347-53.

# High frequencies of ICF syndrome-like pericentromeric heterochromatin decondensation and breakage in chromosome 1 in a chorionic villus sample

Melanie Ehrlich, Fern Tsien, Delma Herrera, Viola Blackman, Jennifer Roggenbuck, Cathy M Tuck-Muller

**EDITOR**—The immunodeficiency, centromeric region instability, and facial anomalies syndrome (ICF) usually involves mutations affecting the catalytic domain in *DNMT3B*, one of the three human genes known to encode DNA methyltransferases.<sup>1-3</sup> ICF always results in defective immunity, a high frequency of chromosomal abnormalities in the vicinity of the centromere (pericentromeric region) of chromosome 1 and/or chromosome 16 in mitogen stimulated lymphocytes, and hypomethylation of a small portion of the genome.<sup>4-6</sup> ICF symptoms are manifested often from infancy and this syndrome can cause early childhood death from infections. The DNA sequences targeted for undermethylation in ICF include the heterochromatin adjacent to the centromeres of chromosomes 1 and 16 (1qh and 16qh), where a high incidence of chromatin decondensation, chromosome and chromatid breaks, and rearrangements to form multiradial chromosomes are characteristically seen in mitogen stimulated ICF blood cultures and in ICF lymphoblastoid cell lines.<sup>6-9</sup> These aberrations are more common in chromosome 1 than in chromosome 16 and only infrequently observed in chromosome 9.<sup>5,8,9</sup> We describe an unusual primary culture from a chorionic villus (CV) biopsy in which a high frequency of ICF-like chromosomal abnormalities was observed. However, follow up indicated that the infant did not have ICF.


A 30 year old, gravida 4, para 0, ab 3 white female was referred for genetic counselling and CV sampling because of a previous pregnancy with trisomy 13. Both the patient and her husband were phenotypically normal and healthy apart from their reproductive history. The patient's first two pregnancies ended in spontaneous abortion at 15 and 10 weeks. No fetal studies had been performed; parental chromosomes were analysed and reported to be normal. The third pregnancy was found to be affected with trisomy 13 (47,XY,+13) and was then terminated. During the fourth pregnancy, the patient was offered and accepted CV sampling for prenatal diagnosis of trisomy conditions.

In this CV sample, routine cytogenetic analysis of 20 metaphases from an eight day culture in Chang B medium with Chang C supplement (Irvine Scientific) showed four cells with pericentromeric breaks in chromosome 1, one with a deletion of the long arm of

chromosome 1, and seven with decondensation of 1qh (fig 1B, C). The high frequency of chromosome 1 abnormalities led to the examination of an additional 100 metaphases from the eight day culture. Forty-one percent of the 120 cells examined had abnormalities in the pericentromeric region of chromosome 1. Decondensation of the pericentromeric heterochromatin of chromosomes 1, 16, and 9 was seen in 38, 5, and 0.8% (one cell) of the metaphases, respectively (fig 1). Eleven cells (9%) had chromosome breaks in the pericentromeric heterochromatin of chromosome 1 such that both arms were present but widely separated, one cell (0.8%) had a similar break at 16qh, and one (0.8%) had a pericentromeric break of only one chromosome 1 chromatid. Three cells (2.5%) had a deletion of 1q. In addition, a triradial(1)(p,q,q) was observed (fig 1D).

We passaged these CV cells three times at 1:5 splits after the clinical analysis and examined 100 additional metaphases. The frequency of 16qh decondensation increased from 5% to 26% and decondensation of 1qh increased from 38% to 49% at passage 3 compared to the initial eight day primary culture. At passage 3, there were 11 metaphases with a deletion of 1q, six with a chromosome break at 1qh, two with a multiradial chromosome (a triradial(1)(p,p,q) in one and a quadriradial(1)(p,p,q,q) in the other), one with an isochromosome composed of two pericentromerically fused 1q arms, and one with a deletion of 16q.

Because the ICF syndrome, in which these specific chromosomal anomalies are found, is always accompanied by hypomethylation of limited portions of the genome, including the major DNA sequence in 1qh and 16qh, satellite 2 (Sat2), we examined methylation of chromosome 1 Sat2 DNA sequences in the



**Figure 1** Examples of the different chromosome 1 and 16 abnormalities found in the proband's CV sample after an eight day culture. (A) Normal chromosome 1, (B) decondensation of chromosome 1 at the qh region, (C) whole arm deletion of 1q, (D) triradial(1)(p,q,q), (E) normal chromosome 16, (F) decondensation of 16qh.

*J Med Genet*  
2001;38:882-884

**Human Genetics Program/Hayward Genetics Center, Tulane Medical School, 1430 Tulane Avenue, New Orleans, LA 70112, USA**  
M Ehrlich  
F Tsien  
D Herrera  
V Blackman  
C M Tuck-Muller

**Department of Biochemistry, Tulane Medical School, New Orleans, LA 70112, USA**  
M Ehrlich

**Departments of Pediatrics and Obstetrics and Gynecology, Ochsner Clinic, New Orleans, LA 70121, USA**  
J Roggenbuck

**Department of Medical Genetics, University of South Alabama, Mobile, AL 36688, USA**  
C M Tuck-Muller


Correspondence to:  
Dr Ehrlich,  
ehrlich@tulane.edu

patient's CV sample. This was done as previously described<sup>6</sup> by Southern blot analysis of *Bst*BI digests of DNA from these cell cultures at passage 3 with a Sat2 probe specific for chromosome 1 (fig 2). We found that DNA from the patient's CV sample was hypomethylated in this 1qh sequence compared to normal postnatal somatic tissues. However, the patient's CV DNA was no more hypomethylated than randomly chosen CV samples (fig 2). The undermethylation of Sat2 DNA in these CV samples was the same as that seen in term placenta.<sup>10</sup> The differences in DNA methylation between normal postnatal tissues and CV samples or placenta are consistent with their different cell lineages. Term placenta (from which the embryonic membranes have been removed) and its chorionic villi are mostly derived from extraembryonic cells (see below) as compared to postnatal somatic tissues, which are derived from epiblast cells of the embryoblast (inner cell mass).

One case of ICF had been diagnosed from an amniotic fluid culture in a family known to be at risk because of a previously affected child.<sup>12</sup> The other was diagnosed from a blood sample of a 20 week old fetus who was the sib of an ICF patient.<sup>4</sup> There have been no reports of prenatal diagnosis of ICF by CV sampling, although by linkage analysis ICF was excluded (90% probability) in a CV sample from a family with an affected child.<sup>13</sup>

The present patient was counselled that the cytogenetic findings on the CV sample could reflect a culture artefact, a fetus affected with ICF, or other unknown aetiology. Given the high frequency of ICF-like chromosomal anomalies in the patient's CV cells, a follow up study of amniotic fluid at 16 weeks was done and showed no cytogenetic anomalies. At 39 weeks of gestation, the patient delivered a healthy male infant, weighing 3856 g, with no features of the ICF syndrome. The patient declined a peripheral blood study on the infant but at the current age of 23 months, the child is healthy and thriving.

Sat2 methylation analysis was done on the patient's amniocytes as described above for



**Figure 2** Southern blot analysis showing hypomethylation of Sat2 DNA from chromosome 1 in term placenta, CV samples, and ICF cells but not in postnatal somatic tissues. *Bst*BI digested DNA from the following samples was hybridised to a chromosome 1 Sat2 specific probe and autoradiographed: term placenta; the patient's CV (CV1) culture from passage 3; four random CV samples from passage 3 (CV A, CV C, CV G, and CV H); lung and thymus from normal trauma victims; and a lymphoblastoid cell line (LCL) from an ICF patient.

DNA from the CV cultures. Amniocytes, like postnatal somatic tissues, are derived from epiblast cells of the embryoblast. A high level of methylation of this sequence was seen in DNA from the patient's amniocyte culture as well as in random amniocyte samples (data not shown). These results are incompatible with the patient harbouring ICF type *DNMT3B* mutations because all tested ICF cell populations from diverse tissues or cultured cell types display Sat2 hypomethylation.<sup>4-6 11</sup>

We compared the frequency of ICF-like pericentromeric chromosome 1 anomalies in this patient's CV sample to others. Retrospective examination of 2250 metaphases from 26 clinical CV samples (50-100 metaphases each) from eight day random CV cultures, which had been interpreted as normal, showed that only 47 of the metaphases (2%) had a pericentromeric abnormality of chromosome 1 or 16. However, the majority of the CV samples (58%) displayed low levels of these anomalies with 1-8% (median 2%) of their metaphases showing these chromosome 1 or chromosome 16 aberrations. Ninety-four percent of these anomalies were decondensation of 1qh or 16qh, with 3.4-fold more 1qh than 16qh decondensation. The only pericentromeric rearrangements seen were two whole arm deletions of 1q and one break at 1qh resulting in separated 1p and 1q arms. No clonal abnormalities except for the chromosome 1 and chromosome 16 aberrations were observed in these metaphases from randomly chosen CV samples. These CV samples were obtained over several years and included samples tested at the same time as the patient's sample and all were analysed by the same method. Also, no change in the lot of medium or fetal calf serum can explain the different results obtained from the patient's sample and the random samples.

Anecdotal observations of these types of pericentromeric chromosome 1 and 16 anomalies in normal CV metaphases are common although, to our knowledge, they have been described by only one group in detail<sup>14</sup> and mentioned by another.<sup>13</sup> In the latter case, Bjorck *et al*<sup>13</sup> stated without elaboration that "heterochromatic decondensation can occasionally be seen in both amniocytes and cultured chorionic villi without any pathological significance." The former group, Miguez *et al*,<sup>14</sup> found in a study of 244 24 hour CV cultures that about 9% of the metaphases displayed chromosomal lesions, usually breaks or gaps at various fragile sites. The most common site was at 1qh (1q12) or 1q21.1 although the quality of the chromosomes allowed only 36% of the preparations to be "successfully banded" and the frequency of cases with this anomaly was not given. In another report, this group described decondensation in 1qh, 9qh, 16qh, or Yqh in 2.4, 3.6, and 0.3, and 0.2%, respectively, of the 5820 examined metaphases, with 47% of 339 24 hour CV cultures displaying such condensation in at least one metaphase.<sup>15</sup> In contrast to those investigators who observed decondensation in 9qh to be most frequent, we found



only a single metaphase exhibiting decondensation of 9qh in this study and that was in the CV sample with the high frequency of 1qh decondensation. This difference between their results and ours could be because of the use of one day rather than eight day cultures. The longer culture time affords better quality metaphase chromosomes but selects for extraembryonic mesoderm cells (which are derived from hypoblast cells of the embryoblast) in the CV samples as opposed to mostly cytotrophoblast metaphases (which are trophoblast derivatives) in the one day CV cultures.<sup>16</sup> Cell type specific differences in the frequencies of chromosome anomalies could also explain why we did not observe chromosomal aberrations in the eight day amniocyte culture from the patient who gave such a high percentage of chromosome 1 anomalies in the corresponding CV culture.

The chromosome 1 (and chromosome 16) pericentromeric aberrations observed in this clinical CV sample may have formed during culture in vitro. However, there was nothing remarkable about the CV tissue used for cell culture or in this culture's hypomethylation in the 1qh region that could explain why it yielded such a high frequency of chromosome 1 anomalies. Whatever the cause of the anomalies in this patient's sample, our analysis of CV samples indicates that ICF-like chromosomal abnormalities are part of the normal spectrum for CV chromosomes and need not indicate any clinical condition. Furthermore, we conclude that CV sampling should not be attempted to prenatally diagnose ICF by the chromosome abnormalities used to diagnose this syndrome in mitogen treated blood samples from immunodeficient patients. In families at risk for ICF, prenatal analysis for *DNMT3B* mutations<sup>13</sup> would be preferable.

This work was partially supported by NIH grant CA 81506 (to ME).

- 1 Hansen RS, Wijmenga C, Luo P, Stanek AM, Canfield TK, Weemaes CM, Gartler SM. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. *Proc Natl Acad Sci USA* 1999;**96**:14412-17.
- 2 Xu G, Bestor TH, Bourc'his D, Hsieh C, Tommerup N, Hulten M, Qu S, Russo JJ, Viegas-Pequignot E. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. *Nature* 1999;**402**:187-91.
- 3 Wijmenga C, Hansen RS, Gimelli G, Bjorck EJ, Davies EG, Valentine D, Belohradsky BH, van Dongen JJ, Smeets DF, van den Heuvel LP, Luyten JA, Strengman E, Weemaes C, Pearson PL. Genetic variation in ICF syndrome: evidence for genetic heterogeneity. *Hum Mutat* 2000;**16**:509-17.
- 4 Jeanpierre M, Turleau C, Aurias A, Prieur M, Ledest F, Fischer A, Viegas-Pequignot E. An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome. *Hum Mol Genet* 1993;**2**:731-5.
- 5 Smeets DFCM, Moog U, Weemaes CMR, Vaes-Peeters G, Merckx GFM, Niehof JP, Hamers G. ICF syndrome: a new case and review of the literature. *Hum Genet* 1994;**94**:240-6.
- 6 Tuck-Muller CM, Narayan A, Tsien F, Smeets D, Sawyer J, Fiala ES, Sohn O, Ehrlich M. DNA hypomethylation and unusual chromosome instability in cell lines from ICF syndrome patients. *Cytogenet Cell Genet* 2000;**89**:121-8.
- 7 Fryns JP, Azou M, Jacken J, Eggemont E, Pedersen JC, Van den Berghe H. Centromeric instability of chromosomes 1, 9, and 16 associated with combined immunodeficiency. *Hum Genet* 1981;**57**:108-10.
- 8 Tiepolo L, Maraschio P, Gimelli G, Cuoco C, Gargani GF, Romano C. Multibranching chromosomes 1, 9, and 16 in a patient with combined IgA and IgE deficiency. *Hum Genet* 1979;**51**:127-37.
- 9 Turleau C, Cabanis MO, Girault D, Ledest F, Mettey R, Puissant H, Marguerite P, de Grouchy J. Multibranching chromosomes in the ICF syndrome: immunodeficiency, centromeric instability, and facial anomalies. *Am J Med Genet* 1989;**32**:420-4.
- 10 Narayan A, Ji W, Zhang XY, Marrogi A, Graff JR, Baylin SB, Ehrlich M. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. *Int J Cancer* 1998;**77**:833-8.
- 11 Miniou P, Jeanpierre M, Bourc'his D, Coutinho Barbosa AC, Blanquet V, Viegas-Pequignot E. Alpha-satellite DNA methylation in normal individuals and in ICF patients: heterogeneous methylation of constitutive heterochromatin in adult and fetal tissues. *Hum Genet* 1997;**99**:738-45.
- 12 Fasth A, Forestier E, Holmberg E, Holmgren G, Nordenson I, Soderstrom T, Wahlstrom J. Fragility of the centromeric region of chromosome 1 associated with combined immunodeficiency in siblings: a recessively inherited entity? *Acta Paediatr Scand* 1990;**79**:605-12.
- 13 Bjorck EJ, Bui TH, Wijmenga C, Grandell U, Nordenskjold M. Early prenatal diagnosis of the ICF syndrome. *Prenat Diagn* 2000;**20**:828-31.
- 14 Miguez L, Fuster C, Perez MM, Miro R, Egozcue J. Spontaneous chromosome fragility in chorionic villus cells. *Early Hum Dev* 1991;**26**:93-9.
- 15 Perez MM, Miguez L, Fuster C, Miro R, Genesca G, Egozcue J. Heterochromatin decondensation in chromosomes from chorionic villus samples. *Prenat Diagn* 1991;**11**:697-704.
- 16 Crane JP, Cheung SW. An embryogenic model to explain cytogenetic inconsistencies observed in chorionic villus versus fetal tissue. *Prenat Diagn* 1988;**8**:119-29.

# Supernumerary marker chromosome (1) of paternal origin and maternal uniparental disomy 1 in a developmentally delayed child

Benno Röthlisberger, Tatjana E Zerova, Dieter Kotzot, Tamara I Buzhievskaya, Damina Balmer, Albert Schinzel

*J Med Genet*  
2001;38:885–888

Institut für  
Medizinische Genetik,  
Universität Zürich,  
Rämistrasse 74,  
CH-8001 Zürich,  
Switzerland  
B Röthlisberger  
D Kotzot  
D Balmer  
A Schinzel

Department of  
Medical Genetics,  
Medical Academy of  
Postgraduate Study,  
Kyiv, Ukraine  
T E Zerova  
T I Buzhievskaya

Correspondence to:  
Professor Schinzel,  
schinzel@medgen.unizh.ch

Table 1 Results of molecular genetic investigations

Primer	Locus	cM	Alleles	SMC	Origin of alleles
D1S220	p31.1	82.50	bb,ab,ac	NP	Mat iso
D1S216	p22.2	93.20	bb,bd,ac	NP	Mat iso
D1S2746	p13.2	115.57	ac,ac,bb	b	Mat het
D1S250	p13.2	116.22	ab,ab,aa	a	NI
D1S2687	p13.1	117.79	bc,bc,aa	a	Mat het
D1S189	p13	119.39	cc,ac,bb	b	Mat iso
D1S252	p12	122.73	cc,ac,bc	b	Mat iso
D1S2669	p12	124.35	bb,ab,bb	b	Mat iso
cen, D1Z5	cen	128.0	NP	NP	NP
D1S518	q25.2	194.78	aa,aa,bc	NP	Mat
D1S1656	q42.2	244.98	bc,-,ad	NP	Mat het
D1S180	q44	260.62	ab,ab,cd	NP	Mat het

The alleles are given in the order patient, mother, father. Allele designations (a-d) are arbitrary. Genetic mapping according to the sex averaged linkage map by the Genetic Location Database (LDB). Mat=maternal, iso=isodisomy, NP=not performed, NI=not informative.

EDITOR—At least 168 cases with a supernumerary marker chromosome (SMC) from all chromosomes not including chromosome 15 have been documented.<sup>1</sup> Birth prevalence is estimated at 0.14 to 0.72 per 1000.<sup>2</sup> Subjects with a SMC have a partial trisomy (duplication) and in some cases a partial tetrasomy (triplication) of the genetic material contained in the SMC. The risk of an abnormal phenotype associated with a randomly ascertained de novo SMC derived from acrocentric autosomes (excluding chromosome 15) is estimated to be approximately 7% compared with approximately 28% for SMCs derived from non-acrocentric autosomes.<sup>1</sup> The great variability of clinical findings in patients with SMCs originating from the same chromosome is probably the result of variation in size and genetic content, the degree of mosaicism, and uniparental disomy of the normal homologues of the chromosome from which the SMC derived.

Evidence that subjects with SMCs might have an increased risk for UPD of the structurally normal homologues of the SMCs has been reported by several authors. To the best of our knowledge the coexistence of SMCs with UPD has been described for chromosomes 6, 7, 15, 20, and X.<sup>3-7</sup> Here, we describe a further patient with multiple congenital anomalies, developmental delay, and the unique finding of coexistence of SMC 1 mosaicism and maternal uniparental disomy 1.

## Case report

The female patient was born at term after an uneventful pregnancy. At her birth, her mother was 33 years old and her father was 47 years old. Birth weight was 2500 g and length 49 cm. At the age of 6 years, she was investigated because of mental retardation. Height (1.14 m) and weight (17 kg) were within the normal

range, but head circumference (44 cm) was far below the 3rd centile. Additional findings were temporal narrowing, downward slanting palpebral fissures, long eyelashes, high palate, pointed chin, low set and dysplastic ears, hip dysplasia, and tapering fingers with clinodactyly of fingers 2, 4, and 5.

## Methods

Chromosome preparations from blood lymphocyte cultures were performed according to standard procedures. GTG banded chromosomes were examined.


Chromosome microdissection was performed according to a slightly modified version of the protocol described by Senger *et al.*<sup>8</sup> FISH analysis was performed according to Lichter and Ried<sup>9</sup> using the specific chromosome library generated by microdissection.

Genomic DNA from the patient and both parents was amplified by standard PCR with commercially available highly polymorphic microsatellites (Research Genetics<sup>®</sup>, Huntsville, AL, USA), loaded onto a 6% polyacrylamide/urea gel, and visualised by silver staining.

Probably owing to the low mosaicism in leucocytes, it was not possible to determine the parental origin of the SMC unambiguously by standard methods. We therefore applied a new approach recently developed in our laboratory.<sup>10</sup> In a first step, 20 SMCs were dissected and collected in a PCR tube containing 2 µl collection drop solution (10 mmol/l Tris/HCl, 10 mmol/l NaCl, 3 mg/ml proteinase K PCR grade), and incubated for two hours at 60°C. Subsequently, proteinase K was inactivated at 90°C for 10 minutes. Whole genome amplification was performed according to an improved PEP protocol (I-PEP)<sup>11</sup> with the following modifications: no gelatine, 500 µmol/l dNTP, 1 mmol/l MgCl, and 100 µmol/l totally degenerated 15 nucleotide long primer. Finally, multiple highly polymorphic microsatellites were analysed by time release PCR (0.1 mmol/l dNTP, 0.24 µmol/l primers, 1.25 U AmpliTaq Gold<sup>®</sup> (PE Applied Biosystems, Branchburg, NJ, USA), 1.5–2.5 mmol/l MgCl, using 5 µl aliquots of the preamplified DNA in a final volume of 50 µl in a Techne Progene<sup>®</sup> thermocycler (Techne Incorporated, Princeton, NJ, USA) for 56 cycles, 60–64°C for four minutes, 94°C for one minute, run on a 6% polyacrylamide gel, and visualised by silver staining.

## Results

Chromosome preparations from blood lymphocyte cultures of the patient showed an




**Figure 1** (A) GTG banded karyotype of the patient. The arrow points to the supernumerary marker chromosome. (B) Reverse painting to a normal metaphase using the probe generated from DNA obtained by microdissection of the supernumerary marker chromosome. Note the fluorescent signals in the pericentric region of both chromosomes 1.

additional small marker chromosome (SMC) in 14 of 40 metaphases (35%) investigated (fig 1A). Chromosome analysis of the mother and the father showed normal karyotypes. In order to determine the origin of the SMC, a microFISH experiment with reverse painting to normal metaphases was performed. It could be shown that the SMC was formed by a region of chromosome 1, 1p21.1→1q12 (fig 1B). Application of the “all telomeres” probe (Vysis® Inc, Downers Grove, IL, USA) showed no telomeric signal on the extra chromosome indicating that it is a ring chromosome (data not shown).

Microsatellite analysis on genomic DNA of the patient and the parents showed that the patient had inherited two maternal alleles (heterodisomy and isodisomy respectively at different loci) but no paternal allele at different loci of chromosome 1 (table 1, fig 2A, B). Investigations of several microsatellites from various other chromosomes were in agreement with correct paternity. Based on these results, the karyotype of the patient may be described as 47,XX,UPD(1)mat,+der(1)(p21.1q12)/46,XX,UPD(1)mat.

Probably owing to the patient's relatively low level mosaicism of leucocytes with the SMC, the microsatellite analysis with pericentromeric markers did not result in an unambiguous determination of the parental origin of the SMC. Although some markers showed a weak paternal band, this was not obvious enough for



**Figure 2** (A) Results of parental origin determination of the normal homologues with microsatellite markers. The PCR products are represented in the following order: father, patient, mother. Allele designations (a to d) are arbitrary. (B) Results of parental origin determination of the supernumerary marker chromosome 1 (SMC 1) and the normal homologues with microsatellite markers. The PCR products are represented in the following order: father, patient, SMC, mother. Allele designations (a to d) are arbitrary.

unequivocal parental determination. Therefore, a new approach combining microdissection of the SMC with subsequent PEP-PCR and conventional microsatellite PCR was performed. All investigated markers mapping



to the duplicated region clearly showed one paternal band and no maternal band and were thus in agreement with paternal origin of the SMC (fig 2B). In addition, by investigating the genomic DNA with these pericentromeric markers, three markers mapping within the duplicated region on the short arm of chromosome 1 within a 10 cM distance from the centromere and also two markers at the distal end of the short arm of chromosome 1 showed maternal isodisomy (table 1).

### Discussion

The great variability of clinical symptoms in patients with a SMC of the same chromosomal origin is probably the result of variation of the genetic content, the degree of mosaicism (especially, as in our case, in ring chromosomes), and uniparental disomy of the normal homologues from which the SMC is derived.<sup>1 12</sup>

To allow any karyotype-phenotype correlation, comparison of a sufficient number of accurately investigated cases is necessary. The best way to characterise a SMC is a multistep approach: (1) classical cytogenetic procedures, which provide information about the degree of mosaicism by investigating many cells, if possible, from different tissues; (2) microFISH, which gives detailed information about the chromosomal content of the SMC; (3) microsatellite analysis of the normal homologues, which gives information about uniparental disomy and a clue towards the mechanism of formation; and (4) the absence of telomeres indicated that the SMC is a ring.

In most cases with an SMC originating from chromosome 1, neither FISH analysis with locus specific probes nor molecular investigations with microsatellites was performed.<sup>12</sup> The patients described show great variability of their phenotypes and so far no distinct syndrome has been associated with the group of cases with a supernumerary marker chromosome originating from chromosome 1.

The phenotype of four patients with maternal UPD(1) reported so far<sup>13-16</sup> is normal and therefore suggests that maternally imprinted loci on chromosome 1, if existing at all, probably do not influence the phenotype. Thus, the congenital anomalies in our patient are probably not the result of the maternal UPD of chromosome 1, but are more likely related to the mosaic duplication of chromosome 1 (p21.1→q12).

Several authors assumed that subjects with SMCs might have an increased risk for UPD of the structurally normal homologues from which the SMCs derived. However, the incidence of UPD associated with a SMC is not known, and so far only one case each of chromosomes 6, 7, 20, and X,<sup>3 5-7</sup> as well as nine cases of chromosome 15, seven with Prader-Willi syndrome, and two with Angelman syndrome, have been reported.<sup>4 17-22</sup>

Coexistence of UPD with a SMC is mainly explained by the following two mechanisms.<sup>21</sup> First, duplication of the normal homologue in a zygote which has inherited a SMC in place of

the normal corresponding chromosome “rescues” an aneuploidy. In this case, UPD arises by mitotic non-disjunction and therefore complete isodisomy should always be observed. Second, the zygote may have originated as a trisomy with the single parental chromosome being lost through a breakage event or, alternatively, a disomic gamete was fertilised by a gamete with a SMC formed during meiosis.

Heterodisomy, as reported in our case, can only be explained by the second mechanism. The distribution of isodisomic and heterodisomic segments in our case, pericentromeric and more distal, respectively, indicates an error in maternal meiosis II resulting in the maternal UPD(1). Whether the SMC was formed during paternal meiosis or in an early somatic cell division cannot be differentiated. If it was formed during paternal meiosis, the coexistence of a SMC with UPD may be considered as a coincidence. Even if it was formed postzygotically, our case might at best not contradict the hypothesis that subjects being uniparentally disomic might have an increased risk of bearing a SMC of the same homologue (rather than the reverse). In other words, the presence of two maternal (or paternal) chromosomes in the zygote might constitute a risk for the formation of a paternal (or maternal) SMC through a breakage event.

Parental origin of the normal chromosomes and of the SMC is sometimes difficult to determine. In many instances, only quantitative results can be obtained (mitotically formed mosaicism, supernumerary marker chromosomes). The new technical approach applied in the case reported here allows the unequivocal tracing back of informative alleles from a dissected abnormal chromosome to one of the parental homologues.

In conclusion, we present a case with coexistence of a SMC 1 with maternal UPD(1) and hence mosaicism for complete maternal uniparental disomy and partial trisomy for a small pericentromeric segment of chromosome

- To the best of our knowledge, 10 cases of supernumerary marker chromosome 1 (SMC 1) mosaicism have been reported so far. Most of these ring shaped markers were identified by fluorescence in situ hybridisation (FISH) with centromere specific probes.
- We report another case with SMC 1 mosaicism identified by combining chromosome microdissection with reverse painting to normal metaphases (microFISH).
- Microsatellite analysis showed heterodisomic maternal uniparental disomy (UPD) of the normal chromosomes 1. In addition, a new approach combining chromosome microdissection, primer-extension-preamplification polymerase chain reaction (PEP-PCR) and standard PCR of highly polymorphic microsatellites showed paternal alleles only within the region of the SMC. This indicates that the SMC is of paternal origin.

1 combined with uniparental disomy for the rest of the chromosome. By a new technical approach, which allows the parental origin of the marker chromosome to be determined, even in cases with low level mosaicism, we were able to unequivocally show the paternal origin of the marker.

The authors are grateful to the family for their cooperation. The study was supported by the Swiss National Foundation, grants 32-45604.95, 32-56053.98, and 71P51778.

- 1 Crolla JA. FISH and molecular studies of autosomal supernumerary marker chromosomes excluding those derived from chromosome 15. II. Review of the literature. *Am J Med Genet* 1998;75:367-81.
- 2 Gardner RJM, Sutherland GR. *Chromosome abnormalities and genetic counselling*. Oxford: Oxford University Press, 1996:263-4.
- 3 James RS, Temple IK, Dennis NR, Crolla JA. A search for uniparental disomy in carriers of supernumerary marker chromosomes. *Eur J Hum Genet* 1995;3:21-6.
- 4 Bettio D, Rizzi N, Giardino D, Gurrieri F, Silvestri G, Grugni G, Larizza L. FISH characterization of small supernumerary marker chromosomes in two Prader-Willi patients. *Am J Med Genet* 1999;68:99-104.
- 5 Chudoba I, Franke Y, Senger G, Sauerbrei G, Demuth S, Beensen V, Neumann A, Hansmann I, Claussen U. Maternal UPD 20 in a hyperactive child with severe growth retardation. *Eur J Hum Genet* 1999;7:533-40.
- 6 Miyoshi O, Kondoh T, Tanedo H, Otsuko K, Matsumoto T, Niikawa N. 47,XX,UPD(7)mat,+r(7)pat/46,XX,UPD(7)mat mosaicism in a girl with Silver-Russell syndrome (SRS): possible exclusion of the putative SRS gene from a 7p13-q11 region. *J Med Genet* 1999;36:326-9.
- 7 Yorifuji T, Muroi J, Kawai M, Uematsu A, Sasaki H, Momoi T, Kaji M, Yamanaka C, Furusho K. Uniparental and functional X disomy in Turner syndrome patients with unexplained mental retardation and X derived marker chromosomes. *J Med Genet* 1998;35:539-44.
- 8 Senger G, Lüdecke HJ, Horsthemke B, Claussen U. Microdissection of banded human chromosomes. *Hum Genet* 1990;84:507-11.
- 9 Lichter P, Ried T. Molecular analysis of chromosome aberrations. In situ hybridization. *Methods Mol Biol* 1994;29:449-78.
- 10 Röthlisberger B, Schinzel A, Kotzot D. A new molecular approach to investigate origin and formation of structural chromosome aberrations. *Chrom Res* 2000;8:451-3.
- 11 Dietmaier W, Hartmann A, Wallinger S, Heinmöller E, Kerner T, Endl E, Jauch KW, Hofstädter F, Rüschoff J. Multiple mutation analyses in single tumor cells with improved whole genome amplification. *Am J Pathol* 1999;154:83-95.
- 12 Callen DF, Eyre H, Fang YY, Guan XY, Veleba A, Martin NJ, McGill J, Haan EA. Origins of accessory small ring marker chromosomes derived from chromosomes 1. *J Med Genet* 1999;36:847-53.
- 13 Pulkkinen L, Bullrich F, Czarnecki P, Weiss L, Uitto J. Maternal uniparental disomy of chromosome 1 with reduction to homozygosity of the LAMB3 locus in a patient with Herlitz junctional epidermolysis bullosa. *Am J Hum Genet* 1997;61:611-19.
- 14 Leigh Field L, Tobias R, Robinson WP, Paisey R, Bain S. Maternal uniparental disomy of chromosome 1 with no apparent phenotypic effects. *Am J Hum Genet* 1998;63:1216-20.
- 15 Dufourcq-Lagelouse R, Lambert N, Duval M, Viot G, Vilmer E, Fischer A, Prieur M, de Saint Basile G. Chediak Higashi syndrome associated with maternal uniparental isodisomy of chromosome 1. *Eur J Hum Genet* 1999;7:633-7.
- 16 Lebo RV, Shapiro LR, Fenerci EY, Hoover JM, Chuang JL, Chuang DT, Kronn DF. Rare etiology of autosomal recessive disease in a child with noncarrier parents. *Am J Hum Genet* 2000;67:750-4.
- 17 Cheng SD, Spinner NB, Zackai EH, Knoll JH. Cytogenetic and molecular characterization of inverted duplicated chromosomes 15 from 11 patients. *Am J Hum Genet* 1994;55:753-9.
- 18 Christian SL, Mills P, Das S, Ledbetter DH. High risk of uniparental disomy 15 associated with amniotic fluid containing de novo small supernumerary marker 15 chromosomes. *Am J Hum Genet Suppl* 1998;63:A11.
- 19 Ebrahim SAD, Feldman B, Knaus A, Gyi K, Mills PL, Johnson MP, Evans MI. Prenatal diagnosis of maternal uniparental disomy of chromosome 15 in association with de novo supernumerary marker chromosome 15. *Am J Hum Genet Suppl* 1998;63:A162.
- 20 Woodage T, Deng ZM, Prasad M, Smart R, Lindeman R, Christian SL, Ledbetter DL, Robson L, Smith A, Trent RJ. A variety of genetic mechanisms are associated with the Prader-Willi syndrome. *Am J Med Genet* 1994;54:219-26.
- 21 Robinson WP, Wagstaff J, Bernasconi F, Baccichetti C, Artifoni L, Franzoni E, Suslak L, Shih LY, Aviv H, Schinzel AA. Uniparental disomy explains the occurrence of the Angelman or Prader-Willi syndrome in patients with an additional small inv dup(15) chromosome. *J Med Genet* 1993;30:756-60.
- 22 Lebbar A, Dupont JM, Cuisset L, Pinton F, Vasseur C, Le Tessier D, Denavit MF, Ponsot G, Delpech M, Rabineau D. Clinical features of Prader-Willi syndrome in a girl with methylation status of Angelman syndrome. *Eur J Hum Genet Suppl* 1998;6:97A.

## Sponastrime dysplasia: presentation in infancy

A C Offiah, M Lees, R M Winter, C M Hall

EDITOR—The case of a white female with sponastrime dysplasia is presented.

### Case report

The patient is the first and only child of healthy, non-consanguineous parents. During routine ultrasound scanning, the fetus was noted to have extremely short limbs and a tentative diagnosis of achondroplasia was made. The pregnancy was otherwise uncomplicated. The baby was delivered at 40 weeks' gestation by emergency caesarian section because of breech presentation. Birth weight was 2460 g and length 44 cm (both below the 3rd centile). During infancy and early childhood, her height remained well below the 0.4th centile.

Examination showed a small baby with mid-face hypoplasia and a small, slightly upturned nose. With increasing age, the prominent forehead, saddle shaped nose, and midface hypoplasia became more obvious. There was rhizomelic and mesomelic shortening of her upper and lower limbs (fig 1). She was noted to have short, broad hands and feet with deep palmar creases, short toes, and dimples in the elbows and knees. In addition, she had marked generalised joint laxity except at the elbows where extension was limited. A skeletal survey at 5 months was not diagnostic, but achondroplasia was excluded.

Chromosomal analysis was normal (46,XX).

At 4 months of age, she was noted to have an eczematous skin rash, and there followed several hospital admissions for recurrent chest infections; investigations showed hypogammaglobulinaemia. Both the skin rash and the hypogammaglobulinaemia gradually normalised, effectively excluding a diagnosis of a short limbed dwarfism syndrome in association with immunodeficiency.

Despite a dysplastic (but not dislocated) left hip, crawling and walking were not delayed; however at 2 years of age she developed a waddling gait, and at 2 years 5 months a dislocated left hip was diagnosed. At 3 years, an open varus reduction and derotation osteotomy was performed. She made good recovery from her operation, and at 4 years 3 months the internal fixator was removed.

Developmental milestones were reached at appropriate ages, and mental development was normal.

### RADIOGRAPHIC FINDINGS

The radiographic findings are illustrated in figs 2-7.

### Spine (figs 2 and 3)

These x rays show the typical changes in the shape of the vertebral bodies as described by Langer *et al* in 1996 and again in 1997<sup>2,3</sup>:

platyspondyly improving with the patient's age; a distinct junction (apparent in early/mid-childhood) between the anterior and posterior parts of the vertebral bodies (this is as a result of the anterior portions having convex end plates compared to the straight end plates of the posterior portions); a central anterior beaking of the vertebral bodies; and increasing concavity of the posterior surfaces of the vertebral bodies (posterior scalloping). There is a progressive kyphoscoliosis and mild osteopenia. Additionally, there is loss of the normal increase in interpedicular distance from L1 to L5 which can be appreciated in the radiograph taken at birth (fig 2A).

### Long bones (figs 4-7)

Characteristic changes in the proximal femora consist of a pronounced bony projection of the lesser trochanter, short femoral necks, and loss of the normal metaphyseal flare. These give a "spanner-like" appearance to the proximal



Figure 1 Clinical photograph of patient aged 4 years 8 months. Note the significant (rhizomelic) shortening, prominent forehead, and depressed nasal bridge.

*J Med Genet*  
2001;38:889-893

Department of  
Radiology, Great  
Ormond Street  
Children's Hospital,  
London WC1N 3JH,  
UK

A C Offiah  
C M Hall

Department of  
Medical Genetics,  
Great Ormond Street  
Children's Hospital,  
London WC1N 3JH,  
UK

M Lees  
R M Winter

Correspondence to: Dr Hall,  
hallc@gosh.nhs.uk






Figure 2 (A) AP spine at birth, showing platyspondyly and loss of the normal increase in interpedicular distance from L1 to L5. There is no significant curvature of the spine. (B) AP spine at 4 years 8 months. A kyphoscoliosis has developed. Note the relative increase in height of the vertebral bodies (improved platyspondyly) and the mild osteopenia.



Figure 3 Lateral spine at 2 years 6 months. The platyspondyly is less marked than in infancy. There is a distinct junction between the anterior and posterior portions of the vertebral bodies and posterior scalloping.

femora (fig 4A), which becomes less marked with time (fig 4B). There was progressive development of coxa vara deformity, which although complicated by dislocation on the left, could be appreciated bilaterally.

Vertical metaphyseal striations are best seen around the knee and in the distal radius. These striations developed with age, and were not demonstrable radiologically until 4 years 8 months (figs 5 and 6).

There is retardation of bone age (fig 5) when compared to the standards of Greulich and Pyle (2 years 6 months at a chronological age of 4 years 8 months, SD 11.65 months). A pseudoepiphysis of the first metacarpal is seen, a finding which has also been seen in several other patients.<sup>3 4</sup> All epiphyses are small for age and slightly irregular.

Other features include a predominantly rhizomelic shortening of the limbs and flaring of the distal humeral metaphyses, giving them a rather bulbous appearance which becomes more pronounced with time. In addition, there is a curious appearance of the proximal humeral diaphyses (fig 7), consisting of a linear radiolucency affecting the medial cortex and running obliquely. Beneath this, there is cortical thickening (buttressing) and mild angulation of the humeral shaft. This appearance, reminiscent of focal fibrocartilagenous dysplasia, was bilaterally symmetrical.

### Discussion

Sponastrime dysplasia is a rare but distinct entity which can be categorised as a spondyloepimetaphyseal dysplasia. The acronym was derived by Fanconi *et al*<sup>6</sup> from the *spondylar* and *nasal* alterations which occur in addition to the *striations* of the *metaphyses*. It has been documented in several sets of sibs,<sup>2 3 5 6</sup> but in the 13 cases reported to date (including ours) the parents have been non-consanguineous. It would appear that sponastrime dysplasia is inherited as an autosomal recessive disorder although germline mosaicism is a possibility.

Other than ours, 12 cases of true sponastrime dysplasia have been reported,<sup>2-6</sup> of which only one, described by Langer *et al*,<sup>2</sup> was an infant. Comparing the findings of Langer *et al*<sup>2</sup> to those in our patient, there would appear to be specific findings which may allow the diagnosis of sponastrime dysplasia to be made at birth and in infancy. Clinically these are non-specific and include midfacial hypoplasia, a saddle shaped nose, short limbs, and short stature. Radiological features, however, are more specific; the proximal femora have a characteristic radiological “spanner-like” appearance with a bony projection of the lesser trochanter, short curved femoral necks, and loss of the normal metaphyseal flare. This appearance of the proximal femora becomes less apparent with age. In the spine there is a significant platyspondyly with loss of the normal progressive widening of the interpedicular distances from L1 to L5. While present in all eight of the previous cases in which the result of spinal radiography was available, this is the first time that the gradual reduction in interpedicular distance has been



Figure 4 (A) The hips at 13 months. (B) The hips at 3 years 1 month. The spanner-like appearance of the proximal femur seen in the infant period (and early childhood) will become less obvious with age. The left hip is subluxed. The patient subsequently developed bilateral coxa vara.

confirmed in the neonate and infant. As in other reported cases,<sup>4-6</sup> patients may develop a scoliosis, which, as in our patient, may be significant.

Lachman *et al*<sup>6</sup> obtained biopsies from the iliac crests of two patients with sponastrime dysplasia. Light and electron microscopic examination findings suggested a specific morphological appearance for sponastrime dysplasia. Unfortunately, despite open surgery, a histological sample was not obtained in our patient to confirm this appearance.

Short stature is a universal finding. The severity of short stature seen in our patient (fig 1) was made worse by the development of a progressive (and significant) kyphoscoliosis (fig 2B).

Our patient developed bilateral coxa vara deformity, which has been documented in two other patients.<sup>3</sup> There have been two published cases of patients who both developed thoracolumbar scoliosis warranting surgery<sup>5</sup>; our patient has also developed a significant scoliosis.

Including our patient, mild osteopenia has been described in all eight of the patients in whom this information is available.

This is the first case of sponastrime dysplasia in which transient hypogammaglobulinaemia has been reported.



Figure 5 Left wrist and hand at 4 years 8 months. Bone age is delayed (2 years 6 months according to the standards of Greulich and Pyle). The first metacarpal has a pseudoepiphysis. Note the metaphyseal striations of the distal radius.

In our patient, there was a predominantly rhizomelic limb shortening and prominence of the distal humeral metaphyses which had a rather bulbous appearance. These changes have not previously been described in sponastrime dysplasia.

The appearance of the proximal humeri was reminiscent of focal fibrocartilaginous dysplasia, a known cause of tibia vara. On plain film it appears as a tongue-like cortical defect. It affects the medial cortex and leads to varus deformity centred at the lesion. On MRI, there is no associated soft tissue mass.<sup>13</sup> Although it has previously been reported in the upper limb,<sup>14</sup> to our knowledge it has never been seen bilaterally. Histologically, there is abnormal growth and remodelling of fibrocartilaginous tissue at the growth plate interface between the tendon and its bony attachment.<sup>15-16</sup> Comparing this with the histological findings of Lachman *et al*<sup>6</sup> in sponastrime dysplasia, we wonder if a similar (abnormal) process is occurring in the two conditions. Interestingly, neither the humeral shaft changes nor the metaphyseal striations around the wrist and knees were radiologically obvious at birth or in infancy, but became apparent in mid-childhood (4 years 8 months). The natural history of focal fibrocartilaginous dysplasia is that of spontaneous resolution<sup>17</sup>; as we have neither histology nor radiographs beyond 4 years 8 months in our patient, we feel that radiographic follow up may be useful.

Fig 8 shows the patient's metacarpophalangeal pattern profile (MCP) performed at 4 years 8 months according to the method of Garn *et al*.<sup>18</sup> All 19 bones had negative Z values, confirming shortening. Z scores ranged from -1.2 (distal phalanx 3) to -3.6 (metacarpal 3). The normal Z score range for the metacarpals is +2 to -2. All metacarpals in this patient had a value of less than -2, again confirming




Figure 6 Left knee at (A) 2 years 6 months and (B) 4 years 8 months. Metaphyseal striations around the knee become more obvious with age.



Figure 7 Left upper limb at 4 years 8 months. There is rhizomelic shortening. The humeral metaphyses are bulbous and there is a linear radiolucency of the medial cortex of the proximal humeral diaphysis running obliquely with cortical thickening (buttressing) below this. This appearance became apparent in mid-childhood.

brachymetacarpus as a feature of sponastrime dysplasia. Fig 8 illustrates an up and down variation in the hand pattern, particularly affecting the phalanges. In our patient, this is not as pronounced as in the cases of Cooper *et al*<sup>4</sup> and Fanconi *et al*.<sup>6</sup> The MCPP obtained by Camera *et al*<sup>7</sup> shows a much flatter pattern, further supporting the likelihood of a different condition in their patient. The pattern variability index (OZ) in this patient, based on the method described by Garn *et al*,<sup>19</sup> was calculated to be 0.51. A score greater than 0.7 is said to indicate hand dysmorphogenesis; Cooper *et al*<sup>4</sup> calculated a value of 0.73 for their patient. Their patient was 6 years 7 months old and ours 4 years 8 months; age is therefore an unlikely explanation for the differences and MCPP analyses are required in more patients




Figure 8 Metacarpophalangeal pattern profile (4 years 8 months). An up and down pattern variation (especially of the phalanges) and brachymetacarpus are illustrated.

with sponastrime dysplasia, in order to evaluate its use in aiding the diagnosis.

Intelligence in patients with true sponastrime dysplasia is normal. Several patients reported as cases of sponastrime dysplasia<sup>7-9</sup> are likely to be cases of spondyloepimetaphyseal dysplasia (SEMD) with large joint dislocations (first characterised by Hall *et al*<sup>10</sup>). The two sisters described by Camera *et al*<sup>11</sup> and the patient described by Verloes *et al*<sup>12</sup> do not seem to have either sponastrime dysplasia or SEMD with large joint dislocations. Table 1 summarises and compares the findings in these conditions.

As previously reported,<sup>2,3</sup> the metaphyseal striations are not a prominent feature in the early stages, and in our patient were not radiologically apparent until the child was almost 5

Table 1 Differential diagnosis of sponastrime dysplasia

Feature	Sponastrime	SEMD with large joint dislocations <sup>10</sup>	Camera <i>et al</i> <sup>11</sup>	Verloes <i>et al</i> <sup>12</sup>
Intelligence	Normal	Normal	Severe retardation	Severe retardation
Short stature	+	+	+	+
Midface hypoplasia	+	+	+	+
Saddle nose	+	+	+	+
Rocker bottom feet	-	-	-	+
Joint laxity	+	++	?	+
Hypotonia	+	+	+	+++
Large joint dislocations	-	++	-	-
Osteopenia	+	-	+	+++
Microcephaly	-	-	+	+
Wormian bones	-	-	-	+
Striated metaphyses*	+/+++	+	+	-
Irregular metaphyseal margins*	+	-	-	-
Epiphyseal involvement	+	++	+	-/+
Delayed bone age	+	+	+	+
Scoliosis	+/++++	+	-	+
Characteristic age related vertebral changes*	++	-	-	-
Lumbar lordosis	+	+	+	-
Reduction in interpedicular distances from L1 to L5	+	+	-	-
Gracile metacarpals	-	+	?	-
Brachymetacarpus	+	-	?	+
Pseudoepiphyses of metacarpals	+	-	-	+
Long slender phalanges	-	+	?	-
MCPP	Up - down variation	?	?	Relatively flat

\*Major radiological diagnostic features of sponastrime dysplasia.

+ mild; ++ moderate; +++ severe; - absent; ? not mentioned in paper.



years of age, so sponastrime dysplasia was not considered as a possible diagnosis; indeed this patient has previously been presented by Slaney *et al*<sup>1</sup> as a new syndrome of spondyloepimetaphyseal dysplasia, eczema, and hypogammaglobulinaemia. We therefore tend to agree with Langer *et al*<sup>2,3</sup> who feel that less emphasis should be placed on these striations and more on the findings in the spine. They suggest that the condition be called “spondylometaphyseal dysplasia with midface hypoplasia and depressed nasal bridge”. However, because of the mild epiphyseal abnormalities, and because it is now present in textbooks and databases as sponastrime dysplasia, we feel that “spondyloepimetaphyseal dysplasia (SEMD), sponastrime type” is a more appropriate term.

- 1 Slaney SF, Hall CM, Atherton DJ, Winter RM. A new syndrome of spondyloepimetaphyseal dysplasia, eczema and hypogammaglobulinaemia. *Clin Dysmorphol* 1999;8:79-85.
- 2 Langer LO Jr, Beals RK, LaFranchi S, Scott CI Jr, Sockalosky JJ. Sponastrime dysplasia: five new cases and review of nine previously published cases. *Am J Med Genet* 1996;63:20-7.
- 3 Langer LO Jr, Beals RK, Scott CI Jr. Sponastrime dysplasia: diagnostic criteria based on five new and six previously published cases. *Pediatr Radiol* 1997;27:409-14.
- 4 Cooper HA, Crowe J, Butler MG. Sponastrime dysplasia: report of an 11-year-old boy and review of the literature. *Am J Med Genet* 2000;92:33-9.
- 5 Lachman RS, Stoss H, Spranger J. Sponastrime dysplasia: a radiologic-pathologic correlation. *Pediatr Radiol* 1989;19:417-24.
- 6 Fanconi S, Issler C, Giedon A, Prader A. The SPONASTRIME dysplasia: familial short-limb dwarfism with saddle nose, spinal alterations, and metaphyseal striation. *Helv Paediatr Acta* 1983;38:267-80.
- 7 Camera G, Camera A, Pozzolo S, Costa P. Sponastrime dysplasia: report on a male patient. *Pediatr Radiol* 1994;24:322-4.
- 8 Masuno M, Nishimura G, Adachi M, Hotsubo T, Tachibana K, Makita Y, Maizumi K, Kuroki Y. Sponastrime dysplasia: report on a female patient with severe skeletal changes. *Am J Med Genet* 1996;66:429-32.
- 9 Nishimura G, Mikawa M, Fukushima Y. Another observation of Langer-type sponastrime dysplasia variant. *Am J Med Genet* 1998;80:288-90.
- 10 Hall CM, Elcioglu NH, Shaw DG. A distinct form of spondyloepimetaphyseal dysplasia with multiple dislocations. *J Med Genet* 1998;35:566-72.
- 11 Camera G, Camera A, Di Rocco M, Gatti R. Sponastrime dysplasia: report on two siblings with mental retardation. *Pediatr Radiol* 1993;23:611-14.
- 12 Verloes A, Mission JP, Dubru JM, Jamblin P, Le Merrer M. Heterogeneity of SPONASTRIME dysplasia: delineation of a variant form with severe mental retardation. *Clin Dysmorphol* 1995;4:208-15.
- 13 Meyer JS, Davidson RS, Hubbard AM, Conrad KA. MRI of focal fibrocartilaginous dysplasia causing tibia vara. *J Pediatr Orthop* 1995;15:304-6.
- 14 Lincoln TL, Birch JG. Focal fibrocartilaginous dysplasia in the upper extremity. *J Paediatr Orthop* 1997;17:528-32.
- 15 Bell SN, Campbell PK, Cole WG, Menelaus MB. Tibia vara caused by focal fibrocartilaginous dysplasia. Three case reports. *J Bone Joint Surg (Br)* 1985;67:780-4.
- 16 Niyibizi C, Vinsconti CS, Gibson G, Kavalkovich K. Identification and immunolocalization of type X collagen at the ligament-bone interface. *Biochem Biophys Res Commun* 1996;222:584-9.
- 17 Bradish CF, Davies SJ, Malone M. Tibia vara due to focal fibrocartilaginous dysplasia. The natural history. *J Bone Joint Surg (Br)* 1988;70:106-8.
- 18 Garn SM, Hertzog KP, Poznanski AK, Nagy JM. Metacarpophalangeal length in the evaluation of skeletal malformation. *Radiology* 1972;105:375-81.
- 19 Garn SM, Leonard WR, Poznanski AK. Applications of the pattern variability index (OZ) to the quantification of dysmorphogenesis in the hand. *Am J Med Genet* 1987;27:143-52.